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Summary 
 
The overall aim of this thesis was to evaluate the feasibility of implementing Process 
analytical Technology (PAT) into pharmaceutical manufacturing.  First of all the 
implementation of PAT was looked at from a bird perspective, taking all unit 
operations into account.  This task was divided into two parts, the first one developing 
a PAT strategy that could result in a real time release in tablet manufacturing for one 
product, identifying the critical variables in the manufacturing process and selecting 
the analytical techniques to measure these critical variables.  The second part of the 
bird perspective determined the economical feasibility of the PAT implementation 
based on the strategy formed in part one for three products.  After determining the 
overall feasibility of the PAT implementation a closer look was given to special 
technologies which contribute to the PAT philosophy in ways of product efficiency, 
manufacturing flexibility, process understanding and building quality into the 
products instead of testing quality into products. 
  
Critical process variables were determined by analysis of validation data, discussion 
with plant operators and literature analysis of the fundamental operation of each 
process step.  The critical process variables were determined to be moisture content, 
identity, and particle size distribution of the raw materials, blend homogeneity of the 
mixing steps, particle size distribution after granulation, content uniformity of the 
drug substance and hardness of tablets, coating thickness, final tablet moisture 
content, droplet size distribution of coating solution, identity of material packaged and 
package integrity.    
Analytical techniques to measure each of the critical variables were chosen based on a 
literature search to evaluate what techniques are available and further narrowed based 
on availability of equipment.  Diffuse reflectance near infrared spectroscopy (DR-
NIR) is recommended for determining component identity, moisture content, blend 
homogeneity, hardness, coating thickness, and material identity.  Transmittance NIR 
(T-NIR) is recommended for determining content uniformity.  Laser light diffraction 
(LLD) is recommended for determining particle size distribution.  The PAT strategy 
that combines process monitoring and product characterization will hopefully 
 9
eliminate or at least reduce the need for Quality Assurance / Quality Control (QA / 
QC) laboratory testing. 
The first technologies to be implemented should be the ones that are easiest to 
implement and least expensive.  Full adoption of the PAT philosophy will require an 
alteration of the method used to develop pharmaceuticals.  A better scientific 
understanding of the process and materials will be required so as to result in a process 
that is fully understood, has a process model and produces materials with built-in 
quality assurance for real time release. 
The two areas where PAT can provide the greatest savings were found to be: (1) 
reduction in Quality Control (QC) testing, leading to real time release and (2) 
improvement of product yield from better process control.  The financial analysis is 
sensitive to the time when these benefits begin to take effect.  Since there is some 
uncertainty as to when real time release will be approved, two scenarios were created 
for implementation of PAT.  The first scenario (base case) assumes that QC savings 
start accruing after the installation and qualification of analytical instruments, at the 
end of the first year.  The second scenario is a conservative case in which it is 
assumed that the QC savings begin in the third year, after correlations have been 
developed for tablet friability, disintegration time and dissolution time.   
PAT implementation is envisioned to occur in three stages.  The first phase involves 
the installation of on-line analytical equipment and results in benefits related to 
savings in QC costs, reduced time for investigations, and reduced throughput time.  
During the first phase of PAT implementation, correlations will be developed for 
process understanding and to replace current analytical tests such as disintegration, 
dissolution and friability.  The second phase is the implementation of process control 
systems which results in savings due to fewer Food and Drug Administration (FDA) 
audits, fewer investigations, fewer batch rejections, shorter throughput times, and 
increased product yield.  The third phase is the integration of PAT into the 
development process of a new product, resulting in quality by design.  The third phase 
was not addressed within this project as PAT implementation was only evaluated for 
products already on the market and so concentrating on the production side.  In order 
to investigate the impact of PAT on the development process of a new drug product a 
separate dissertation work would be necessary.   
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For the first scenario (QC savings after the first year), the results of the economic 
analysis indicate that the implementation of PAT for solid tablet manufacturing is 
very cost-effective.  The Return on Investment (ROI) for implementation of PAT after 
phase I is 69% for Product X, 49% for Product Z and 46% for Product Y.  The Return 
on Investment for implementation of PAT in phase II is 147% for Product X, 92% for 
Product Z and 60% for Product Y. 
For the second scenario (no QC savings in phase I), the Return on Investment drops to 
130% for Product X, 81% for Product Z and 49% for Product Y.  Thus, PAT 
implementation is cost-effective even in the conservative case.   
Companies tend to move ahead with a project when the Return on Investment is at 
least 25% and these results demonstrate that PAT should be implemented.  The 
Return on Investment results indicate that the installation of on-line analytical 
equipment creates great savings for companies while implementation of control 
systems is even more cost effective. 
 
In matters of new manufacturing technology, the Glatt Multicell®was evaluated as an 
innovative approach for granulation.  The Multicell®, being a semi-continuous 
granulator producing small sub-batches of approximately 7kg, is able to circumvent 
the unpleasant practice of scale-up as it is capable of producing one sub-batch or just 
as many as required.  The capacity of the Multicell® was compared to the capacity of 
conventional granulation equipments.  It did not only show that it could hold up with 
the conventional granulation but also increased capacity dramatically and at the same 
time reducing the needed personnel or Full Time Equivalents (FTE) from 18 down too 
7, bringing in yearly savings of approximately 1100kCHF.   
Another technology which contributes to process understanding and building quality 
into the product is the MCC Presster®.  The Presster® is a rotary press simulator which 
is capable of replicating different rotary presses by utilizing the same compression 
tooling and using the same dwell time as the original rotary press with only one pair 
of punches.  This allows the comparison of different rotary presses with only one 
machine and very little powder formulation.  In this study the Presster® was used to 
replicate the results of three different rotary presses.  Two commercial product 
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formulations were run on all three rotary presses with different dwell times.  The two 
product formulations were chosen considering their flowing properties, one product 
having bad flowing properties and the other very good flowing properties.  It was 
shown that the Presster® was capable of simulating the effects of a full scale tableting 
machine if the Presster® is equipped with the corresponding compression tooling.  
Further it was shown that prolonged pre-compression dwell time due to pneumatic 
compensation leads to tablets with higher crushing strength than regular pre-
compression rolls.   
Last but not least a Near Infrared (NIR) Spectrometer was evaluated for 
implementation on a packaging line.  This technology also contributes to the proposed 
PAT philosophy by enhancing process understanding and enabling 100% real time 
analysis of the product being packed.  For this study a packaging line simulator was 
used with an integrated NIR spectrometer system from Visiotec called VisioNIR®.  
The products used for this study were all strengths of Sandimmun Neoral® which are 
in soft gelatin capsules and different tablet products for mix-up studies.  The aim of 
this study was to estimate which product flaws the VisioNIR could detect within the 
soft gelatin capsules, such as capsules without content, capsules with wrong content 
and product mix-ups.  It was shown that the VisioNIR was capable of distinguishing 
empty capsules, excessively smudged capsules and capsule mix-ups from the 
Sandimmun Neoral® capsules for all strengths.  It became apparent that Sandimmun 
Neoral® strengths which were grey were harder to analyze as the lighter soft gelatin 
capsules as the halogen light did not penetrate deep enough into the capsule shell.   
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1. Preface  
 
1.1. Introduction 
 
 
The pharmaceutical industry is exposed to an increasing pressure from the authorities 
and health insurance companies today, to reduce their prices.  At the same time 
however, the costs of the development of new drugs rise.  Thus, the development of a 
new medicine takes on the average 12 – 13 years and costs around 800 – 900 million 
$US.  In order to amortize these investments by the sales of the medicine again, the 
development companies have seven too eight years time, until the patent protection 
runs out.  Afterwards the generics manufacturers can bring a generic on the market, 
which is substantially cheaper.  In order to be able to profit for as long as possible 
from the exclusive position by the patent protection on the market, the time up to the 
introduction on the market of the new medicine must be kept as short as possible.  In 
order to shorten this “Time-to-Market”, new technologies must be integrated into the 
conventional production process.   
 
In the last years the Food and Drug Administration (FDA) has been rather reserved in 
the cases of new technology implementation, in order to uphold the safety of the 
patient.  Their focus was rather much more that the drugs were supposed to be 
produced exactly according to specification with proven and established devices.  
Recently a change in this situation has appeared.  The FDA is now pushing the 
pharmaceutical industry to improve their quality standards and implement innovative 
manufacturing methods.  Therefore the FDA published a guideline, which describes 
new technological concepts to quality control, which are summarized under the name 
PAT (Process Analytical Technology) 
 
The core of this thesis is PAT.  As can be seen in figure one below, it is tried in this 
thesis to take on all of the recommendations of the FDA in their PAT guidance.  At 
first a PAT implementation strategy will be presented with an adjacent economic 
analysis of the PAT implementation.  Then in order to address terms as “Process 
Understanding” and “Quality by Design” a semi-continuous granulation machine was 
looked at and a rotary press simulator.  Finally, the most common PAT technology 
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was tested on a packaging line.  The PAT strategy and the economic analysis will be 
presented in a separate chapter as well as all the different technologies.   
 
Multicell MCC Presster
• IMA Comprima
• Courtoy Modul
• Fette 2090
VisioNIR
• Efficiency
• Scale-up
• Flexibility
• Process Understanding
• Scale-up
• Real Time
Analysis
Quality by Design  
Figure 1: An overview of the thesis scope. 
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2. PAT implementation strategy and PAT’s economic impact 
 
2.1. Introduction 
 
The pharmaceutical industry faces a unique set of challenges in the manufacture of its 
products. Due to the nature of the products, governments exercise a significant degree of 
regulatory control over the manufacturing process. In order to ensure the safety of drug 
products to consumers, the manufacturing process must be validated extensively. Any 
deviation in the process requires a time-consuming and expensive approval process. As in 
many other industries, the advantage of being first to market with a new product is enormous. 
Additionally, delays in the rollout of a new product result in lost sales. As a result, there is a 
great deal of pressure to develop and validate the manufacturing process for new drugs as 
quickly as possible. The confluence of these two factors, desire for speed to market and rigid 
regulatory control, results in manufacturing processes which are frozen into place before 
optimal conditions can be determined. 
 
There are a number of disadvantages to manufacturing drugs in this way. Quality assurance is 
performed after the product has been made, so products are sequestered for as much as a 
month after production while testing of samples is completed. If irregularities are found, it is 
too late to adjust the process parameters, and the irregularities must be identified and 
explained in a time-consuming investigation, or the out-of-specification material must be 
thrown away or re-worked. The difficulties associated with changing the process also mean 
that improvements in manufacturing technology which evolve during the life of the product 
cannot be easily applied. The final result of this situation is that the pharmaceutical industry 
is lagging behind other related industries in implementing new manufacturing technologies 
which have the potential to improve product consistency, reduce delays in product release, 
and cut overall manufacturing costs. 
 
In recent years the US Food and Drug Administration (FDA) in cooperation with leading 
pharmaceutical manufactures is looking into the method of Process Analytical Technology to 
improve production efficiency and reduce costs.  The FDA has defined PAT as a system for 
 18
designing, analyzing, and controlling manufacturing through timely on-line measurements of 
critical quality and performance attributes of raw materials and in-process materials with the 
goal of ensuring final product quality.  The FDA has also stated that the goal of PAT is to 
develop a basic understanding of the manufacturing process and control it accordingly.  
Quality cannot be tested into the products; it should be by design.  Through a better 
understanding of the manufacturing process, the critical variables can be determined and the 
quality of the product can be determined by on-line measurements or correlation of measured 
variables to other product attributes.  Electronic records of the process parameters can then 
replace post-process testing for quality control and assurance.  The philosophy of PAT is 
appealing to the pharmaceutical industry as it will aid in the ease of product manufacturing, 
but the true economic benefit is yet to be determined. 
 
2.2. Background 
 
At present, pharmaceutical companies manufacture solid tablet drugs with a process which 
entails a significant number of manual steps. Quality control is accomplished through offline 
laboratory testing both during and after the completion of the manufacturing process. This 
leads to long periods (20-30 days) during which the final product is warehoused while the 
QA tests are completed.  A more automated system of process and quality control will allow 
for speedier release of product to consumers.  
 
A solid tablet production facility is to serve as the starting point for part one, for the effort to 
develop a PAT implementation strategy.  A high volume product (which will be called 
product X from now on) process has been chosen because the impact would be more 
noticeable.  Presented below are two flow sheets.  Figure 1 gives a rough overview of the 
general solid tableting process, while figure 2 gives specific details concerning the 
production of product X.  
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For part two, the economic analysis of the PAT implementation in a solid tablet production 
facility was the focus. Table 1 illustrates the most frequently produced drugs at the 
production facility. Evaluation of the costs and benefits of implementing PAT for the 
production of Product X, Product Y, and Product Z was selected for this project. 
 
Raw Material    
Dry Granulation 
Fluidized Bed Drying    Wet Granulation
Tabletting Coating Packaging Product
Blending & Sieving    
Drying 
 
Figure 1: General Tableting Process 
 
The specific steps in the tableting process are as follows: 
• The first step is the weighing out of the various raw materials, which include both 
active ingredients and excipients, into small bins. 
 
• The separate powders are transferred into a single large container and mixed for a set 
length of time, then sieved. The mixer rotates the container as a whole, as opposed to 
agitating the powder inside the container.  
 
• Following the initial mixing step, the mixture undergoes one of two granulations 
steps. 
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o In wet granulation, a set quantity of water is added to the powder to 
agglomerate the particles. The wet granulate is then dried in a fluidized bed 
drier. The mixture is then sieved again as described above. 
 
o In dry granulation, the powder is compacted by a pair of rollers into flat 
ribbons.  The ribbons are then milled and sieved. 
 
• After granulation, a lubricant is added and the container is mixed once again. 
Generally, magnesium stearate is used as a lubricant to ensure release of the tablets 
from the die in the tableting step that follows. 
 
• Following granulation, the powder is transferred to an automatic rotary press which 
forms tablets by compressing the powder in a die. The rotary press currently has a 
feedback control system that manipulates the tablet volume in order to control the 
tablet mass. 
 
• Tablets are coated with a liquid which is sprayed at a low flow rate onto the tablets in 
a rotating drum. The process relies on a tumbling action of the tablets as the drum 
rotates to ensure even coating. 
 
• After coating, the tablets are fed into an automatic packaging line and inserted in 
blister packs. 
 
Figure 2 is a flow sheet of the specific procedure for the product X.  The individual steps are 
as described previously.  The A and B referenced in the flow sheet refer to sub-batches of 
identical materials that are processed in series as a result of volumetric limitations on some of 
the processing equipment. 
 
 21
 
Raw Material 
A, B
Blending Sieving CompactingBlending
Sieving
Blending
A, B & Mg Tableting
Packaging
Coating
Diovan
Add Magnesium 
Stearate
Drying
Figure 2: Flow sheet for manufacture of product X. 
 
Product X 
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  Formulation 
Batches 
2002 
Batches 
2003 
Projected 
Batches 2004 
Product X 
Dry 
Granulation 
859 900 856 
Product Z 
Wet 
Granulation 
556 656 400 
Product Y 
Wet 
Granulation 
478 490 195 
q 
Dry 
Granulation 
331 469 518 
w Capsule 362 402 389 
e 
Wet 
Granulation 
310 300 214 
r Dry Mixing 48 72 213 
Table 1: The volume of the most commonly manufactured drugs at the site. 
 
2.3. Objectives for part one 
 
The final and overarching goal of this chapter is to put the manufacturer in a position to move 
from a post-process quality control system to one which operates at the same time as and 
interacts with the manufacturing process in real time. This system will allow the 
manufacturer to achieve real time release, which means that the company can release the 
product to consumers as soon as the manufacturing process is over. The quality assurance 
system is to be built directly into the process control system. To this end, a number of 
specific objectives have been defined. 
 
1. Evaluate the current manufacturing process for solid tablets from raw materials to 
packaging with a focus on product X, looking for opportunities to implement PAT. 
 
2. Identify critical variables that affect the quality and consistency of the final product. 
 
One key goal of PAT is to be able to predict key quality attributes of the product based on 
monitoring and control of the critical variables. A high degree of confidence in the 
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relationship between the final product attributes and the controlled variables is necessary if 
post-production testing is to be eliminated. 
 
3. Suggest automated manufacturing processes to eliminate human error and reduce 
processing variability. 
 
Increasing the level of automation goes hand in hand with improving the consistency of the 
final product. Additionally, manual tasks do not produce the type of electronic records which 
are needed to state with confidence that the manufacturing procedure has been followed 
precisely. Automation should be investigated to the extent that it contributes specifically to 
the goal of real-time release with PAT. 
 
4. Identify specific technology to monitor and control critical variables on-line. 
 
This objective involves finding and selecting specific vendors and models as well as 
identifying the general analytical techniques that are most appropriate for the implementation 
of PAT. 
 
5. Suggest a central control structure that is able to interface with the individual monitoring 
and control devices. 
 
This objective seeks to tie together the separate analytical and control devices which are to be 
suggested. The system should be capable of compiling a “batch report” which contains the 
important details of each stage of the manufacturing process. This report will essentially 
replace the current QA report which is generated during production and after a batch has 
been completed. 
 
2.4. Method of approach 
 
The final result of this project is to develop a PAT strategy for solid tablet manufacturing.  
The project  focused specifically on solid tablet  manufacturing so that the time could be 
spent researching PAT technologies and developing a PAT strategy which is more in-depth, 
rather than spending a large amount of time learning about different manufacturing processes 
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for all varieties of pharmaceutical products.  The project focused on the manufacture of one 
solid tablet product, product X, so that there is a specific example for which a PAT strategy is 
developed.  
 
2.5. PAT for the solid dosage manufacturing process 
 
Within this section, the solid dosage manufacturing process is broken down by unit operation. 
The outline follows the manufacturing process for Product X, but the unit operation 
evaluations should be taken as general for all solid dosage products.  In each subsection, a 
short description of the unit operation itself, along with the relevant physical phenomena 
involved, is presented. A distinction is made between critical variables and process 
parameters, both of which will be identified. The term variable will refer to quantities which 
describe the condition of the process material, such as particle size distribution, moisture 
content, or tablet hardness. In contrast, process parameters refer to those quantities that are 
directly controllable such as the compaction force or inlet air temperature. Once the critical 
variables have been identified, a summary of analytical methods will be given, along with a 
recommendation of one technology. Finally, a list of suitable vendors of each technology 
type will be presented.   
 
2.5.1. Dispensation of raw materials 
 
The first step in the production process is the weighing out of the raw materials from bulk 
storage into individual bins. For the Product X process, the batch is split into two identical 
halves, denoted A and B which are processed separately until the final blending step. For 
each half-batch, the individual powders are transferred to small bins and weighed by hand.  
 
There are several opportunities for improved monitoring in the dispensation step, and they 
are best illustrated by a description of failure modes for the step. Currently, there is no 
electronic record-keeping of the material weights which are actually placed in the bins. While 
there is extensive manual checking and sign-offs, an additional electronic record of the 
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material weight would allow for more confidence that the correct proportions of raw 
materials were used if questions arise later. A second possible failure mode is that the wrong 
powder might end up in the bin. This could be due to mislabeling of the bulk storage hopper 
or simple human error during the weighing step. Analytical confirmation of the identity of the 
powder being weighed will increase the degree of confidence that the correct raw material 
has been distributed. The last potential failure mode will be addressed is the possibility that 
the raw material in question may be out of specifications. The two variables that have the 
greatest effect on the downstream process are the particle size distribution and moisture 
content on the roller compaction and mixing steps, respectively [1-3].  As there is a 
possibility that these properties can change over time and within a bulk shipment, it is 
recommended that these measurements be made during the dispensing step, rather than (or as 
well as) on a bulk scale when raw materials arrive. 
 
To address the question of electronic record keeping for the weights, the recommendation is 
two-fold: a scale which can report the measured weight should be coupled with a bar-coding 
system. It is recommended that each bin have a bar-code tag that would be linked to a 
computer file containing the specifics of the bin such as capacity and empty weight. After the 
bin has been loaded, the operator would scan the bar-code, and an electronic record would be 
kept concerning the bin, as well as the weight of powder added.  
 
For purposes of material identification, a host of analytical techniques are available, so the 
choice was based primarily on ease of use. One does not wish simply to transfer an analytical 
laboratory out onto the production floor. For this reason, Diffuse Reflectance Near Infrared 
(DR-NIR) spectroscopy is the best choice. As opposed to HPLC or UV spectroscopy, DR-
NIR does not require any sample preparation, so the identification can be performed simply 
by inserting a handheld probe into the powder and taking a spectrum. Diffuse reflectance NIR 
works by measuring the reflectance spectrum of the material being assayed over the 
wavelength range of 1100 – 2500 nm. This range contains overtones and combinations of the 
vibrational modes chiefly for bonds involving hydrogen such as C-H, O-H, and N-H. Due to 
the lower absorption at these wavelengths, no dilution of the sample is required [1]. Raw 
material spectra can be taken and compared to calibration spectra performed earlier to give 
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the operator a “yes or no” answer on the identity of the powder.  One significant advantage of 
using DR-NIR to determine raw material identity is that the same equipment can also be used 
to monitor moisture content. Water has two strong absorption bands in the near infrared, at 
approximately 1450 and 1940 nm. By comparing the relative height of these peaks to other 
peaks in the spectrum which are unaffected by the presence of water, it is possible to 
determine moisture content [1, 4-6]. 
 
Particle size distribution (PSD) is a fairly complicated metric to measure, as particle size 
itself can have a number of meanings.  Presently, particle size of raw materials is only 
measured by pharmaceutical companies when the vendor is selected during development.  
There are several methods that can be used to measure particle size – sieving, image analysis 
[7-9], and laser light diffraction [7-11].  Sieving is the method most commonly used to 
determine particle size distribution, but requires operators to perform several sieving steps 
and weight measurements.  The image analysis method involves taking a photograph of a 
sample and determining the particle size distribution by analysis of a gray scale image [7].   
This method is the most accurate for measurements that involve irregularly shaped particles, 
but can be very time consuming because large samples ~1,000,000 particles must be 
measured to get an accurate representation of the distribution [7].  Laser light diffraction 
measures the intensity of light scattered by a particle, which is a function of wavelength, 
particle diameter, and relative refractive index [11].  Particles are illuminated with a parallel 
beam of monochromatic light and the light patterns are measured on a photo detector.   Laser 
light diffraction is the recommended method to determine the particle size distribution of the 
raw materials because it can give a more detailed particle size distribution than the sieve 
analysis with simpler data analysis than image analysis.   Laser light diffraction 
measurements can be taken of solids suspended in air, thereby simplifying the sample 
preparation process.  The solids are suspended in air by the measurement instrument by the 
flow of an air stream through the sample. (E.g. see Malvern Instruments Mastersizer).   
 
2.5.2. Pre-blending 
 
The pre-blending unit operation as it is evaluated here is actually composed of three separate 
steps. Currently, the raw materials are combined in a large container and mixed in a tumble 
blender for 30 minutes at a low speed of 10 rpm. The mixture is then run through a Frewitt 
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sieve mill in order to remove any lumps which may have formed and/or remain after the first 
blending step. Finally, the powder mixture is blended again under the same conditions for an 
additional eight minutes. It has been assumed that the powder does not experience forces 
which are likely to lead to significant changes in the PSD during the first sieving step, so it is 
ignored in the PAT strategy. This assumption could be tested fairly easily by measuring the 
PSD for a batch before and after the first sieving step.  This subsection thus focuses on the 
question of successful blending. 
 
Achieving a uniform powder blend is a key step in the production of solid tablets. It is 
essential that the active drug compound be dispersed evenly in the powder so that tablets will 
contain the correct dosage of active substance. This, however, is not a sufficient condition to 
guarantee successful blending, as the excipients each have a specific and important role to 
play in the formation of acceptable tablets. For example, insufficient dispersion of glidant can 
result in difficulties during roll coating, as the ribbon will have a tendency to adhere to the 
roller. 
 
Powder blending is a combination of convection, in which large groups of particles move 
relative to each other, diffusion, in which individual particles move relative to each other, and 
shear, which is the change of configuration of particles due to slipping of layers[12, 13]. 
Unfortunately, the complicated process of powder blending is very specific to the material 
being mixed, so there has been little success in using theory to predict mixing behavior. 
 
A complete, validated theoretical description of blending different 
powders does not exist. The majority of theoretical descriptions of powder 
blending involve the mixing of materials that differ only in color and do 
not account for any cohesion or interaction between the components being 
mixed. The theory derived from such studies is not useful for describing 
practical pharmaceutical powders and, as a result, most powder mixing 
science in use in the pharmaceutical industry is empirical. 
      Professor Charles L. Cooney [14] 
      Massachusetts Institute of Technology 
      Department of Chemical Engineering 
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The determination of blend uniformity in powder blends has historically been an expensive 
and time consuming process that is frequently criticized as inaccurate[13, 15]. Traditionally, 
a thief probe is inserted into a number of positions within the mixing vessel, and the small 
(order 1 gram) sample is analyzed using traditional laboratory methods (HPLC or UV 
Spectroscopy) to determine the content of active drug substance. In 1993, the Barr decision 
(United States vs. Barr Laboratories) established 90% -110% of the theoretical active 
composition in a sample limited to three times the dosage weight as the criteria for 
establishing uniform blending [16]. This standard does not take into account the uniformity 
of the other excipients, upon which critical tablet parameters depend.  
 
The traditional thief probe method for monitoring blend uniformity has been shown to 
introduce errors in the blending measurements due to disturbance of the powder bed as the 
probe is inserted. Differences in the flowability of the blend components can also affect the 
rate at which powders flow into the sampling cavity, so that free-flowing powders are 
preferentially sampled[17, 18]. This is not an issue for methods that do not involve disturbing 
the powder bed. Non-invasive spectroscopic monitoring methods such as DR-NIR and Light 
Induced Fluorescence (LIF) thus carry an additional advantage of accuracy over the 
traditional measurement method apart from the immediately apparent savings in process time 
and cost that are afforded by an on-line measurement.  
 
The most mature, well studied, and commercially available technology for online 
determination of blend uniformity is Diffuse Reflectance Near Infrared Spectroscopy (DR-
NIR). The determination of blending uniformity involves comparing consecutive spectra 
taken of the powder mixture as the mixing progresses. When the variation in the spectra as a 
function of time decreases to a minimum, this signals that blending is complete [15, 19]. One 
key advantage to NIR spectroscopy is that it monitors the dispersion of both the active drug 
substance as well as the excipients. Below are the individual DR-NIR spectra for the 
components of a model pharmaceutical blend, followed by the blend spectra taken over the 
course of a 25 minute mixing cycle from Sekulic et al.[13]. 
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Figure 3: DR-NIR spectra of pure blend components from Sekulic et al. (1996) 
 
 
 
Figure 4: Typical DR-NIR spectra collected for an entire mixing rung from Sekulic et al. (1996) 
 
As is apparent from figure 4, the spectra begin to look very similar to each other almost 
immediately, so a quantitative analysis of the spectra is required to glean a clear picture of 
the progress of blending. This is currently accomplished by one of several statistical 
strategies. In many cases, the spectra are first pretreated by multiplicative scatter correction 
(MSC), principle component analysis (PCA), or second derivative, standard normal variant 
(SNV).  This will be handled thoroughly in chapter 5.  Figure 5 shows the second derivative 
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spectra calculated from the absorbance spectra in figure 4.  Statistical pattern recognition 
software is then used to determine the endpoint of blending. Figure 6 is the standard 
deviation of a moving block standard deviation of the spectra shown in figure 5. The uptick 
in the standard deviation at the end of the mixing time in figure 6 is due to an addition of Mg 
stearate at the 20-minute mark in the experiment, and should be ignored. 
 
Figure 5: Second derivative of DR-NIR spectra from Sekulic et al. (1996) 
 
Figure 6: Final mixing metric (Sekulic et al. 1996) 
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Other non-invasive techniques that were considered include NIR imaging (NIR-I), in which 
images of the top of the powder bed are collected using bandpass filters consistent with 
absorption bands for the powder components. The individual pixels of the images are 
analyzed to determine the level of variation in the concentration of each powder component. 
NIR-I is able to sample a larger quantity of material than NIR spectroscopy, which allows for 
greater statistical confidence in the results. While this appears to be a promising technology, 
it has yet to be studied as extensively as DR-NIR spectroscopy, particularly with regard to 
monitoring powder blending. The technique is also limited to the top surface of the powder 
bed, so it may be more useful in concert with another technology as a check [18]. 
 
Light Induced Fluorescence (LIF) is another emerging analytical technique which is being 
applied to the monitoring of powder blending [20]. This technique takes advantage of the fact 
that many drug substances fluoresce when excited by the correct wavelength of laser light. 
The emission spectra from the powder mix can then be analyzed to determine the uniformity 
of the drug substance. LIF has an advantage over DR-NIR spectroscopy in that it is quite a bit 
more sensitive, and might be a good replacement for DR-NIR in cases in which the 
concentration of the drug substance is too low to detect by DR-NIR. However, there are 
several limitations to LIF as well. First, not all drug substances fluoresce. Lai and Cooney 
report that over 60% of the top 200 pharmaceutical molecules fluoresce [21]. Second, the 
technique is limited to monitoring the active drug substance, so excipient dispersion is 
ignored. Finally, the technology is currently in the development stage, and few commercial 
systems for monitoring powder blending are currently available. While this technique is not 
yet ready for application in the manufacturing setting, it is worthwhile to keep abreast of its 
development, as it may be very useful for specific monitoring needs in the future. 
 
Several practical issues concerning the use of DR-NIR spectroscopy for this purpose merit 
discussion. The first is the question of how to attach probes to the mixing vessel. Currently, 
interchangeable containers are attached to the mixer, and are tumbled whole during the 
mixing step. This creates a difficulty in terms of probe attachment that may require some 
creativity to overcome. First, one must determine whether to dedicate one container to 
mixing, or if it is more advantageous to outfit all containers to allow for NIR monitoring. 
Secondly, a fiber optic wire is generally required to transmit spectra to the spectrometer. The 
tumbling motion of the container will require that a bearing of some sort be coupled to the 
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probe in order to avoid twisting the fiber optic cable. This difficulty is further aggravated by 
the fact that a single probe is insufficient for an accurate measurement, so probes positioned 
in different places around the container are necessary[18]. Wire twisting then becomes a 
significant barrier. In a number of studies, investigators have inserted probes through the axle 
on V-blenders, however, that is not an option for the current mixer configuration. The 
development of wireless probes will go far to ameliorate this difficulty.   
 
2.5.3. Dry granulation 
 
The dry granulation process consists of two discrete sub-processes which are best analyzed 
separately. The first step, roller compaction, serves to compress the powder into ribbons of 
agglomerated material. These ribbons are subsequently milled into particles in the second 
step, sieving. 
 
The physical principle behind roller compaction is to agglomerate smaller particles into a 
large ribbon by deforming them beyond their region of elastic deformation [22]. The 
deformation characteristics of the product ribbon are affected by three key process 
parameters: feed rate, roller speed, and gap width. Together, these determine the compaction 
force experienced by the powder as it is compressed. The porosity of the exiting ribbon is 
closely tied to the compaction force. The purpose of the dry compaction step is to create 
denser, larger, and better flowing particles [23]. A balancing act must be performed, 
however. The mechanism that allows dry granulation to work, namely the irreversible plastic 
deformation of the particles, is the same mechanism at work in the tableting process, and the 
particles have a limited total deformation. Thus, if the particles are compacted too tightly 
during compaction, the tablets produced will have significantly greater friability [22]. On the 
other hand, too little compaction force can result in incomplete agglomeration, in which case 
the percentage of fines will increase. There is currently a control system in place on the roller 
compactor which varies the powder feed rate in order to maintain a set compaction force. As 
the current control system allows for control over the operation of the roller compactor, no 
additional instrumentation is recommended. The force vs. time data needs to be recorded and 
included in the electronic batch file so that it can be included in any multivariate analysis that 
is performed on the data captured by the PAT devices. 
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The second step in the dry compaction process is the sieving step, in which the ribbon 
produced during roller compaction is milled against a sieve plate to produce granules of a 
certain size range. The particle size distribution of the granules, which is the key output 
variable for the sieving process, is largely dependant on the size and layout of holes on the 
sieve plate. The mechanism for breaking up the ribbon is partially due to the forcing of 
material through the holes in the sieve plate, and partially due to the shearing action of the 
oscillating arm against the top surface of the plate. As it is known to have a significant effect 
on both the flow and tableting properties of the blend, the particle size distribution is the key 
variable to be measured during the sieving step. It is recommended that this measurement be 
made for purposes of understanding the phenomenon involved and verification that the 
process is within specifications. It is not recommended that the PSD be used for feedback 
control. As the sieve plate dimensions are set during the development phase, this parameter is 
not a good candidate for feedback control. The oscillation rate of the shearing arm may be 
varied, but a significant correlation between PSD and oscillation rate would first have to be 
established. 
 
The granulate PSD can be measured using laser light diffraction on-line.   This method was 
chosen using the same rationale as that for PSD measurements of the raw materials.   
Additionally, since the PSD measurement at this point in the process needs to be an on-line 
measurement, the only technique that has commercially available on-line equipment is laser 
light diffraction. 
 
Granule bulk density is an important factor in setting the die volume to achieve the correct 
tablet weight, and is currently measured during validation. While this is not a quantity which 
is easily measured on-line, it is recommended that an effort be made at the development level 
to establish a correlation between incoming raw material particle size, compaction force, and 
the granule bulk density.   
 
2.5.4. Final blending 
 
The final blending step is somewhat more complicated than the pre-blending steps described 
previously. The purpose of the final blending step is to disperse the portion of magnesium 
stearate that is added after the granulation step. The magnesium stearate is weighed and 
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added manually through a hand sieve into the container that holds the granulate. The purpose 
of the magnesium stearate which is added at this point is to serve as a lubricant during the 
tableting process. Specifically, it aids in the release of the tablet from the die after 
compression. The lubricant extends the life of the punch set significantly. There is, however, 
a balance to be reached between even dispersion and over-mixing. If the magnesium stearate 
is mixed with the granulate for too long, a hydrophobic film will form over the granules. This 
can lead to a number of problems with the tablets including decreased tablet strength, and 
increased disintegration and dissolution times.  
 
This mixing step is performed on the same mixer as the first blending step, and it would be 
advantageous to use the same analytical equipment to monitor both steps. Fortunately, this is 
indeed the case. DR-NIR is the most appropriate candidate for monitoring the dispersion of 
magnesium stearate, for the same reasons that it is the best choice for monitoring the pre-
blending. Thus, the hardware used to monitor the two blending operations should be the 
same, although a separate spectrum analysis routine will need to be created that is 
specifically sensitive to the presence of magnesium stearate [24]. From a model-building 
perspective, it would be instructive to monitor the force required to eject tablets from the die 
in the tableting step. This metric would provide insight into the effectiveness of the lubricant.   
 
2.5.5. Tableting 
 
Viewed from a macroscopic perspective, the tableting step is the heart of the solid dosage 
production process. It is in this step that the powder is finally transformed into discrete 
tablets. As a result, a significant portion of the quality concerns for the process are focused on 
this step. One must monitor tablet mass, hardness, friability, drug content, and several other 
output quantities in order to insure that the process is proceeding satisfactorily. In contrast to 
the complexity associated with ensuring that the process is producing satisfactory tablets, the 
mechanics of the tablet forming process are less complicated. There are two primary events 
that occur during this step: the filling of the die with granules, and the compression, which 
proceeds in two steps within the die.  In the die-filling portion, granules flow into the die 
cavity, then are leveled off mechanically so that, as long as the die has filled completely, a 
consistent volume of granulate will be pressed into a tablet. In order to achieve a consistent 
tablet mass, the die must fill completely, and the granules must be of a consistent bulk 
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density. Once the die has been filled, the only parameters that affect the condition of the 
tablets are the compression force and the time over which the force is imparted, the dwell 
time.  The punch gap is set on the rotary press resulting in higher compression force the 
closer the punch tips are to each other, while the dwell time is a direct result of the speed the 
machine is run at.  The compression is mechanistically similar to what happens during roller 
compaction in the dry granulation stage. 
 
Unlike some of the other unit operations, the tablets that are produced must meet a number of 
criteria. In light of this, two points are important. First, the condition of the incoming 
granulate plays an important part in the quality of the tablets produced. Second, there is not a 
simple relationship between the operating parameters and any of the tablet properties. With 
this fact in mind, any special relationships will not be suggested (i.e. if hardness varies 
upward, adjust the compression force downward) for use in controlling the unit operation.  
 
2.5.5.1.Tablet mass 
 
The mass of tablets produced is obviously important for achieving the correct dosage level in 
each tablet.  Compression force is monitored during manufacturing and this measurement is 
actually a very good example of a PAT implementation.  As soon as the monitored 
compression force exceeds the given tolerances it indicates that the amount of granulate in 
the die is not correct.  This information is then fed into a control loop and the dosing of the 
granulate into the die will be corrected.   There is currently online monitoring of tablet mass 
by sampling tablets in the Checkmaster system (roughly 60-80 out of every 120,000, or 
0.05%).  This is sufficient to replace the current post-production testing from a regulatory 
standpoint; however, the data should be fed to a centralized “batch report” and incorporated 
into a larger empirical model relating the granulate properties recorded previously to the die 
volume that is filled before compression.   
 
2.5.5.2.Tablet hardness 
 
In the current process, tablet hardness is measured by placing the tablet between two metal 
plates, and then recording the force required to crush the tablet.  There are several 
disadvantages to this method.  It is destructive, so there is a limit to the number of tablets that 
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can be tested. It is also off-line and time-consuming for plant personnel.  As an alternative to 
crush-testing, several researchers have attempted to show a linear dependence between the 
logarithm of the hardness and the density of a tablet.  Unfortunately, this relation does not 
appear to be valid over a significant range of densities, so other avenues must be pursued for 
monitoring tablet hardness [25]. 
 
A great deal of attention has been paid in the last decade to the use of DR-NIR spectra taken 
on intact tablets to predict hardness [26, 27]. For tablets of identical composition but varying 
hardness, the diffuse reflectance NIR spectra show an increase in baseline absorption with 
increasing hardness.  Figure 7 illustrates this trend [28]. 
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Figure 7: DR-NIR spectra for 20% theophylline tablets at seven hardness levels ranging from 2.87 – 17.2 Kp. 
 
This baseline can be affected by both the tablet hardness and the position of the tablet being 
sampled, so steps must be taken to confirm that the tablet to be tested is oriented correctly.  
Various calibration methods have been proposed, either taking a best-fit regression of the 
entire spectrum, or else using a few specific wavelengths to quantify the baseline shift as 
compared to a standard. Both methods have been demonstrated to be as accurate as the crush 
test described previously [29].   
 
2.5.5.3.Dissolution time and disintegration time 
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The question of finding an online replacement for dissolution and disintegration time testing 
is a difficult one for a number of reasons. Both phenomena are the result of a number of 
mechanical and chemical features of the tablet, and can be affected by changes in any of 
them. As opposed to hardness, there is not a singular physical property of the tablet that can 
be measured that can accurately predict these quantities. We are thus forced to retreat to a 
position that has been unthinkable in the past, but is a centerpiece of the PAT philosophy. A 
multivariate predictive model should be built in order to elucidate the most important powder 
and tablet characteristics that effect dissolution and disintegration times. The ability of water 
to reach and be absorbed by the crospovidone or other disintegrant is a major factor in the 
rate of disintegration, and consequently dissolution. Over-compressing a tablet can have the 
effect of sealing the surface of the tablet, slowing the absorbance of water into the interior of 
the tablet. Another possibly important factor is the extent of final blending. As described 
previously, too much mixing with mg stearate can cause a hydrophobic film to form over the 
surfaces of the granulates.  In this case, the entire tablet may be made hydrophobic, which 
will surely slow the rate of dissolution.  These and other contributing factors must all be 
considered and incorporated into an empirical model. It is recommended that parameters (and 
variables from upstream unit operations) to be considered for such a model include: 
compression force both in the roller compactor and the rotary press, rotary press speed, 
granule bulk density, granule PSD, extent of dispersion of Mg stearate, distribution of 
disintegrant, and moisture content of granulate.   
 
2.5.5.4.Content uniformity of the drug substance 
 
Unlike a number of the other tablet properties that have been discussed, the content 
uniformity is set as soon as the granulate in question has flowed into the die. The 
compression has no effect on the content of drug in the tablet. As a result, there is an 
opportunity to make an easier analytic measurement that will be equivalent to its more 
difficult cousin.  By measuring the proportion of active substance in the granulate as it is fed 
into the rotary press, one can, in concert with tablet mass, deduce the drug content of each 
tablet.  The advantage to this approach lies in the fact that it is much easier to monitor the 
chemical makeup of a (relatively) physically homogeneous powder mix than it is to measure 
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with the same degree of accuracy the drug content in a shaped tablet because the orientation 
of the tablet must be tightly controlled to achieve accurate analyses in the latter case. 
 
Measuring the content uniformity of bulk powder is essentially the same process as 
measuring blend uniformity, so it naturally follows that the best analytical technique remains 
DR-NIR spectroscopy. It is recommended to install an NIR device to monitor the drug 
content in the granulate just as it flows into the rotary press feeding mechanism. While this 
equipment will be making the same measurement that was made in the previous blending 
step, the additional measurement point will serve as a final check of mixing efficacy, and will 
allow for a better understanding of the effect fines segregation has on content uniformity. 
This will lead to a better understanding of the acceptable limits of the particle size 
distribution of the granulate emerging from the dry granulation step. 
 
If for any reason companies would be more comfortable measuring the content uniformity of 
the tablets after they have been formed, two spectroscopic techniques that are capable of 
doing so in an on-line manner are transmittance near-infrared (T-NIR) and DR-NIR 
spectroscopy [30, 31]. Each technique has advantages over the other, but many vendors offer 
spectrometers that can operate in either mode. In both cases, measurements are dependent on 
other tablet properties: hardness, porosity, particle size, tablet size, and imprints on the 
surface; thus, each requires chemometrics that eliminate these variations. Reflectance is 
faster than transmittance, however transmittance tends to be more accurate than reflectance 
[30, 32, 33]. This may be due to the fact that transmittance measures whole tablet while 
reflectance only looks at the surface and requires a uniform distribution throughout. In both 
modes, sample presentation is absolutely essential to accurate measurements, so care must be 
taken to orient the tablet properly. 
 
2.5.6. Coating  
 
Coating is the final processing step before the completed tablets are packaged. In the case of 
Product X, the coating is non-functional, which means it is applied for aesthetic purposes as 
well as to aid in swallowing and taste masking.  Once in the body, however, the coating 
quickly dissolves and does not affect the bioavailability of the tablet.  In the coating step, the 
cores are rotated in a revolving pan while a coating solution in an adequate dispersion is 
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sprayed on the bed of cores [34].  As droplets hit the cores, they spread out, forming an even 
coating.  The coating is then dried by warm air which is constantly flowing through the 
coater.  
 
There are a large number of formulation and processing parameters that can influence the 
quality of the final film, but they all in one way or another boil down to the condition of 
droplets as they land on the tablets [35, 36]. The inlet air temperature, flow rate, and humidity 
all have an effect on the degree that the droplets dry in the air before they reach the tablets, as 
well as the time it takes for the water to be driven off of the surface of the tablets after the 
droplets land [35]. The viscosity (and by extension, temperature) of the coating solution, the 
atomizing air pressure, and the solution flow rate all affect the size of the droplets as they 
leave the nozzle [36]. Rather than to monitor these parameters only to ensure that they remain 
within specified bounds, companies should record parameter values for incorporation into a 
modeling effort. 
 
In terms of a control strategy, the best process variables to monitor are the size and moisture 
content of the droplets just before they reach the bed of tablets. While no specific 
technologies have been identified that are intended for this specific task, it may be worth the 
company’s time to discuss with NIR vendors the possibility of using reflectance NIR to 
monitor the moisture content and mean particle size of the falling droplets. The specific 
situation of a disperse field of falling liquid droplets does not appear in the literature, but in 
principle, water content and mean particle size are both quantities people have claimed to 
measure with reflectance NIR spectroscopy [37]. 
 
In terms of quality control, a more direct measurement of tablet coating quality is needed. To 
determine coating thickness, reflectance NIR spectroscopy appears to be the only viable on-
line analytical technique [38-40]. Much like content uniformity and hardness testing, this will 
require tight control on the orientation of the tablet.  
 
2.5.7. Packaging 
 
Potential failures in the packaging line are identified below: 
• Broken tablets in the feed. 
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• Incorrect tablet in the feed. 
• Pin holes or cracks in the packaging foil. 
• Missing or surplus of tablets in a blister. 
• Misalignment of the packaging foil.  
• Leakage of sealed blisters. 
• Impurities in the blister pack. 
• Incorrect printing on the blister foil lid. 
• Missing leaflet. 
• Missing or surplus of blister layers in the box. 
• Incorrect printing on the carton box. 
 
VisioTec is proposing a strict step-by-step control on the packaging line to avoid errors 
caused in any packaging step.  According to their proposal, non-transparent forming 
materials can be inspected by the VisioScan system.  The correct size, color, shape, position, 
and drug content of the product can be checked by the VisioNIR system.  The misalignment 
of the foil lid and the printing errors can be picked up by the VisioRead HR system.  The 
impurities in the blister pack can be detected by the VisioChrom HR system.  The 
VisioCount system can check that there are the correct number of blister layers and the 
existence of a leaflet in a closed carton box.  VisioTec also recently introduced their new 
system which is able to detect blister leakage online during packaging.   
 
2.5.8. Wet granulation 
 
The wet granulation step does not appear in the Product X process, but it is an important step 
in the production of most solid dosage forms, so it is being presented out of order here. 
Within the wet granulation step, there are three key variables that should be priorities for 
monitoring; the extent of mixing during the wet massing stage, the moisture content of the 
powder during the drying phase, and the final particle size distribution (PSD) of the granulate 
produced. The online measurement of PSD is reviewed in sections 2.5.1 and 2.5.3, so that 
analysis will not be repeated in this section. 
 
2.5.8.1.Wet massing 
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In the wetting step, the individual particles are agglomerated into larger particles by the 
formation of liquid bridges connecting the particles. It is the key that the wet massing step be 
ended at the correct time. Faure et al. write: 
 
 “In high-shear granulation, the fast dispersion of the binder is 
taken for granted. The spraying conditions are therefore not critical. The 
coalescence into granules is mainly affected by the mixing conditions and 
the proportion of liquid used [41].” 
 
 “The principle difficulty with wet granulation in high-shear mixers 
is to decide ‘when to stop’: hence, the importance of control of the end-
point [41].” 
 
 
Presented below is a diagram of the stages of agglomeration experienced by a powder as 
more binder liquid is incorporated into the agglomerates. The transition between states is not 
strictly linear. The formation of liquid bridges between agglomerates often begins before the 
transition between the funicular and capillary states has been completed. The phase behavior 
of the moist powder is governed by the amount of water present as well as the energy 
imparted to the mixture by the agitator. As a rule, in the production of solid dosage forms, the 
quantity of water to be added to the powder during the wet granulation stage is fixed during 
the development stage. As a result of this, the key parameter which must be controlled during 
the process is the length of time over which agitation occurs, or “when to stop”. 
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Figure 8: Stages of wet agglomeration from Goldszal and Bousquet [42]. 
 
The most widely studied method for determining the end-point for the wet massing step is to 
monitor the power consumption of the agitator motor. The method was first proposed in 1979 
by Bier et al. [43], but it is by no means a mature technique. Research on the analysis of 
power consumption profiles during the wet massing stage of wet granulation continues at 
present [44].  
 
While the power consumption profile varies significantly with equipment model and with the 
specific particle properties of the powder to be agglomerated, most powder mixtures exhibit 
several distinct regions of power consumption. These can be related to the various stages of 
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agglomeration described above. Empirical modeling will be required to determine the 
correlation between wet massing and the power consumption curve for each drug formulation 
[42]. 
 
Several other methods have been studied for determining the endpoint of the wet massing 
step. Closely related to monitoring power consumption is the method of monitoring the 
viscosity of the mixture with a torque rheometer [41]. Other researchers have investigated the 
use of vibration probe to determine the level of densification of particles. Finally, a number 
of techniques have been proposed to monitor the moisture level of the powder including NIR, 
capacitance sensors, and conductivity probes [41].  
 
Power consumption monitoring is presented as the preferred method for controlling the wet 
massing step. None of the alternate methods mentioned above have been shown to be 
superior to the more mature technology of power consumption measurement [44].  
 
2.5.8.2.Wet granulation: Drying 
 
During the drying phase of the wet granulation process, the water which served to 
agglomerate the particles in the wet massing stage is driven off, resulting in particles which 
are larger than the original powder. The key parameters that control the drying process are 
inlet air temperature, and the drying time [4, 45]. The air temperature is generally set just 
below the melting point of the lowest melting material in the powder mix, normally not 
below 50 – 60°C. The current practice is to dry for a set time then test the granulate moisture 
content off-line by Loss on Drying (LOD), at which point the material is dried further if 
necessary. In the case that the powder is over-dried, the entire step may be repeated.  
 
There are two drying regimes that occur during the process, which are rate limited by 
different phenomena. In the first drying stage, water is driven off by the heat introduced with 
the air. During this stage, the drying is evaporation-limited. The air generally leaves the fluid 
bed at a relatively constant temperature throughout this stage. Eventually, all the readily 
available water is driven off, at which point the drying becomes diffusion limited. As the 
evaporation rate drops off, the exit temperature of the air increases markedly, approaching the 
entry temperature [4]. 
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Historically, fluid bed drying has been monitored using temperature probes to measure the air 
temperature at both the inlet and outlet. At the transition point between the two drying stages, 
a sharp increase in the outlet air temperature signals the end of evaporative drying. The 
moisture level can then be correlated to the exit air temperature as it approaches the inlet air 
temperature. Unfortunately, this method is limited in its accuracy [4]. Diffuse reflectance 
NIR spectroscopy represents an alternative non-intrusive online analytical tool for monitoring 
the progress of the drying step [5].  NIR is attractive as an analytical technique for moisture 
measurement for a number of reasons.  First, NIR measures the overtones and combinations 
of vibrational modes for bonds involving hydrogen.  As opposed to IR spectroscopy, the 
lower absorptivities of the NIR radiation allows spectra to be taken without any sample 
preparation.  Coupled with the fact that glass does not absorb NIR radiation, the method is 
ideally suited to serve as an on-line monitoring tool. 
 
The absorption spectrum of water shows strong absorption bands near 1940 nm and 1450 nm. 
Commercial NIR systems generally use these two peaks, as well as other reference 
wavelengths that are less affected by the presence of water, to quantify the level of moisture 
in the fluid bed [1]. 
 
NIR monitoring of moisture has the potential to replace the current process control method, 
which is to subject the dried granulate to a loss on drying (LOD) test in an off-line laboratory. 
In addition to saving processing time and laboratory costs, on-line monitoring will eliminate 
the need for remunerative steps to be taken when the granulate is either too wet or too dry, 
both of which contribute to uncertainty concerning the final condition of the granulate 
product. 
 
As a final point to be considered, the tight control on the drying process made possible by 
NIR opens the door to time-saving techniques which would be too risky to implement using 
the traditional control methods.  The drying step can be sped up by increasing the inlet air 
temperature, which speeds up evaporative drying.  Air temperature is limited by the lowest 
melting point among the substances that make up the powder mixture.  For drug substances 
with low melting points, this limitation can lead to significant drying times.  During the 
evaporative portion of the drying step, the phase change of the water absorbs energy as fast 
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as the air can supply it.  As a result, the granules never “see” the inlet air temperature until 
evaporation rate becomes diffusion-limited.  Recent research has shown that the inlet air can 
be supplied well in excess of the melting temperature during the evaporative region without 
any ill-effects on the granules, as long as the temperature is reduced before the system 
crosses over into the diffusion regime.  In this way, drying times can be cut by as much as 
50%. Using NIR spectroscopy, it is possible to accurately monitor the moisture content and 
thus predict the transition point, making this time-saving method possible without the risk of 
exceeding the material melting point [4]. 
 
2.6. PAT methods to replace current quality assurance testing 
 
Current Quality Assurance/Quality Control (QA/QC) testing of Product X tablets takes 12-15 
days.  If an investigation is required, an additional 3 days or more may be required.  The 
average batch time for Product X production is 70 days, from the weighing of materials at 
dispensation until the final product leaves the company.  One of the goals of PAT and this 
project was to reduce the holding time for laboratory testing of samples.  This testing holds 
up the production process and requires products to be held after production is completed.  
The remainder of this section will detail what QA/QC testing is currently done and how the 
proposed PAT strategy can eliminate many of the laboratory tests with on-line or at-line 
measurements.   
 
The PAT strategy encompasses two types of approaches to eliminating end product testing.  
The first is to replace a measurement currently made in the lab with one that can be done in-
line or at-line by an automated process.  The second approach involves correlating process 
characteristics to final product characteristics, which will not be possible until the process is 
better understood and monitored.  Table 1 is a summary of the quality tests currently 
performed during solid tablet manufacturing and how they will be replaced in the proposed 
PAT strategy. 
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Measurement Current Method Proposed Method
Cores Aspect IPC Lab IPC Lab
Thickness IPC Lab - Checkmaster At-Line Checkmaster
Hardness Compression Test NIR
Friability Tumble Tablets Correlation from Controlled Process
Disintegration Rate At-Line Checkmaster Correlation from Controlled Process
Average Mass At-Line Checkmaster At-Line Checkmaster
Content Uniformity HPLC NIR
Assay SD of Content Uniformity SD of Content Uniformity
Tablets Appearance IPC Lab IPC Lab
Aspect IPC Lab IPC Lab
Shape IPC Lab IPC Lab
Code IPC Lab IPC Lab
Dimensions IPC Lab Checkmaster
NIR - Coating Thickness, At-Line 
Check Master
Disintegration Rate Time to Dissintegrate Tablet Correlation from Controlled Process
Average Mass IPC Lab Checkmaster At-Line Checkmaster
Humidity Loss on Drying NIR
Identity TLC & HPLC NIR
Degradation Products HPLC NIR (?)
Dissolution Rate Time to Dissolve AI Correlation from Controlled Process
Packaging Package Integrity Blue Liquid Test At-Line Package Monitoring
Dates QA Lab At-Line Package Monitoring
Table 2: Quality assurance tests. 
 
2.6.1. Quality assurance of core tablets 
 
2.6.1.1.Aspect 
 
Tablet cores are analyzed in the In-Process Control (IPC) laboratory to evaluate the quality of 
the tablet by visual inspection.   The analysis insures that tablets are smooth, have the 
specified shape of the product, and are blemish free and intact.  This analysis will continue to 
be performed by IPC laboratory personnel or operators within the PAT strategy because it is 
not time-consuming, and much more difficult to accomplish automatically.   
 
2.6.1.2.Thickness 
 
Certain tablet dimensions are currently measured by the Checkmaster in the IPC laboratory.  
The Checkmaster is an at-line piece of analytical equipment that can measure mass, hardness 
and tablet dimensions.   There are Checkmasters attached to the rotary press for at-line testing 
and in the IPC lab.   The only measurement that is done at-line is the tablet mass.  It is 
recommended that the PAT strategy make full use of the Checkmaster’s capabilities and 
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perform the measurements of all dimensions of the tablet core at-line, on a portion of tablet 
cores, as they exit the rotary press. 
 
2.6.1.3.Hardness 
 
Tablet hardness is currently measured by a compression test in the IPC lab.  A tablet is 
compressed between two metal plates until it is crushed and the force required to crush the 
tablet is measured.  Drawbacks of this method are that it is destructive to the tablets and 
requires an operator to take the measurements. The PAT strategy will replace the current 
testing method with a DR-NIR measurement on selected tablets after they have exited the 
tableting machine.   
 
2.6.1.4.Friability 
 
Tablet friability is measured in the IPC lab by tumbling tablets for 20 minutes.  This 
measurement determines tablet brittleness.  There is a specified amount of weight that the 
tablets can lose during the test.   In the PAT strategy, friability will be predicted based on 
correlations with other process parameters such as granulation compression force, tableting 
compression force and tablet hardness.   
 
2.6.1.5.Disintegration time 
 
The disintegration time of a tablet is measured in the IPC lab by determining the amount of 
time that the tablet takes to break up in an aqueous environment.  A given drug formulation 
has a specified time over which the tablet should break up in order to make the drug available 
to the patient.  The disintegration time depends on the tablet hardness and the distribution of 
excipients throughout the tablet.   Certain excipients expand when contacted with water to 
break up the tablet.   In the PAT strategy the disintegration time will have to be predicted 
from the correlation of several process variables such as tablet hardness and distribution of 
the excipients throughout the tablet.  Further study will be required to determine the exact 
relationship between tablet hardness and excipient distribution that predicts tablet 
disintegration time. 
 
 48
2.6.1.6.Average mass 
 
The mass of 20 tablet cores (approximately 0.05%) exiting the rotary press are measured at-
line by the Checkmaster through an automatic sampling mechanism at 10 different time 
points throughout the tableting process for feedback control to the tableter.  The tablet mass 
is determined for a second time in the IPC lab using the Checkmaster.  This at-line mass 
measurement made by the Checkmaster will be utilized in the PAT strategy without repeating 
the test in the IPC lab. 
 
2.6.1.7.Content uniformity of the drug substance 
 
The content uniformity of tablets is currently measured by selecting ten tablets or cores, 
produced throughout the tableting process, to test the amount of active drug substance in each 
by HPLC in the QA lab.  HPLC is a very accurate method, but it is a time consuming test to 
perform and it is destructive to the tablet.  The PAT strategy will replace HPLC testing of 
content uniformity with a DR-NIR measurement of the powder flowing into the tableter or a 
T-NIR measurement on selected tablets as they exit the rotary press. 
 
2.6.1.8.Assay 
 
The average amount of active drug substance is measured in several tablets by averaging the 
content uniformity results.  This procedure will be continued within the PAT strategy. 
 
2.6.2. Film coated tablets 
2.6.2.1.Appearance 
 
The appearance of film coated tablets is analyzed to ensure that the tablets have been coated 
with the appropriate color coating solution.  This test will continue to be performed by IPC 
lab personnel or operators within the PAT strategy. 
 
2.6.2.2.Aspect 
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The aspect of film coated tablets are analyzed by IPC lab personnel to ensure that the tablets 
have been fully coated, the tablet is free of particles or blemishes, that the tablets have 
remained intact, that the tablet coating is intact, and that the coating is smooth.   This is a 
procedure that will continue to be done by IPC lab personnel or operators after the film 
coating process in the PAT strategy. 
 
2.6.2.3.Shape 
 
The tablet shape is assessed after the tablets have been film-coated by IPC laboratory 
personnel.   This test is done to ensure that the tablets were formed using the correct die.  
This is a procedure that will continue to be done by IPC lab personnel after the film-coating 
process in the PAT strategy. 
 
2.6.2.4.Code 
 
The drug type is imprinted into the tablet during the tableting step.  IPC laboratory personnel 
visually inspect the tablet to ensure that the proper code has been imprinted.  This is a 
procedure that will continue to be done by IPC lab personnel after the film coating process in 
the PAT strategy. 
 
2.6.2.5.Dimensions 
 
The film coated tablet dimensions are measured in the IPC laboratory by the Checkmaster.   
This measurement is done to analyze the thickness of the film coating and check that the 
tablet has the proper dimensions.   The PAT strategy will change this current method of 
testing so that the coating thickness, of a fraction of tablets, is measured by diffuse 
reflectance NIR and the film-coated tablet dimensions are measured by a Checkmaster in the 
coating area or within the IPC lab. 
 
2.6.2.6.Disintegration time 
 
The disintegration time of film coated tablets is measured using the same method as 
described above, for tablet cores, in the IPC laboratory.  The PAT strategy will involve a 
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correlation of process parameters to disintegration time to determine if the tablet will meet 
the FDA specifications.  
 
2.6.2.7.Average mass 
 
The average mass of the film-coated tablets is measured in the IPC lab using the 
Checkmaster.   The PAT strategy proposes that this measurement be done at-line as the 
tablets are being transferred out of the coating vessel by the Checkmaster. 
 
2.6.2.8.Moisture content (Loss on Drying) 
 
The water content of film-coated tablets is measured in the IPC laboratory by a loss-on-
drying (LOD) test.  This test is performed to measure the amount of water that the tablet 
absorbed during the film coating process as water can be detrimental to tablet stability.  The 
PAT strategy will measure the water content of film coated tablets using DR-NIR 
spectroscopy at the same time coating thickness measurements are taken  
 
2.6.2.9.Identity 
 
The identity of the drug substance is currently determined by two different methods in the 
QA lab, TLC (thin layer chromatography) and HPLC.  DR-NIR spectroscopy will be used in 
the PAT strategy to confirm the identity of the drug substance. 
 
2.6.2.10. Degradation products 
 
The concentration of drug substance degradation products are currently measured in the QA 
lab by HPLC.  The FDA has set specifications on the levels of the different degradation 
products that can be contained in the final tablet. NIR may be used in the PAT strategy to 
measure the amount of degradation products in film coated tablets, but it is very doubtful that 
NIR has the sensitivity to differentiate degradation products from the active drug substance.  
An alternative option after the PAT strategy has been implemented is to correlate processing 
conditions to degradation of drug substance. 
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2.6.2.11. Dissolution time 
 
The dissolution time of drug substance is measured by placing six tablets in a stirred tank at 
physiological pH and checking to ensure that a desired amount of drug substance has been 
solubilized in a given amount of time.  The concentration of drug substance is measured by 
HPLC.  The dissolution time should be able to be predicted after the implementation of PAT 
as more information about the process is known and variables that effect dissolution time are 
measured such as content uniformity and tablet hardness.   
 
2.6.3. Packaging 
2.6.3.1.Package integrity 
 
The tablet packaging integrity is currently tested at-line by immersing that package in blue 
liquid.  The package passes if no blue liquid is seen with in the package blisters.   The PAT 
strategy would like to replace the off-line blue ink test with an on-line leakage test to detect 
problems in the packaging, like the newly offered VisioLeak from VisioTec. 
 
2.6.3.2.Expiration date verification 
 
The expiration date on the tablet packaging is verified by the QA lab.  The PAT strategy 
proposes to include on-line video system for print verification in the packaging line to ensure 
the correct expiration date was printed on the package. 
 
2.7. Recommended changes in development process 
 
The philosophy of PAT needs to be integrated into the drug development process.  In the 
future, the PAT strategy needs to be in place by the time drug manufacturing begins so that it 
is a part of the initially validated process.   The PAT philosophy requires that a deeper 
understanding of the process needs to be achieved [46].  There is an opportunity to develop 
this greater understanding during the development process through the experiments that are 
performed to determine the formulation and operating parameters.  Development needs to be 
steered towards determining cause and effect relationships, determining critical variables, 
always performing physical characterization of materials used, and in doing so will avoid 
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process problems [47].  Current development methods are empirical and operating parameters 
are determined by trial and error until they result in tablets that fall within specification.   
PAT requires that the process is understood, more mechanistically, and this requires that a 
scientific approach be taken to process development.   
 
One aspect of this ultimate goal is gaining a deeper understanding of the operation of each 
process step in the solid tableting line.  Each unit operation needs to first be studied in 
general terms and then with respect to each material that is processed.  Only when the unit 
operations are fully understood, especially with respect to the role of each parameter, can the 
critical process variables be determined.   
 
Steps that should be taken in the beginning of the drug development process are to first 
understand the material properties of the drug substance.  The dominant mixing mechanism, 
and consequently the overall performance of the blender, depends greatly upon the physical 
properties of the mixing materials, the type of geometry of the blender as well as the 
operation conditions [24].  Additionally, only when the final blend has desirable flow 
characteristics are uniform mass and content possible in the final tablets.  Useful properties to 
know include flowability, moisture absorption isotherms, and particle size distribution.  Other 
useful informations that should be determined during development are the desired particle 
size distribution of the final blend and the real relationship between dissolution and hardness. 
 
At first the development process may take longer while the critical variables are determined 
for each unit operation as it is specific to each product.  In time, a large scientific knowledge 
base of how particular properties affect the granulation and tableting process will be amassed.  
Therefore, in the future, the development process will be faster as fewer tests are needed to 
determine operating conditions because they will instead be set by previously documented 
scientific understanding.     
 
2.8. Conclusions 
 
There has been developed a PAT strategy to monitor the Product X tableting process that is 
general to the solid tablet manufacturing process.   The critical variables were determined 
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based on scientific understanding of each unit operation.   In summary the critical variables 
are as follows. 
 
• The particle size distribution of the granulate leaving the sieve, that follows the roller 
compaction process, can be measured.  The measurements will be taken by an on-line 
laser diffraction particle size analyzer. 
 
• Blend homogeneity is the critical variable in all three blending steps.  DR-NIR can be 
used to monitor the blending process and to determine the process end point.  In the 
blending step before granulation the moisture content can also be measured by DR-
NIR because it is critical in roller compaction. 
 
• The content uniformity and hardness of the tablets can be measured at the tableting 
machine.  Content uniformity will be measured either by analyzing the powder 
entering the tableting machine or of the tablets that exit the tableting machine by NIR 
spectroscopy.   Tablet hardness will be measured at-line by DR- NIR. 
 
• The critical process variable for coating is the droplet size distribution of the coating 
solution prior to contacting the tablets.  The critical product variables of the tablet are 
coating thickness and tablet moisture content.  The tablet’s coating thickness and 
moisture content can be measured by DR-NIR. 
 
• Moisture content, material identity and the particle size distribution of the raw 
materials needs to be determined in dispensation.  The moisture content and material 
identity can be measured by DR-NIR.  The particle size distribution can be measured 
by laser light scattering. 
 
• The critical attributes to monitor in the packaging line are identity and packaging 
integrity.   Product identity measurements can be determined by NIR. 
 
• PAT has the potential to reduce manufacturing times significantly for Product X as 
well as other products.  Due to the reduction of in-process testing delays and 
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elimination of the 12-15 day post-production waiting period there an approximate 
20% reduction in throughput time. 
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2.9. Recommendations after part one 
 
The first PAT technology to be developed should be the one that is the fastest and cheapest 
so that the success of PAT can be established.  A first success will demonstrate the benefits 
of PAT and pave the way for the implementation of more PAT technologies.  The priority of 
each PAT technology implementation will need to be evaluated based on the benefit and cost 
of implementation.    
 
Therefore, the next step to take with this project is to determine the cost associated with 
implementation of each technique.  The implementation cost will be a function of the cost of 
the equipment, labor costs of setting up the equipment and amount of production time that is 
lost as a result.   The benefit will be a function of the time saved on quality assurance and 
quality control testing, the increased process efficiency, and the increased process yield due 
to fewer tablets out of specification from better process control.  
 
It is recommended that PAT be implemented at the development level.  PAT requires process 
understanding and quality by design, and process understanding must begin in the 
development phase.  Only when the process is fully understood can an effective PAT strategy 
be defined.      
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2.10. Economic analysis of PAT (part two) 
 
The next step for this project was to critically evaluate and complete the strategy proposed in 
the first part.  Then the cost of PAT implementation, time savings and cost savings were 
evaluated to determine if implementation of PAT is economically advantageous for 
pharmaceutical companies.   
 
2.10.1. Lean Manufacturing 
 
An accurate economic evaluation requires a good estimate of the base case for the 
manufacturing processes of Product X, Product Y and Product Z.  Therefore it was needed to 
estimate the current production timeline and the projects being planned to improve upon that 
timeline.  ‘Lean Manufacturing’ is currently being implemented in different companies.  
Lean manufacturing aims at reducing the time spent in non-value-added steps during the 
manufacturing process such as waiting times between different unit operations and holding 
times in the warehouse.  The main objectives of Lean Manufacturing can be broadly 
summarized as follows: 
• Increase productivity and capacity 
• Improve customer service 
• Reduce throughput times 
• Reduce inventory hold-ups  
• Reduce problems in manufacturing.  
 Some of the key attributes of the Lean manufacturing thinking for achieving those goals are: 
• All processes should be driven by demand rather than forecast. Coordination between 
Country Pharma Organizations (CPOs), Global Supply Chain Management (GSCM) 
and Pharmaceutical Operations needs to be improved. 
 57
• Business process integration within the manufacturing site involving Supply Chain 
Management (SCM), production, and QA/QC needs to be improved to reduce time 
delays. This integration is illustrated in figure 9. 
• Organization should be aligned and focused to satisfy the customer.  
CPOs
Pharm OpsGSCM
Shipping Warehouse
ProductionSCM QA/QC
 
Figure 9: Business process integration in Lean manufacturing. 
 
• Processes should be well defined and well documented.  Processes should be linked 
together in a continuous flow so that production moves forward via downstream 
signals. 
• Inventory hold-ups should be reduced considerably. The essence of lean 
manufacturing is to have an efficient and optimized manufacturing process that 
produces rapidly on-demand rather than have large inventory hold-ups to prevent 
stock-out risks.   
• Problems should not be allowed to linger unresolved and should not be passed 
downstream.  This leads to further increases in throughput time and inventory hold-
ups.  
Lean manufacturing projects have yielded positive results. Lean manufacturing is currently in 
the planning stages at the site in question and is expected to be implemented for some 
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important products later this year. Based on this information, it was decided that for the 
economic analysis of PAT, it will be assumed that lean manufacturing has been implemented 
in.  Cost and time benefits of implementing PAT on a lean manufacturing process were 
determined.  Details about current processing times and lean targets are presented in section 
2.13. 
2.11. Objectives 
The objective of this project was to weigh the costs and benefits of employing a process 
analytical technology (PAT) strategy at a pharmaceutical production facility.  The evaluation 
studied the use of PAT to monitor solid tablet formulations made by both wet and dry 
granulation, focusing on Product X, Product Y, and Product Z.  To meet the objective of PAT 
economic analysis, several sub-objectives were established: 
 
1. Continuation of the first part to verify critical variable lists and PAT methods to 
control them, selecting certain products as examples.  These products are expected to 
be the focus for the first implementation of PAT.   
 
2. Identification of parts of the process that offer the greatest potential for time and cost 
savings by implementation of PAT. 
 
3. Proposal of preliminary PAT process designs, with modified process flow diagrams 
(PFD), as well as process and instrumentation diagrams (P&ID). 
 
4. Determination of the times associated with each processing step, to allow for the 
determination of where PAT will aid in reduction of overall batch time. 
 
5. Identification of costs associated with production of one batch, for both the current 
situation and after the installation of PAT.  These costs include those incurred by 
capital equipment as well as operating expenses. 
 
6. Comparison of the current and proposed designs using total batch costs, as well as 
savings gained by reducing delays from QA/QC and investigations. 
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7. Performance of a sensitivity analysis to determine which production costs have the 
greatest impact on the economic benefits of PAT. 
 
Lean manufacturing throughput time was chosen as the base case for batch evaluation instead 
of the current throughput time.   This decision was reached because during 2004 lean 
manufacturing will be implemented at the site for Product X, Product Y and Product Z.   
Additionally, PAT will only be implemented on lean manufacturing processes where the time 
savings of eliminating laboratory tests will have the greatest impact.  
 
2.12. Method of approach 
 
To approach the project objectives, the costs and timing of the current process were 
calculated or estimated from records at the site.  In addition, records from investigations 
identified process areas that would benefit the most from PAT.  An iterative approach was 
attempted to acquire the data needed for the cost-benefit analysis.  General process data were 
requested, analyzed, and used to form preliminary conclusions.  From these conclusions, key 
areas of the process were identified and more detailed information was requested.  With more 
in depth information, final, definitive, conclusions were formed on the cost-benefit analysis 
of PAT implementation.  The modified process flow diagrams and P&IDs were proposed, 
and the design’s economics were calculated.  The project focused on the manufacturing 
process from dispensation to the release of the product by quality assurance.  The packaging 
line was not considered as the time spent after QA release depends solely on purchase orders 
received for the product and cannot be influenced by PAT. 
 
The calculation strategy assumes that PAT will be implemented in three stages.  Phase I will 
be the installation of on-line analytical equipment with computer archiving of data and 
multivariate data analysis (MVDA).  “Quick wins” for Phase I of PAT implementation, 
which were benefits that were included in the economic analysis in the first years after 
implementation, are as follows: 
• Faster release of products will be possible after installation of analytical equipment 
and correlation development because tests previously done in the QC and IPC labs 
will be replaced by tests performed during processing.    
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•  QC time and cost will be greatly reduced because most tests previously done in these 
labs will be performed during processing. 
 
 
• Investigations time will be reduced due to easier access to process data provided by 
electronic records.  MVDA will also aid in identifying the root cause of an 
investigation. 
 
•  Inventory levels will be reduced due to shorter throughput times associated with the 
reduction in QC testing.   
 
The FDA has stated that they will approve a process for real time release when on-line 
analytical measurements are shown to be equivalent to current laboratory testing.  A 
company must demonstrate that each on-line test is an alternative analytical procedure and 
real time release will occur when equivalence for all laboratory testing has been 
demonstrated for every test.  Before real time release can be realized testing that is to be 
replaced by correlations with other measured variables will have to be developed. 
 
The combined process analytical measurements and other test data 
gathered during the manufacturing process can serve the basis for real 
time release of the final product and would demonstrate that each 
batch conforms to established regulatory quality attributes. 
FDA Guideline 
PAT-A framework for Innovative 
Pharmaceutical Manufacturing 
and Quality Assurance 
 
ICH (International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use) is a group that represents the 
regulatory agencies of the US, Europe and Japan and pharmaceutical companies 
and is currently in the process of drafting a guideline to support PAT.  This 
indicates that European regulatory agencies are likely to support PAT initiatives 
of pharmaceutical companies.    
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Phase II of PAT implementation involves the installation of process control systems for each 
critical variable and will have the following midterm benefits: 
• Visual batch sorting will be reduced because control systems will correct problems 
as they occur resulting in only the production of tablets with the desired level of 
quality. 
 
• IPC lab costs for PAT products will be completely eliminated due to on-line 
analytical tests and correlations that have been developed. 
 
• Production yields for each batch will be increased as the control systems will 
carefully steer the process to its desired end point eliminating material losses. 
 
• The number of batch rejections will be reduced as processing problems will be 
corrected as they occur. 
 
• The FDA has stated that there will be fewer audits of PAT processes.  The FDA 
believes that a PAT-approved process is being continually monitored by the 
company and does not need as much regulatory intervention. 
 
• Inventory levels will be further reduced after implementation of control systems 
because the process will be more stable and have a lower associated risk of failed 
batches. 
 
Phase III of PAT implementation involves integration of PAT in the development phase of 
new products.  Integration of PAT into the development phase involves costs associated with 
increasing the understanding of each unit operation in solid tablet manufacturing and 
determining the critical variables associated with each unit operation for a particular product 
during development.  These long term benefits and costs were not addressed in this project as 
the focus was only on products currently on the market.  The benefits associated with PAT 
implementation in development are as follows: 
• The time and cost associated with the process development of solid tablets will be 
reduced when there is a deeper understanding of each process step.  However there 
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will need to be a significant effort within development to first acquire a deeper 
understanding of process steps. 
• Increased understanding of solid tablet unit operations will allow for the best 
formulations and process to be applied to a particular product.  This approach to 
process development addresses a major goal of PAT which is quality by design 
 
2.13. The site’s production data 
2.13.1. Process flow diagram 
 
Throughput time for a batch is defined as the duration of time from dispensation until QA 
release of the batch.  The scope of this project does not include looking into time durations or 
delays from the release of raw material by QA to dispensation and from packaging to 
shipping. The flow diagram for this process is shown in figure 10. 
 
2.13.2. Current manufacturing times 
 
From figure 11, it can be observed that the total time of value adding steps in the process is a 
very small portion of the throughput time. There are a lot of waiting steps in the current 
process where there is no value addition, which leads to losses due to the financial cost of 
inventory. In the current manufacturing scenario, after coating, the product waits five weeks 
in the warehouse for packaging orders. The QC analytical testing is time consuming, around 
three weeks, but since it is done during the waiting time period it is not currently a bottleneck 
 
2.13.3. Implementation of lean manufacturing 
 
As mentioned in section 2.10.1, planning has begun for lean manufacturing in the site and is 
expected to be implemented soon.  The target throughput time for lean manufactured 
products is projected to be around 20 days and the average throughput time for all solid tablet 
products in the site is expected to be around 35 days. Hence, 
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Figure 10: Process flow diagram for solid tablet manufacturing 
 
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58
Current
LEAN
5
20
2
Mfg Que &store Package QC Batch ReleaseDispense
9 30 3
~ 20 days
~ 50 days
 
Figure 11: Current manufacturing and waiting time. 
 
this project will use 20 days as the baseline throughput time for making cost and time benefit 
analyses. After implementation of lean manufacturing, QC analysis is expected to become a 
bottleneck, due to the long time required for analysis and resource constraints in QC.  PAT 
 64
will prove to be most beneficial in lean manufacturing processes. According to estimates 
from, after implementation of lean, PAT can further help to reduce throughput time by five 
days by replacing QC testing.  This five day reduction will result in savings of the financial 
cost of bulk product in the warehouse due to faster QA release of the batch.     
 
2.14. Batch costs 
 
The following section summarizes the production costs for batches of Product X, Product Y 
and Product Z.   
The active ingredient cost was on average 85% of the ideal Product X batch cost.  An ideal 
batch is one in which there were no manufacturing problems or investigations.  The cost 
breakdown of an average, ideal Product X batch, excluding the cost of active ingredient is 
shown in figure 12, below: 
 
Exipients
CHF 1,840 
Overhead
CHF 5,400 
Total Direct Labor
 CHF 3,820 
Total Equipment 
Cost
 CHF 2,360 
Analytical and 
Compliance
 CHF 2,010 
Material Handling
 CHF 1,580 
 
Figure 12: Cost breakdown, excluding active ingredient for an ideal product X batch. 
 
For Product Z, the production costs were acquired.  The cost breakdown is shown below. 
 
The active ingredient cost is 88% of the average ideal Product Z batch cost.  The production 
price per batch, excluding the cost of the active ingredient, is shown in figure 13, below: 
 65
           
Exipients
 CHF 1,410 
Overhead
CHF 4,240 
Total Direct Labor
 CHF 4,240 
Total Equipment 
Cost
 CHF 2,011 
Analytical and 
Compliance
 CHF 2,135 
Material Handling
 CHF 1,556 
 
Figure 13: Cost breakdown, excluding active ingredient for an ideal product Z batch. 
 
There is only one formulation of Product Y produced.  With only one set of production cost 
no average was used to assess the cost of a Product Y batch.    
 
The active ingredient cost is 75.6% of the average ideal cost of a Product Y batch.  Other 
(non-active ingredient) costs are compared in figure 14. 
Exipients
CHF 3,522 
Overhead
CHF 5,721 
Total Direct Labor
 CHF 4,646 
Total Equipment 
Cost
 CHF 2,688 
Analytical and 
Compliance
 CHF 2,379 
Material Handling
 CHF 3,761 
 
Figure 14: Cost breakdown, excluding active ingredient for an ideal product Y batch. 
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2.15. The site’s compliance data 
2.15.1. Standard testing 
2.15.1.1. QC data 
 
The following data from the Quality Control (QC) department were provided for the purposes 
of quantifying the time and cost of standard testing and QC investigations.  Table 3 contains 
an overview of the total testing and investigations in one year for each of the three products 
evaluated. 
 
  Product X Product Z Product Y 
Analysis time (minutes) per Batch 510 440 550 
Number of Batches Analyzed 752 634 533 
Human Resources Needed (FTE) 3.6 2.6 2.8 
Number of Out-Of-Spec. Due to Product Failure 1 0 0 
Time for QC Investigation (hours) 1 0 0 
Number of Out-Of-Spec. Due to Analytical Error 1 5 2 
Time for QC Investigation (hours) 2 158 7 
Table 3: Quality control analytical testing and investigations. 
 
Table 4 is a summary of the equipment used by the QC department, the number in use, the 
equipment life and the annual depreciated value. 
 
Type of Equipment 
Cost of new 
equipment [CHF] 
Numbe
r in use 
Life 
(yrs) 
Depreciated 
value/year 
HPLC 65000 22 10 143000 
Dissolution Tester 17000 9 15 10200 
Balance  15000 9 12 11250 
Shaking Machine  4000 25 7 14285 
Ultrasonic Bath  8000 3 10 2400 
UV Spectrophotometer 40000 3 10 12000 
IR Spectrophotometer 55000 1 20 2750 
Halogen Dryer 12000 2 10 2400 
Potentiometric Titration  20000 1 10 2000 
Table 4: Quality control equipment list 
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2.15.1.2. IPC lab data 
 
The following data for the IPC lab tests and testing times summarized and is shown in the 
table below 
 
Test no. of Tablets Testing time (min) 
After Tableting     
Aspect     
Thickness 10 5 
Hardness 10 
Average weight 20 
Std. dev. Weight 20 
10 
Friability 20 25 
Disintegration 6 2-10 min 
      
After Coating     
Aspect,shape,code   5 
Length,diameter 1 1 
Width 1 1 
Thickness 10 
Average weight 20 
Std dev weight 20 
10 
Disintegration 6 2-10min 
Loss on drying 10g 10 
Table 5: IPC lab tests and testing time.  
 
The IPC lab has 8 FTE’s (over 3 shifts) working year round.  After the IPC and the QC 
testing, the results are compiled and sent to the QA department.  Batch records are reviewed 
by QA.  If all the test results are within specifications and the batch records conform to the 
regulations, the batch is released by QA.  This takes anywhere between 1-3 days. However, if 
 68
the testing results or batch records do not conform to specification, then an investigation is 
carried out to find the cause of the problem.   
 
2.15.2. Investigations, rejections, resorting and audit data 
2.15.2.1. Investigation data 
 
Investigations can be classified into a number of different categories such as: production 
investigations, QC investigations, QA investigations, and packaging investigations. 
Implementation of PAT will impact production and QC investigations but not necessarily QA 
investigations.  QA investigations might be due to issues that PAT cannot address such as 
human errors in paper batch records. Packaging is not included in the list of the project 
objectives and this report does not analyze packaging investigations.  
The following data for investigations were summarized. 
 
  Product X Product Z Product Y 
Total no. of Investigations 48 35 14 
Production Investigations 29 19 12 
QC Investigations 1 5 2 
Others 18 11 0 
Table 6: Investigation data 
 
The times for QC investigations were provided and were given previously in table 3.  The 
times required for production investigations vary significantly depending on the nature of the 
problem and accurate records are not kept, making it extremely difficult to get accurate 
estimates. After discussion of investigation times with QA it was decided that a production 
investigation lasts an average of 10 days. In extreme cases, the investigation time (and batch 
quarantine time) may extend up to 90 days.  The labor costs associated with investigations 
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was also hard to quantify as investigations are carried out by different people and vary 
considerably in terms of their complexity and man-hours required.  After discussions with 
manufacturing, it was decided to approximate the labor cost for investigations by assuming 
that 2 full-time equivalents (FTEs) of labor (1 FTE in production and 1 FTE in QA) are 
involved full-time in dealing with investigations.  
 
2.15.2.2. Batch rejection data 
The QA department receives investigation reports and then must determine to release or 
reject the entire batch. Batch rejection leads to significant write-off costs and losses. The 
following data on Batch rejections was provided by QA. 
 
Technical 
Defect
12
46%
Human Error
4
15%
Others
3
12%
Weak Point
7
27%
 
Figure 15: Breakdown of batch rejections for all products 
 
Implementation of on-line analytical equipment and installation of programmable logical 
controllers (PLC’s) with feedback control loops is expected to significantly reduce the batch 
rejections due to technical defects, human errors, and weak point rejections.  For the three 
products of interest (Product X, Product Y and Product Z), the following data on batch 
rejections were provided by QA. 
Total batch rejections: 26 
  
 
 
 
Product 
No. of 
rejected 
batches 
Origin of the problem 
Composition of tablet not in accordance with requirements; 
 excess weight of 5.35 kg in one of the compounding steps Product X  
2 
(0.2%) 
Underside of tablet was flat instead of convex due to wrong punch 
      
Aspects of most tablets doesn't comply- rough and porous surface 
Too low hardness and friability of tablet core 
Product Z  
3 
(0.4%) Aspects of most tablets doesn't comply- residue of dust in break  
notch and badly readable embossing 
      
Product Y 0   
Table 7: Batch rejection data for product X, Y and Z during one year. 
 
 
2.15.2.3. Resorting data 
 
The data for resorting Product X, Product Y and Product Z during one year were provided by 
QA and is presented in table 8. 
Currently, resorting is performed manually by two operators sorting out the defected tablets. 
The time spent on resorting varies greatly and depends on what proportion of the batch has 
been affected. The costs for manual resorting were provided by manufacturing.  For a 
resorted batch, it was assumed that 20% of the batch was sorted manually by 2 workers (at 89 
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CHF/h) over 4 days using a sorting machine that costs 7 CHF/h.  The remaining 80% was 
sorted using an automatic sorting machine, over 1.5 days at a rate of 184 CHF/h.  The 
automatic sorting machine requires only one FTE while in use.  
 
Product 
No. of 
resorted 
batches Reasons 
Product X  31  
17 Oversized tablets due rotary press malfunction 
4 Rough surface, white spots  
1 Broken off edges, damaged edges 
1 damaged tablets 
4 damaged edges, rough surface, cavities 
3 damaged edges, cracks, bubbles, bonding surface 
 1 Broken off edges 
   
Product Z  6  
4 broken off edges, pimples, rough surface 
1 cavities, rough surface 
 1 broken off edges 
   
Product Y 1 bonding surface, rough surface 
Table 8: Resorting data for product X, Y and Z during one year. 
 
The implementation of on-line analytical equipment alone is however not expected to 
significantly reduce the number of batches affected by cosmetic defects that need resorting. 
The installation of control systems with feedback control loops along with all the on-line 
analytical tools should significantly decrease the number of batches with cosmetic defects 
and the labor for resorting.  
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2.15.2.4. Audit inspection data 
 
The following data regarding audits and inspections were provided 
 
Year FDA RFS EMEA Others 
1997 3 1 1 0 
1998 4 8 2 1 (Canada) 
1999 0 0 0 2 (Mexico+Bosnia) 
2000 2 2 1 0 
2001 4 0 2 0 
2002 1 1 0 0 
2003 2 2 0 1 (Brazil) 
Total: 41 16 15 6 4 
Table 9: Inspections performed at the site by different regulatory authorities.
 
It is quite difficult to quantify the exact cost of an FDA audit.  This is because an FDA audit 
places additional responsibility on the compliance and production personnel, making it 
difficult to determine an audit’s financial impact.  The number of FTE’s involved and the 
number of man-hours spent on an FDA audit varies from audit to audit.  There were some 
average numbers provided for man-hours for an FDA audit which are presented in table 10.  
 
Task FTEs No. of Days 
Audit Preparation  4 – 5 15-20 
Spy Inspection 20  3 - 4 
Replying and Follow-up  10 – 15  1 - 2 
Table 10: Labor personnel and man-hours required for an FDA autit.
 The numbers in table 9 show that there have been 16 FDA audits in the last 8 yrs 
(approximately 2 FDA audits per year).  The number of FDA audits depends on the FDA’s 
confidence about the process.  The essence of PAT is to develop a basic understanding of the 
process, implement complete control to ensure quality by design and manufacturing right the 
first time.  Hence, implementation of on-line analytical equipment along with control systems 
is expected to increase FDA’s confidence of the company’s manufacturing process and 
quality control, and thereby reduce the number of FDA audits. 
 
2.16. PAT implementation costs 
2.16.1. Overview of PAT strategy 
 
Above the proposed PAT strategy for solid dosage manufacturing was described.  After 
further research and economic evaluations of costs associated with implementing PAT for 
solid tablets, several modifications were made to the proposed PAT strategy. 
 
• Dispensation currently utilizes a computer system to monitor the weighing of raw 
materials for solid tablet production.  A bar coding system is used to identify the 
materials that are received from the warehouse.  The operator is then told by the 
computer the amount of material to be transferred by hand and is only allowed to 
finish when the mass is within +/- 0.5% of the specified amount.  This is the same 
strategy that was proposed in part one to ensure that the proper amount of material 
is added to each batch.  DR-NIR equipment and LLD equipment need to be 
purchased to identify the raw material, determine the moisture content and the 
particle size distribution.   
 
• The content uniformity of tablets, instead of powder flowing into the rotary press, 
will be measured in order to reduce the number of NIR spectrometers that need to 
be purchased and the number of NIR measurements taken.  An NIR spectrometer is 
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to be placed at the exit to the rotary press to sample a portion of tablets to measure 
tablet hardness.  Therefore, with one measurement, and separate data analysis of the 
resulting spectrum, content uniformity and hardness can be determined.  It is desired 
to limit the number of NIR spectrometers as equipment and validation costs are 
high.   
 
• The change in temperature of the fluidized bed throughout drying during wet 
granulation is proposed as the method to control the drying time instead of DR-NIR.  
Descriptions of both types of measurements are in part one. This change is 
suggested because thermocouples are much less expensive than NIR spectrometers.  
The company has prior experience in monitoring the operation of the fluidized bed 
dryer by the change in temperature of the fluidized bed and has found this method 
satisfactory.  There is also no equipment investment required to monitor the change 
in temperature.  Temperature measurements are currently made to guide the 
operation of the fluidized dryers by operators but there is no feedback control 
system implemented at the site. 
 
• The In Process Control (IPC) lab will be eliminated.  Part one report recommended 
that aspect, appearance, shape and code continue to be analyzed by IPC lab 
personnel.  It is now recommended that these tests be performed by operators to 
eliminate all labor costs in the IPC laboratory. 
  
Figures 16, 17 and 18 contain process flow diagrams (PFD) for Product X, Product Y and 
Product Z, respectively.  The PFD's indicate all unit operations involved in the manufacture 
of these products.  The proposed PAT strategy is described by indicating all critical variables 
and the corresponding analytical methods proposed to monitor the critical variables. 
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Figure 16: Product X process flow diagram 
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Figure 17: Product Y process flow diagram 
 
Figure 18: Product Z process flow diagram. 
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2.16.2. Equipment selection and costs 
 
The production of Product X, Product Y and Product Z were analyzed to determine the 
number of analytical instruments required to implement the proposed PAT strategy.   The 
results are summarized in table 11.  
   
• Dispensation requires a total of 3 NIR spectrometers and 3 LLD systems one for each 
of the three dispensation booths used for the dispensing of solid tablet raw materials.   
 
• One NIR spectrometer is required for the blender that is used by all solid tablet 
products.  NIR probes must be attached to the container to monitor blending.   The 
Bruker Optics Matrix-I NIR spectrometer can be adapted for use with a tumbling 
blender with wired probes.  Bruker is currently developing an NIR system for 
blending that will involve wireless probes and it is expected to be on the market in 3-6 
months.  It is recommended that companies look into using a wireless NIR system for 
monitoring blending.   The equipment quote obtained from Bruker (See References) 
for blending is for the Matrix-I instrument and would be an aggressive estimate for 
the new wireless system.     
 
• A total of 11 tandem NIR units are required.  There is one unit required for each of 
the eight rotary presses and one unit required for each of the three spray coaters that 
are all used in production of the three products of interest.  The tandem NIR units 
have the capability to sample and perform NIR measurements on tablets, a scale to 
measure tablet mass, and the ability to determine tablet dimensions.   
 
• Four on-line LLD particle size analyzers are required for four different sieves used in 
the different granulation processes.   There is one sieve used in Product Y production 
and one sieve used in Product Z production following drying.   There are two 
different Product X granulation rooms and both require an on-line particle size 
analyzer to monitor the particle size distribution of the material exiting the sieve that 
follows the roller compactor.  The particle size analyzer will be placed on-line as the 
materials exit the sieve before entering the powder storage container. 
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• Thermocouples to detect the temperature in the fluidized bed dryer and power 
consumption meters for the high shear wet granulation mixtures do not need to be 
purchased as the equipment is currently equipped with these types of sensors.   
 
The analytical equipment purchased for the unit operations, other than those involved in 
granulation, are shared amongst the three products.  Analytical equipment changes will not 
be required when production process changeovers occur, but instrument cleaning will be 
required.  The cost of PAT equipment attributed to one product is therefore reduced by 
implementing PAT for multiple products simultaneously.  In the future when PAT is 
implemented for other solid tablet products the total equipment cost will be reduced as much 
of the required equipment will already be in place. 
 
Equipment vendors were contacted to determine budgetary cost estimates for PAT 
equipment.    
Individual equipment costs are contained in table 11along with the total equipment cost, 
5.9M CHF, for the implementation of PAT equipment for Product X, Product Y and Product 
Z.  The equipment cost attributed to each product is approximately one third of the total PAT 
equipment cost. 
 
Equipment 
Type Model Vendor Measurements Location
Total 
Number
Unit 
Equipment 
Cost (CHF)
Total 
Equipment 
Cost (CHF)
Reference
NIR MPA Bruker Optics Identity, Moisture Content Dispensation 3 96,000 288,000  Bruker 
NIR Matrix Bruker Optics Blend Homogeneity Blender 1 86,000 86,000  Bruker 
NIR Tandem Bruker Optics
Content Uniformity, 
Hardness, Coating 
Thickness, Moisture 
Content
Tabletting, 
Coating 11 396,000 4,356,000  Bruker 
LLD Helos Sympatec Particle Size Distribution Dispensation 3 160,000 480,000
 
Sympatec 
LLD TWISTER & MYTOS Sympatec Particle Size Distribution Granulation 4 179,000 716,000
 
Sympatec 
5,926,000 Total
 
Table 11: PAT equipment costs. 
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2.16.3. Chemometric development time and cost 
 
Chemometrics must be developed for each type of NIR measurement that is desired and for 
each product.  Chemometrics are data analysis methods to extract the desired information 
from an NIR spectrum.  The development of chemometrics is time consuming and expensive 
process for NIR spectrometers.  The total cost of chemometric development, 1.9M CHF, is 
over 40% of the NIR spectrometer cost, see table 12.    
 
 
Type of Measurement
Material Costs 
(CHF)
Chemometric 
Devlopment Cost 
(CHF) Number of Products Total Cost (CHF) Reference
Identity 0 40'500 1 40'500 Solvias
Moisture Content 0 40'500 3 121'500 Solvias
Blending 0 27'000 3 81'000 Solvias
Content Uniformity 54'000 94'500 2 297'000
 Company 
experience 
Hardness 54'000 94'500 3 445'500
 Company 
experience 
Coating Thickness 54'000 94'500 3 445'500
 Company 
experience 
Tablet Moisture Content 54'000 94'500 3 445'500
 Company 
experience 
1'876'500 Total
Table 12: Chemometric development cost. 
 
Estimates for chemometric development were received from Solvias AG (See References) 
and from a cost estimate that has been proposed for the PAT pilot project currently underway 
at another site, to replace content uniformity measurements by HPLC with DR-NIR.  Solvias 
AG is a company that performs NIR spectrometer qualification and chemometric 
development.  The pilot PAT project will develop chemometrics for content uniformity of 
Product X tablets and therefore this cost is not included.  It was assumed that chemometric 
development for other tablet properties will be similar to that for content uniformity. 
Chemometric development for solid tablet measurements has additional material costs as 
tablets need to be produced that range in the variable of interest.  The additional tablets are 
usually produced by development.  As an example, chemometric development for content 
uniformity tablets must be performed by measuring tablets with 80%, 100%, and 120% of the 
specified amount of drug substance.  It is recommended that chemometric development be 
outsourced to Solvias AG rather than performed by personnel within the companies as there 
is seldom a group within companies that specializes in chemometric development.  Solvias 
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has proposed that chemometric development, qualification, and training could be completed 
within six months.  Calculations were performed assuming that by working on all products 
and all instruments simultaneously, chemometric development and equipment qualification 
could be completed within one year.   
 
2.16.4. Equipment qualification cost 
 
All equipment must be qualified and calibrated before being utilized in production.  NIR 
equipment qualification costs were estimated by discussions with Solvias AG.  The NIR 
instruments must be calibrated for each type of measurement that is to be performed and for 
each product that it will be used to analyze.  The cost to qualify a second instrument for the 
same measurements may be reduced.  Solvias AG recommended that only in certain cases 
will the qualification costs be reduced and therefore it is estimated that the NIR spectrometers 
used in dispensation and blending will each need to be fully qualified.   It was suggested that 
the qualification of additional content uniformity measurements would be reduced to only the 
steps for the execution of the protocol.  Therefore, all tandem NIR qualifications are assumed 
to be reduced for multiple pieces of equipment.  Estimates for the qualification of LLD 
particle analysis systems were received from Sympatec Switzerland.   It is recommended that 
the equipment vendors perform equipment qualification.  The overall cost of equipment 
qualification is about 30% of the cost of the equipment.  Equipment qualification costs are 
contained in table 13 below.     
 
Equipment 
Type Model Vendor Location
Number of 
Measurements
Total 
Number
Number of 
Processes
Initial 
Qualification 
Cost (CHF)
Secondary 
Instrument 
Qualification 
Cost (CHF)
Total 
Qualification Cost 
(CHF)
Reference
NIR MPA Bruker Optics Dispensation 2 3 1 81'000 81'000 243'000  Solvias 
NIR Matrix Bruker Optics Blender 1 1 3 54'000 0 162'000  Solvias 
NIR Tandem Bruker Optics Tabletting 3 8 3 128'000 18'000 762'000
 Company 
experience 
NIR Tandem Bruker Optics Coating 3 3 3 128'000 18'000 492'000
 Company 
experience 
LLD HELOS Sympatec Dispensation 1 3 1 2'700 2'700 8'100  Sympatec 
LLD TWISTER & MYTOS Sympatec Granulation 1 4 1 3'200 3'200 12'800  Sympatec 
1'679'900 Total
 
Table 13: PAT equipment qualification costs. 
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2.16.5. Yearly maintenance costs 
 
The equipment vendors were contacted to determine the cost associated with full 
maintenance contracts for the PAT equipment.  The NIR maintenance contracts include the 
cost of personnel from Solvias AG to recalibrate equipment on site.  The LLD maintenance 
contracts with Sympatec include all travel related expenses, unlimited visits per year and 
spare parts for the equipment.  The exact costs of the maintenance contracts are shown in the 
table below and total 280,000 CHF per year. 
 
Equipment 
Type Model
Total 
Number
Maintenance 
Cost (CHF) Reference
NIR MPA 3 12,000  Bruker 
NIR Matrix 1 4,000  Bruker 
NIR Tandem 11 44,000  Bruker 
LLD Helos 3 88,908  Sympatec 
LLD TWISTER & MYTOS 4 123,979  Sympatec 
272,887 Total  
Table 14: PAT yearly maintenance costs. 
 
2.16.6. Multivariate data analysis 
 
Multivariate data analysis (MVDA) tools need to be implemented when the PAT analytical 
equipment is installed to aid in data collection, data analysis, and the building of empirical 
correlations.  Empirical correlations need to be developed so that analytical lab tests for 
dissolution, disintegration, and friability can be replaced with correlations to variables 
measured on-line.  Correlation development is required in order to create models for control 
systems.  The MVDA system consists of SIMCA Batch On-Line software by Umetrics for 
real time connectivity to various data sources.  The cost for equipment, software and 
validation for each of the three products will be 360,000 CHF. 
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2.16.7. Correlation development cost 
 
The cost associated with developing correlations for friability, disintegration, and dissolution 
was attributed to the labor of three engineers for one year.  The cost for these three engineers 
was approximated to be approximately one and half times the yearly labor cost of an 
operator.   The cost for correlation development occurs in-between PAT equipment 
installation and implementation of control systems.  Savings from laboratory testing 
associated with friability, disintegration and dissolution testing will not be realized until after 
correlations have been developed which was predicted to coincide with control system 
implementation. 
 
2.16.8. Control system costs 
 
Phase II of PAT implementation is the installation of control systems to steer the process and 
prevent manufacturing problems.  MVDA will allow for model building and greater process 
understanding which will lead to the ability to implement control systems.  The P&ID 
diagrams for Product X, Product Y and Product Z in the appendix contain suggestions for 
control strategies based on the current understanding of the parameters that effect critical 
variables.  The P&ID diagrams indicate where PAT tools are to be installed to monitor 
critical process and product variables along with proposed feedback control loops.  The 
strategies may need to be altered when a better process understanding is realized.   
 
The main costs associated with control implementation are the cost to program PLC 
controllers, the central PC and software associated with the PLC controller.  The equipment 
cost is minimal (~2700 CHF).  The cost to program the controllers was estimated from a 
budgetary quote received from Panacea Technologies to program four controllers for wet 
granulation.   The assumption was made that there would be similar costs for programming 
each of the controllers required for the PAT strategy.  The estimate for control system costs 
should be further refined by companies when the exact control strategy is determined after 
better process understanding is achieved. There are a total of 21 control systems required to 
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control the manufacture of all three products, and it was assumed that the same control 
system could be used on the same piece of equipment for multiple products. There are 
reduced costs associated with programming multiple controllers for the same application.  
The charge for the first controller is 160,000 CHF and the charge for each additional 
controller is 40,000 CHF.  The costs of control systems for each unit operation are 
summarized in table 15. 
 
Process Step
Number 
Process 
Instruments
Cost (CHF)
Blending 1 167'192
Compression Force 8 429'524
Coating Droplet Size 3 242'144
Product Z Wet Granulation 1 167'192
Product Z Drying 2 204'668
Product Y Wet Granulation 3 242'144
Procuct Y Drying 3 242'144
Total 21 1'695'008  
Table 15: PAT control system costs. 
 
2.16.9. Process change requests costs 
 
Change requests must be filed with regulatory agencies for approval of any changes to the 
manufacturing process.  The project team discussed the cost of such requests to the FDA with 
the CMC Regulatory Department of the company.  It was advised that re-registration of the 
process would not be required for PAT implementation.  There are two types of reports that 
can be filed: (1) prior approval requests for 8,000 CHF and (2) all other change requests for 
1,500 CHF.  The FDA does not charge a company for filing change requests and these costs 
are charged by the CMC Regulatory Department for preparation of the reports.  Multiple 
changes can be requested in the same report without affecting the cost.  As an aggressive 
estimate all requests were assumed to be prior approval requests.  The assumption was made 
that all change requests for the same piece of equipment will be filed together.  Change 
requests will be required for changes in analytical testing methods, implementation of on-line 
analytical tools and implementation of control systems.  The assumption was made that a 
change request would not need to be filed to include additional analytical testing in 
dispensation (material identity, PSD, and moisture content); as they do not alter the current 
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production process, these changes will be reported in the annual report.  The total cost 
(100,000 CHF) for change requests to the FDA are summarized in table 16. 
 
PAT Equipment 
Cost (CHF)
Control Systems 
Cost (CHF)
Total Cost 
(CHF)
Product X 10'667 8'000 18'667
Product Z 16'000 24'000 40'000
Product Y 16'000 24'000 40'000
Total 42'667 56'000 98'667  
Table 16: Change request costs. 
 
Change requests for European Union countries are more expensive as multiple countries are 
involved and the number of countries that the change request must be filed with will vary.   
Companies will need to further determine the exact strategy for filing these requests because 
the costs may turn out to be quite significant.  The costs for particular changes are 
summarized below. 
 
Product X Product Z Product Y
Minor 0 73'000 73'000
Major 90'000 150'000 150'000  
Table 17: Costs for change requests for EU (CHF). 
2.16.10. Summary of implementation costs 
 
A summary of the implementation costs attributed to each of the three products studied 
herein is given in the table below. 
 
 
Table 18: PAT implementation costs. 
Product X Product Z Product Y
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2.17. Cost-Benefit analysis 
 
A preliminary analysis of savings indicated that two areas where PAT can provide the 
greatest benefits are: (1) reduction in QC testing, leading to real time release and (2) 
improvement of product yield from better process control.  The financial analysis was found 
to be sensitive to the time when these benefits begin to take effect.  Since there is some 
uncertainty as to when real time release will be approved, two timelines were evaluated for 
the financial analysis (see figure 19). The first scenario assumes that QC savings start 
accruing after the installation and qualification of analytical instruments, at the end of the 
first year. The second scenario is a conservative case in which it is assumed that the QC 
savings begin in the third year, after correlations have been developed for tablet friability, 
disintegration time and dissolution time. The first scenario is treated as the base case in 
sections 2.17.1 through 2.17.3. The second scenario is treated in the sensitivity analysis on 
Section 2.17.3.4. 
 
 
Figure 19: Implementation timelines. 
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2.17.1. Calculations used in Cost-Benefit Analysis.   
 
There are several types of calculations used in assessing the benefits of installing new 
equipment in a production line.  The simplest method is the earnings before tax and interest 
calculation (EBIT).  EBIT for year i is calculated by adding the savings for each year, Si, to 
the cost in year i, Ci, and depreciation of the invested capital per year,DepIC. Equation 1 
shows the calculation for EBIT. 
Equation 1 
ICii DepCS −−=iEBIT  
The net cash flow for year i, CFi, is calculated by equation 2: 
Equation 2 
iii CSCF −=  
Here, Si is the money saved by the investment in year i. Likewise, Ci represents any extra 
costs of the installed equipment in year i. These extra costs are primarily maintenance, as 
well as any other expenses. 
Calculating the net present value (NPV) of an investment is another tool used in estimating 
the return of an investment.  Like EBIT, NPV is a sum of cash flows.  Unlike EBIT, NPV 
uses a discount rate, DR, to reduce the value of future costs.  The NPV of an investment is 
calculated by equation 3. 
Equation 3 
( )∑= +=
N
year
year
i
DR
CF
0 1
NPV   
Another method of evaluating financial benefit is internal rate of return (IRR); the discount 
rate that would make the net present value of all cash flow equal to zero.  The equation used 
to calculate IRR is equation 4, below: 
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Equation 4 
( )∑= +==
N
year
year
iCF
0 IRR1
0NPV
This equation must be solved numerically to find IRR.  Most software used in financial 
calculations, such as Microsoft Excel, has built-in functions to calculate IRR. 
For situations where new process equipment must be purchased, a key indicator of economic 
efficacy is the return on investment (ROI).  The calculation of ROI weighs the average EBIT 
of the investment versus the average depreciating investment cost for year i, (DICi=IC*(1-
i/Life)).  Equation 5 is the definition of ROI. 
Equation 5 
C)AVERAGE(DI
IT)AVERAGE(EBROI =
 Organizations consider the risk of a new venture to be acceptable when the ROI is greater 
than a certain percentage, typically 25%. 
With equipment investments, there is a period of time before there are net profits. This 
payback time is often considered when evaluating a project’s economic impact.  The payback 
time, Tpayback, is simply defined as the time when the NPV is zero, as shown in equation 6. 
Equation 6 
( )∑= +==
paybackT
year
year
i
DR
CF
0 1
0NPV
To solve for Tpayback in equation 6, interpolation is typically used over the year that profits are 
first realized.  Payback time is useful for estimating how long it will take for an investment to 
begin to make returns. 
These five financial calculations: EBIT, NPV, IRR, ROI, and payback time were used to 
evaluate the cost savings of implementing PAT at the company’s production facility.  In 
order to make these calculations, however, several assumptions and approximations must be 
made about the benefits of PAT. 
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The sensitivity of the financial calculations to process parameters must also be performed to 
identify the most sensitive parameters.  To accomplish this, the derivative of the financial 
calculation is approximated by varying a single process parameter.  Equation 7 shows how 
the sensitivity of IRR (SensIRR) is calculated with respect to arbitrary process parameter, P, 
using a parameter variance X.  For the purposes of this report, X is assumed to vary from 1% 
to 30%. 
Equation 7 
( )( ) ( )( )
( ),......,IRR2
1...,IRR,...1...,IRR
PX
,...XPXPSensIRR ⋅⋅
−⋅−+⋅=  
 
2.17.2. Assumed savings used in financial calculations 
 
To evaluate the benefits of on-line analytical measurements with and without feedback 
control, the savings of each must be estimated.  Several assumptions were made regarding the 
implementation of PAT.  An outline of the assumptions made for both on-line analytical 
testing as well as with feedback control is shown in table 19. 
 
 
On-line 
Testing 
Control 
Audit Labor Reduction 0% 50% 
Investigation Labor Reductions 50% 95% 
QC Analytical Time Reduction 90% 99% 
Batch Rejection Reduction 0% 75% 
TPT Reduction (days) 4 6 
Yield Improvement 0 +1% 
Reduction in IPC Labor per Product 35% 99% 
Investigation Holding Time (days) 4 1 
Table 19: Assumed benefits of PAT.
 
These savings are applied to the existing production costs proportional to each of the drug 
products examined.  By applying these assumptions, annual savings from on-line analytical 
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testing and PAT can be calculated.  The benefits from on-line analytical testing alone are 
termed short-term benefits, the benefits of implementing the control strategy is classified as 
mid-term benefits.  A breakdown of the annual savings possible by on-line analytical testing 
alone is shown in table 20 and in figure 20.  It is clear that the majority of the short-term 
benefits from PAT will be from the reduced analytical time needed per batch.  Secondary 
cost reductions stem from reduced investigations and reduced IPC labor. 
 
  Product X Product Z Product Y 
  
kCHF % of Total 
kCH
F 
% of Total kCHF % of Total 
Savings From Reduced Audits 0 0% 0 0% 0 0% 
Savings From Investigations 83 7% 43 5% 33 4% 
Savings from Quality Control 907 76% 679 77% 700 83% 
Savings from Batch Writeoffs 0 0% 0 0% 0 0% 
Savings from Batch Resorting 0 0% 0 0% 0 0% 
Financial Cost of Inventory 87 7% 73 8% 49 6% 
Savings from Improved Yield 0 0% 0 0% 0 0% 
Reduction in IPC Labor 112 9% 83 9% 62 7% 
Savings from Reduced Holding Time 8 1% 6 1% 2 0% 
Total Savings 1197 100% 883 100% 846 100% 
Table 20:Break down of short-term PAT benefits.  
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Figure 20: Quick wins. 
The breakdown of the annual savings possible with both on-line analytical testing and control 
system is outlined in table 21 and figure 21, below. 
 
 
  Product X Product Z Product Y 
  kCHF % of Total kCHF % of Total kCHF % of Total 
Savings From Reduced Audits 21 1% 18 1% 17 1% 
Savings From Investigations 170 6% 91 4% 66 4% 
Savings from Quality Control 968 32% 717 32% 741 47% 
Savings from Batch Writeoffs 171 6% 253 11% 0 0% 
Savings from Batch Resorting 413 14% 80 4% 13 1% 
Financial Cost of Inventory 127 4% 105 5% 72 5% 
Savings from Improved Yield 856 28% 712 32% 485 31% 
Reduction in IPC Labor 319 10% 236 11% 177 11% 
Savings from Reduced Holding Time 12 0% 9 0% 3 0% 
Total Savings 3057 100% 2222 100% 1572 100% 
Table 21: Breakdown of mid-term PAT benefits.
 
Y 
Z 
X 
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Figure 21: Mid-terms savings. 
 
From table 21 and figure 21, it is apparent that, as with on-line analytical testing alone, the 
largest benefit from including a control system will be the reduced analytical time needed per 
batch.  The second largest cost reductions in this case are from reduced investigations and the 
assumption of an improved product yield.  Comparing the values in table 21 with the PAT 
implementation estimates in section 2.16, the most significant costs and most significant 
savings can be identified. Table 22 summarizes the three most significant costs and three 
most significant savings when PAT with feedback control is implemented. 
 
 
 
 
 
 
 
 
Y 
Z 
X 
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   Product X Product Z Product Y 
   
kCH
F 
% of Total kCHF % of Total kCHF 
% of 
Total 
Savings from Quality Control 8.6 36% 6.4 37% 7.6 60% 
Savings from Improved Yield 6.0 25% 5.0 29% 3.4 27% 
Reduction in IPC Labor 2.5 11% 1.8 11% 1.4 11% 
Total Savings 23.8 100% 17.3 100% 12.7 100% 
Sa
vi
ng
s 
                
PAT Cost  2.4 47% 2.2 42% 2.2 39% 
Maintenance Cost for 10 years 1.1 21% 0.8 15% 1.1 19% 
Qualification, Approval, and 
Training 
0.7 13% 0.7 13% 0.7 13% 
C
os
ts
 
Total Costs 5.1 100% 5.3 100% 5.7 100% 
 Net Total   18.7   12.1   7.0   
Table 22: Major savings and costs for PAT implementation. 
 
2.17.3. Financial calculation results 
2.17.3.1. Short-term PAT implementation 
 
As mentioned in section 2.12, implementing PAT has several short term benefits.  Most 
notable of these is the reduction or elimination of the analysis work needed to release a batch.  
Other benefits include the reduction of the number of investigations, and their associated 
labor. The reduction in batch release time will reduce the inventory time associated with 
QA/QC delays.  The short term phase of PAT benefits begins with the qualification of the 
PAT equipment as on-line analytical tools to replace QC testing.   
 
The short term analysis was made using a 10 year life for all of the PAT equipment.  The first 
year is spent building a database of spectra to characterize the process, followed by training 
personnel and qualifying the equipment.  During this year it is assumed that there are no cost 
benefits realized by the PAT system.  After qualification, there is a reduction in the QC and 
investigation expenses.  The financial calculations were determined over the life of the PAT 
equipment.  Table 20 suggests there are some benefits of implementing the analytical 
technology alone.  Based on the data, the costs of implementing PAT will be paid back as 
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soon as the middle of the fifth year; four years after the equipment is qualified.  Figure 22 
shows the discounted cumulative cash flow for the new process when the PAT equipment is 
qualified at the beginning of year 2. 
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Figure 22: Discounted cumulative cash flow for on-line equipment. 
 
As indicated by figure 22, the product with the greatest returns is Product X.  This is due to 
several factors: 
• Product X is produced in greater quantities per year, allowing more analysis time to 
be saved with on-line analytical equipment. 
• Product X has disproportionately large investigation and resorting labor costs.  
• Product X has the largest production levels so that when plant-wide savings (e.g. 
reduced audits) were divided among the products, Product X receives the greatest 
fraction of the savings.   
X 
Z 
Y 
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For the PAT equipment, the total annual cost, including discounted annualized cost per year 
as calculated using straight-line depreciation plus maintenance costs. Phase I of PAT 
implementation requires the largest investment during the first year; when chemometrics, 
training and equipment qualification take place.  However, the total savings calculated in 
table 20 illustrates the enormous economic benefit of Phase I.  The results of these 
calculations are shown in table 23, below: 
 
 
Product 
X 
Product 
Z 
Product  
Y 
10 yr NPV (Millions CHF) 4.8 3.0 2.8 
IRR 20% 10% 10% 
ROI 69% 49% 46% 
Payback Time (years) 5.6 7.7 8.2 
Table 23: Effects of phase I PAT implementation. 
 
2.17.3.2. Mid-tem benefits of PAT 
 
The inclusion of a feedback control system after implementation of on-line analytical 
equipment is the beginning of phase II of PAT implementation.  For the purposes of this 
evaluation, the control system was assumed to be fully functional in the third year after the 
PAT equipment was installed.  The cost-benefit analysis was performed in an identical 
fashion as in section 2.17.3.1, with the only difference of additional costs and benefits 
applied in the third year.  With these additional factors, the 10-year analysis was repeated.  
The benefits of applying a control strategy far outweigh the costs associated with 
implementing it.  Figure 23 plots the discounted cumulative cash flow at the end of each year 
over the life of the PAT equipment.
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Figure 23: Discounted cumulative cash flow for PAT. 
 
Before year 3, the discounted cumulative cash flow for PAT is identical to the on-line 
analytical equipment alone.  However, after the third year, the implementation of the control 
system increases the rate of return for the process.  This is despite the fact that the annual cost 
with the control system is greater than when PAT equipment is used by itself. As shown in 
table 18, the cost of control implementation is slightly greater than on-line analytical 
equipment alone.  Yet, the savings possible by using feedback control are quite significant, as 
shown in table 21.  Therefore, the savings from employing a control and on-line analytical 
system is greater than the savings possible by on-line analytical system alone.  The results of 
this analysis are shown in table 24.   
 
 
Product 
X 
Product 
Z 
Product  
Y 
10 yr NPV (Millions CHF) 8.6 4.8 2.3 
IRR 40% 30% 20% 
ROI 147% 92% 60% 
Payback Time (years) 4.2 5.3 6.6 
Table 24: Effects of mit-term PAT implementation. 
X 
Z 
Y 
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2.17.3.3. Benefits of PAT for other products and other production facilities. 
 
After the PAT systems are installed, other products produced at the same site would have the 
benefit of PAT monitoring without the expense of PAT.  To examine this effect without 
acquiring production data for other products, the calculations in the above section were 
repeated with the control system and PAT installation costs set to zero.  Chemometrics costs, 
equipment qualification costs, and maintenance costs were assumed to be identical as before.  
This evaluation also assumes that the new products will have very similar production and 
QA/QC costs.  The results of this calculation are shown in the table below: 
 
 
Product 
X 
Product 
Z 
Product  
Y 
10 yr NPV (Millions CHF) 11.0 7.1 4.5 
IRR 100% 60% 50% 
ROI 441% 270% 200% 
Payback Time (years) 3.0 3.6 4.0 
Table 25: Benefits of Zero equipment cost.
 
Because the equipment installation cost constitutes the largest portion of the PAT 
implementation cost, the return on investment is now about three times greater.  Another 
benefit from PAT is that the chemometrics developed for one product can be used for the 
same product at other production plants.  To study how this would translate into financial 
benefits, the calculations in section 2.17.3.2 were performed again with the chemometrics 
cost and time set to zero.  All other expenses (installation cost, library building cost, 
maintenance costs) were not changed.  This calculation will be most relevant for other 
facilities that are similar to the pilot site with respect to both production, as well as QA/QC 
costs.  The results of evaluating zero chemometrics time and cost are shown in the table 
below: 
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Product 
X 
Product 
Z 
Product  
Y 
10 yr NPV (Millions CHF) 9.6 5.8 3.3 
IRR 40% 30% 30% 
ROI 151% 95% 63% 
Payback Time (years) 3.7 4.5 5.3 
Table 26: Benefits of Zero chemometrics time and cost.
 
The financial calculations improve somewhat; however, the chemometrics cost is only about 
10% of the PAT implementation cost.  Consequently, the ten-year EBIT and NPV increase 
only slightly.  The most significant benefit is from the reduction of payback time by a factor 
greater than the chemometrics time.  A comparison of tables 26 and 24 show that the payback 
time for Product X shifts from 4.2 years to 3.7 years, Product Z goes from 5.3 to 4.5 years, 
and Product Y is reduced from 6.6 years to 5.3 years.  These changes are mostly due to the 
additional six months of PAT savings. 
 
2.17.3.4. Benefits of PAT for delayed regulatory approval 
 
It is possible that the regulatory approval of on-line analytical testing to replace current QC 
testing would be delayed.  For this situation it is important that an evaluation be performed to 
determine if on-line analytical measurements with control is financially sound.  Keeping all 
other values constant and assuming PAT savings only accrue after the third year, the 
financial calculations were performed again.  The results of these calculations are shown in 
the table below: 
  
 
 
Product 
X 
Product 
Z 
Product  
Y 
10 yr EBIT (Millions 
CHF)
22 14 8 
10 yr NPV (Millions CHF) 13 8 4 
IRR 60% 50% 30% 
ROI 360% 210% 220% 
Payback Time (years) 3.9 4.4 5.2 
Table 27: Benefits of PAT with savings after year three.
 
Comparing table 27 to table 24, it is evident that increasing the time before PAT Savings are 
realized causes a drop in the overall profitability.  However, the returns continue to be 
sufficiently high to indicate that PAT implementation is financially feasible.   
 
2.17.3.5. Long-term costs and benefits of PAT implementation 
 
Eventually PAT will begin to be used in the development of new production processes for a 
“quality by design” approach.  Given the impossibility of quantifying this approach, no 
attempt was made to calculate the savings and costs associated with PAT when it is used in 
production development.  This section will qualitatively discuss some of the benefits and 
costs of using process analytical technology in the development of new pharmaceutical 
products.  The advantages of implementing PAT in development, as highlighted before, 
include a fundamental understanding of each unit operation in the solid tableting process.  
This understanding will reduce or eliminate the experimental design needed for process 
development.  Optimal formulations will be found quickly when development is supported by 
process understanding – ‘Quality by Design’.  The savings in cost and time will translate into 
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large benefits, as shortened development times and early launches are absolutely vital to a 
new product’s success.   
The cost of using PAT in development is much more difficult to quantify than the benefits.  
The introduction of PAT to new process development will require additional workers to 
perform both conventional and PAT-enhanced development as quickly as before.  For several 
years, the development staff will have to perform two product developments for each product 
in the same amount of time.  This can be a obstruction for the PAT implementation for many 
companies, as the utilization of more personnel is combined with more costs.   
 
2.17.4. Sensitivity analysis results 
 
A sensitivity analysis for PAT was performed on the parameters used in the financial 
calculation.  Percent variations in the parameters of interest were determined in accordance 
with the level of uncertainty to be 5%, 10%, 20% or 30%.  The effects on the financial 
calculations were measured and normalized according to the parameter deviation.  Large, 
positive values indicate that the parameter has a positive effect on the outcome of the 
calculation.  Sensitivity values near zero mean that the parameter has little effect on the 
calculation.  When the sensitivity values are much less than zero, the parameter will have a 
large negative influence on the calculation.  The sensitivities of various process parameters 
on IRR were evaluated using equation 7 and are tabulated in table 28.  For the instances 
where the sensitivity was greater than 0.5 or less than -0.5, the cell has been highlighted.  
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 % Change 
Product 
X 
Product  
Z 
Product  
Y 
Number of Batches per Year 10 0.62 0.80 1.26 
Investigations per Year 30 0.01 0.01 0.01 
Investigation Labor per Year 20 0.05 0.05 0.06 
Discount Rate for Inventory 5 0.05 0.07 0.08 
Rejected Batches per Year 30 0.04 0.10 0.00 
Resorted Batches per Year 20 0.09 0.03 0.01 
Production Salary 5 0.01 0.01 0.01 
Investigator Salary 5 0.15 0.18 0.23 
Analysis Cost 10 0.39 0.46 0.83 
Production Cost per Batch 10 0.27 0.45 0.43 
Audit Labor Savings 30 0.00 0.01 0.01 
Investigation Labor Reductions 20 0.04 0.04 0.05 
QC Time Saved 20 0.21 0.28 0.54 
Batch Rejection Savings 20 0.04 0.10 0.00 
Batch Resorting Savings 20 0.09 0.03 0.01 
TPT Reduction 20 0.03 0.04 0.05 
Reduction in IPC Labor 20 0.09 0.12 0.16 
New Yield With PAT 20 0.18 0.28 0.35 
PAT Installation Cost 30 -0.56 -0.59 -0.74 
Control Costs 30 -0.04 -0.11 -0.19 
Years to Automatic Control 30 -0.70 -0.64 -0.46 
Annual Maintenance Cost 20 -0.11 -0.09 -0.12 
Chemometrics Cost 30 -0.09 -0.14 -0.19 
Chemometrics Time 30 -0.21 -0.27 -0.37 
Equipment Qualification Cost 30 -0.11 -0.15 -0.20 
Equipment Qualification Time 30 -0.21 -0.27 -0.37 
Table 28: Sensitivity of IRR to various process parameters. 
 
From the table above, the most significant factors are the time to start automatic control, the 
number of batches per year, and the installation cost of the PAT equipment.  Other important 
values are the cost and time of quality control measurements, the improvement in process 
yield, and the time to develop chemometrics.     
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2.18. Conclusions 
 
• Implementing on-line analytical measurements will have significant economic 
benefits, with a return on investment greater than 60%, and an IRR greater than 20% 
for Product X.  
• Implementing on-line analytical measurements will cost 4.0 to 4.6 Million CHF, for 
each of the products studied. 
• Installing a control system to complement the PAT equipment will increase the IRR 
to above 35%, and is estimated to cost from 280 to 760 kCHF for each of the products 
studied. 
• Product X production will benefit most from PAT implementation, followed by 
Product Z, and Product Y.  The large production levels of Product X present the most 
significant potential savings due to analytical time and expense of each batch. 
• From a sensitivity analysis, the parameters that have the greatest effect on PAT 
profitability are the time to start automatic control, the number of batches per year, 
and the installation cost of the PAT equipment. 
• The long term costs and benefits of PAT in development were not quantified, but are 
expected to provide wide-reaching fundamental benefits to the entire process, from 
early development to full production. 
 
2.19. Recommendations 
 
• It is highly recommended that companies implement Process Analytical Technology 
(PAT) by purchasing sensors discussed above. 
• Chemometric development and equipment qualification for all the PAT equipment 
should be outsourced to experienced external vendors.  Most pharmaceutical 
companies lack the human resources and specialized expertise to accomplish these 
tasks in-house.  
• The sensitivity analysis indicates that chemometric development and equipment 
qualification time are very sensitive parameters.  Hence all chemometric development 
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and equipment qualification should be done simultaneously for all PAT equipment by 
outside vendors to help implement PAT faster and lead to greater returns. 
• Once the on-line analytical equipment is installed, computer archiving should be done 
to monitor and record all critical variables.  This will reduce investigation times 
significantly.  In addition to this, alarm systems should be installed with all the PAT 
equipment, until the control systems are in place.  The alarm systems will inform the 
operator to take corrective actions whenever any critical variable goes out of 
specifications. 
• Multivariate data analysis (MVDA) tools need to be implemented when the PAT 
analytical equipment is installed to aid in data collection, data analysis, and the 
building of empirical correlations.  Empirical correlations need to be developed 
product specific so that analytical lab tests for dissolution, disintegration, and 
friability can be replaced with correlations to variables measured on-line.  Correlation 
development will also be required in order to identify critical parameters and create 
models for control systems.    
• After MVDA tools have been implemented and product specific empirical 
correlations have been developed, control systems should be implemented to steer the 
process and prevent any manufacturing problems. PLC’s should be installed with 
feedback control loops to completely automate the control of the manufacturing 
process. The implementation of control systems should be done as soon as 
correlations have been developed because of the high sensitivity of mid-point benefits 
to implementation time 
• Along with implementation of PAT, extra efforts should be made to provide operator 
training and educate them about good manufacturing practices to help increase 
process yields.  
• It is recommended to implement PAT for other high volume, expensive, or important 
products to attain greater benefits.  There will be significant cost savings in PAT 
equipment installation as a number of common machines will already have PAT 
equipment installed.  There will be additional costs for chemometric development and 
equipment qualification.  
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• It is also recommended to consider implementing PAT at other plants manufacturing 
the same products as in the pilot, in other countries.  There will be savings in 
chemometric development costs for PAT equipment. 
• After the implementation of PAT for Product X, Product Y and Product Z, it should 
be looked into implementing PAT for the launch of a new product.  PAT along with 
control systems can eliminate the need for running validation batches as there will be 
complete understanding of the process.  This can eliminate the costly errors during the 
early phase of the production of a new drug and can provide tremendous cost savings 
• Finally and most importantly, a PAT implementation strategy for development should 
be created.  In order to achieve the goal of ‘Quality by Design’ and to develop a 
complete understanding of the process it is essential to implement PAT in 
development.  Development is the place where the biggest cost and time savings will 
be realized by implementing PAT and control systems.  Implementation of PAT is 
essential to accomplish the long cherished vision of the pharmaceutical industry and 
FDA of ‘being right the first time’.  
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Figure 25: Product X P&ID part II. 
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Figure 27: Product X P&ID part IV. 
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Figure 28: Product Y P&ID part I. 
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Figure 29: Product Y P&ID part II. 
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Figure 31: Product Y P&ID part IV. 
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Figure 32: Product Z P&ID part I. 
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Figure 33: Product Z P&ID part II 
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Figure 34: Product Z P&ID part III. 
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Figure 35: Product Z P&ID part IV. 
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3. The implementation of semi-continuous granulation and its economical 
influence. 
 
3.1. Theory 
 
3.1.1. Granulation in general 
 
Granulation has the purpose of changing fine powder particles into bigger 
agglomerates by the formation of liquid bridges connecting the particles.   
 
There are many reasons for the creation of granulate agglomerates: 
 
• A certain Particle Size Distribution (PSD) of the granulate particles is 
essential. 
• The flowing properties and therewith the dosing accuracy are improved. 
• The dust formation is reduced. 
• Adhesive forces are reduced. 
• Segregation tendency of the product blend is avoided.   
• Raw material powders can not always be compressed to tablets as the cohesion 
forces are too weak for stable tablets.   
• The surface texture, the wettability, the porosity, the solubility and the 
disintegration time regarding the bioavailability can be optimized.   
 
Regardless of the granulation method, the following requirements are set for a high 
quality granulate: 
 
• It should be as consistent as possible regarding shape and color.   
• Good flowing properties and lump formation should be avoided; good flowing 
properties are achieved with a particle size of 100µm or bigger.   
• The particle size distribution should be uniform and narrow, whereas the 
median particle size should be adapted corresponding to the intended tablet 
size.   
• The fines proportion in the granulate should not exceed 10% if possible.   
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• The granulate has to contain a certain amount of moisture, i.e. three too five 
percent, depending on the formulation and the raw materials, in order to 
prevent the produced tablets from sticking or capping.   
• It has to exhibit enough mechanical cohesiveness in order not to crumble into 
powder again. 
• The disintegration in water or other solvents should happen fast or controlled.   
 
The types of granulates and the manufacturing methods are very versatile.  There are 
the methods of dry granulation whereas briquette – or melt solidification granulate is 
produced with the help of compression respectively heat.  
 
Dry granulation 
 
 
Compression Heat 
 
 
 
Compaction Melt / Solidification 
 
 
 
Briquette granulate Melt solidification granulate
 
Other methods include the wet granulation.  With binding agents adhesive granulate is 
produced and with solvents crust granulate is produced.  Thereby the small powder 
particles are bound together to bigger agglomerates (constructive granulation) and 
partly those are milled to a certain particle size (retrenching granulation). 
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Wet granulation 
 
 
Binding agent solution Solvent 
 
 
 
Blending of the powder components 
Granulate molding 
Drying 
Sieving 
Blending of the powder components 
Granulate molding 
Drying 
Sieving 
 
 
 
Adhesive granulate Crust granulate 
 
The most common granulation method is the wet granulation which is also used in the 
Multicell® (2).   
 
3.1.2. Conventional discontinuous granulation methods 
 
The classical wet granulation starts with an intensive dry blending of the active 
ingredient and the excipients in a mixer, dampening and dispersing follows in a slow 
moving kneader and ends with the sieving through a sieve.  The long lasting, 
multiple-stage process results in favorable granulate properties concerning flowing – 
and tableting properties, but takes a long time and much effort.  The strict rules of 
GMP can only be fulfilled with high efforts.   
 
Special vertical or horizontal mixing systems equipped with extra milling heads make 
it possible to perform an intensive dry blending, damping and granulation in one 
operation.  By choosing the correct amount of binding agents and controlling the 
granulation with a power consumption measurement, reproducible and immediate 
dryable granulate can be produced.   
 
It is also often possible to dry the granulate in the mixer (e.g. Moritz® - Technology), 
particularly if the container has a heating jacket and a vacuum pump and possibly also 
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a microwave – or inert gas support (e.g. Bohle® - Technology).  These methods are 
useful for crust granulation which are produced with the help of volatile organic 
solvents. 
 
 
Figure 1: Collette Gral drying with the support of inert gas. 
 
During Fluid Bed Granulation the powder is twirled into the air instead of being 
mechanically moved.  Due to the intensive flow process the granulation binding agent 
can be adsorbed by the powder particles and simultaneously the created wet 
agglomerates can be dried in the warm flowing air (one-unit operation).  The 
following sieving is done in order to prevent bigger agglomerates.   
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Figure 2: A typical fluid bed dryer system, 1 = air preparation unit; 2 = product container; 3 = exhaust 
filter; 4 = exhaust blower; 5 = control panel; 6 = air distribution plate; 7 = product; 8 = spray nozzle; 9 
= solution deliver. 
 
The most efficient way to manufacture a compactable product is making direct 
compactable blends, whereas the compaction ability of the blend into tablets is 
dependent on particle structure of the raw materials.  This is true for e.g. 
acetylsalicylic acid which is compactable without prior granulation and also some of 
the benzodiazepines together with adequate excipients.   
 
3.1.3. Discontinuous granulation in a vertical granulator.   
 
In order to be able to compare the semi-continuous granulation method to the other 
conventional methods, the vertical granulation method will be described below: 
 
The processing of the raw materials into a compactable granulate usually takes place 
in a batch production.  One batch is the amount of a drug which is manufactured 
during one manufacturing cycle.   
 
The batch size depends on the bulk density of the mixed raw materials.  Usual batch 
sizes range from about 400kg up to 600kg.  The size of the granulate batches can be 
adapted to the volume of the mixer or to the volume of the container which holds the 
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final blend for tableting.  In the case of the latter, one batch can consist of multiple 
sub-batches.   
 
The raw materials (active ingredients, excipients and binding agent) are filled either 
manually or with the help of a pneumatic pump into the mixer.  There the powder will 
be mixed until it is homogeneous.  The powder particles are centrifugally accelerated, 
resulting in a fluidized powder ring.  Research results have shown that the desired 
homogeneity has been reached after 15 seconds and that longer mixing time do not 
show any improvement.   
 
After the pre-blending of the raw materials the needed amount of binding agent 
solution will be added, manually or with the help of a pump.  The easiest case is 
where it is enough to add water to the powder mixture, whereas a well water soluble 
binding agent has already been added as powder.   
 
The addition of the binding agent solution should occur directly onto the milling 
heads.  The high-speed turning milling heads have the following task: 
It distributes and divides the binding agent and simultaneously densifies the powder 
formulation.  Furthermore it disrupts the rising powder ring and leads the product 
back into the vertical route.  Thereby a frequent passage between the mixing blades 
and the milling heads of the powder particles is secured.  Bigger agglomerates will be 
chopped down and if the milling heads are positioned correctly it also assists during 
depletion.   
 
During granulation the particle size distribution and the cohesiveness of the granulate 
particles can be controlled by the milling heads.  The slower the binding agent is 
added, the better distribution is achieved.  From the power consumption measurement 
of the mixer blades motor, the point in time can be estimated where the granulate 
formation and the granulate liquid amount have reached the optimum point.   
 
The depletion of the wet granulate occurs straight into a fluid bed dryer tray, whereas 
production tests have shown that the quality of the granulate increases if the granulate 
is first sieved, regarding the homogeneity of drying, the sieve analysis and the 
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compression force / Hardness profile.  Also the amount of granulate fitting into the 
fluid bed dryer tray is increased and so improving productivity.   
 
After drying in the fluid bed dryer to the correct absolute humidity, the dry sieving 
follows.  This step is done in order to prevent secondary granulation which occurs in 
the fluid bed dryer during the starting phase and transshipping.  Also the essential 
particle size is achieved.  Before tableting lubricant and disintegrator are added to the 
granulate.   
 
3.1.4. The disadvantages of discontinuous granulation 
 
1) There are many single equipment essential which are expensive and take a lot of 
space: 
 
This is especially crucial when different mixers and dryers with dissimilar dimensions 
are needed for different batch sizes. 
 
In older manufacturing sites for solid dosage forms there are often equipment which 
have been installed individually, i.e. not as a closed equipment network.   
 
2) The granulation process is still associated with a lot of handwork, especially in 
older factories: 
 
• Filling of the raw materials into the mixer.  
• Making of binding agent solution in a planetary mixer or in a tank with an 
agitator.   
• Pouring the binding agent solution onto the granulate. 
 
For older equipment the following handwork might be needed: 
 
• Shoveling the depleted wet granulate through a sieve into the fluid bed drier 
tray. 
• It might be needed to manually sieve the granulate through a dry sieve. 
 123
• If there is no feeding system between the dry sieving and the final container 
carrying the final mixture, then the granulate must be sieved into bins and 
these will then be emptied into the container.  
 
With modern equipment many manual steps can be erased and the system can be 
contained:   
 
• There can be pumps installed for conveying the powder and liquids. 
• During deployment out of the mixer, sieves can be used to assist or the 
deployment and wet sieving can occur by gravitation directly into the fluid bed 
dryer. 
• After the drying of the granulate it could be pneumatically conveyed through a 
sieve into the final container. 
 
3) Reproducibility cannot be guaranteed with batch production / discontinuous 
granulation.   
 
• If the granulate is not conveyed automatically to the next process step, then the 
granulate intermediate stages might stand around for a different amount of 
time and so be changed physically (mainly in humid condition).   
• Sieves can give different particle size distributions depending on the sieved 
mass.  This could lead to different compaction properties.   
 
4) The manufacturing process can be very complicated, depending on the product, and 
therefore high personnel effort needed and high costs.   
 
These will have to be simplified with the appropriate technology – i.e. combining 
process steps and connecting the systems with e.g. a combination of a mixer 
deployment / wet sieving / loading of the fluid bed drier tray (e.g. Collette® Gral with 
Quadro Comil®) or even higher automation like pneumatic conveying systems.   
 
5) The batch size is dependent on the equipment size used at the production site and 
not flexible regarding the market demand when entering the market. 
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For different batch sizes, different equipment for granulation will have to be used.  
Hence, very expensive scale-up exercises will have to be performed in order to adapt 
the batch size to different production dimensions.  The launch of a new product 
specialty starts in a kilogram scale.  Here it is basically about the decision of a definite 
drug application.  For the clinical studies bigger batches will be needed.  At last the 
process must be handed over to the production site and adapted to their dimensions.   
 
6) There is a higher production risk: 
 
As the whole batch is manufactured at once, it is at risk if a failure occurs or the 
equipment should brake down for some reason at all.  Under circumstances the whole 
batch will have to be discarded (1).   
 
3.1.5. Continuous granulation in the pharmaceutical industry 
 
In the following paragraphs some different continuous granulation technologies will 
be introduced.   
 
3.1.5.1.Fluid bed agglomeration 
 
The most widespread continuous fluid bed agglomerators are horizontal moving bed 
granulators/driers (e.g. Glatt GF series, Niro Vibro-Fluidizer, Heinen Drying 
Technologies) (see figure below), 
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Figure 3: Heinen continuous fluid bed granulator. 
 
they are mainly used in the chemical, dairy and food industry (e.g. for the production 
of instant products) and these systems were not specifically designed for 
pharmaceutical use. Inside the granulation chamber several processes are 
accomplished as the chamber is divided into different functional sections which are 
not mechanically separated from each other. After dosing the raw materials into the 
fluid bed at the feed zone and initial heating of the powders, a liquid is sprayed on the 
fluidized particles to induce agglomeration. As the materials are further transported 
down the processing chamber, solid bridges between individual particles are formed 
during drying, consolidating the agglomerates. In the final section the material is 
cooled to allow further processing after discharge of the product from the fluid bed. 
The different functionalities along the chamber originate from the presence of the 
spray nozzles at the agglomeration zone and from the introduction of air having 
different velocities and temperatures in the different sections. Controlled movement of 
material (mainly plug flow) inside the granulation chamber is essential and is due to 
mechanically vibrating the processing chamber (resulting in a shallow powder bed 
height) or controlling the air flow using specific air distributor plates at the bottom of 
the fluid bed, thus ensuring that the fluidized particles are constantly transported from 
the inlet zone to the discharge area while continuously being agglomerated and dried.   
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A more stringent control of the agglomerate particle size is possible by recirculation 
of the fines into the fluidized bed, the fines being separated from the agglomerated 
material during discharge of the material, e.g. using a zigzag sifter separating fines by 
means of elutriation.   
 
Based on the same principle as the standard moving fluid bed Glatt developed the 
spouted bed systems (ProCell® series).  In these systems the air does not enter the 
fluid bed through a rectangular bottom sieve but through a longitudinal slit, a design 
claimed by the manufacturer capable of processing difficult-to-fluidize materials due 
to the high air speed at the point of entry.   
 
Although the concept of continuous moving bed agglomerators can be used within the 
pharmaceutical industry, there are hardly any applications of them for the production 
of solid dosage forms, mainly because they are ideally suited for high-volume 
products: production capacities typically range from 20 kg up to several tons per hour. 
These systems are unable to operate at the lower capacities required during drug 
development when the limited availability of the drug might impose some restrictions. 
Hence, during the development stage another granulation technique is chosen, mainly 
batch-wise as these granulation processes can be downscaled to as low as 50 g per 
batch. When at a later stage higher volumes must be processed (full-scale production) 
the pharmaceutical industry often sticks to the agglomeration technique initially 
selected and does not go for a technology transfer, even if the required production 
capacity would be within the range of these moving bed granulators. 
 
To be able to cover a range of production rates (from lab-scale to full-scale 
production) with the same continuous fluid bed technique, Glatt developed a fluid bed 
(AGTseries) where the material is confined to an enclosed space (similar to batch 
fluid bed processors), but able to continuously discharge agglomerated material 
through an outlet at the bottom of the screen (round-shaped) (see figure below). 
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Figure 4: Glatt AGT® continuous fluid bed granulator. 
 
A counter current air flow through the pipe positioned at the centre of the bottom plate 
ensures that only agglomerated particles are discharged. Only larger particles are able 
to overcome the air velocity, whereas the counter current airflow carries undersized 
particles back into the processing chamber until they are sufficiently agglomerated. 
This allows manufacturing an essentially dust-free product, the velocity of the counter 
airflow determining the particle size of the end product.  This technique can be used 
for spray-granulation (spraying the raw material and building the agglomerates layer 
by layer) as well as conventional granulation (spraying a granulation liquid and 
possibly a binder onto individual particles in order to induce agglomeration). The 
latter method requires a powder dosing unit to continuously replace the solids being 
discharged from the fluid bed, in order to keep the solid/liquid ratio inside the 
processing chamber constant, an important parameter during a wet granulation 
process. This technique has a large dynamic range towards production rate as a lab-
scale model for feasibility studies (throughput: 1 to 2 kg/h) as well as pilot-scale (50 
kg/h) and full-scale production equipment is available. 
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3.1.5.2.Spray-drying 
 
Although conventional one-stage spray-drying can be considered a continuous 
process, the materials obtained using this technique are in most cases not suited for 
tableting purposes without further treatment.  Often a product with poor flow 
properties is obtained, consisting of non-agglomerated single particles or—at the 
best—of loosely bound agglomerates.  Therefore, if one wants to incorporate a spray-
dryer into a fully continuous tablet production line, the spray drying technique has to 
be combined with another agglomeration technique in order to produce a free flowing 
product in agglomerated form.  Multi-stage (two or three) systems, combining a 
spray-drier with an externally or internally mounted fluid bed, allow manufacturing 
products meeting these specifications.  When a spray dryer is linked to an external 
fluid bed the outlet temperature of the drying air is lowered to discharge a moister 
product (compared to 
single-stage spray-drying) from the drying chamber into the fluid bed.  The moist 
surfaces of the particles cause them to stick together, agglomerating the individual 
particles.  The fluid bed, which is an in-line moving bed to allow continuous 
processing, can be used to further agglomerate the powders by spraying additional 
liquid onto the fluidized particles and/or to dry the agglomerates to the moisture 
content required for the down-stream processes.   
 
Another design integrated the fluid bed inside the spray-dryer (see figure below) 
where the spray dryed but still moist particles are collected in a fluid bed at the 
bottom of the spray chamber.  
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Figure 5: Spray-dryer with integrated fluid bed.  1. atomization and drying of droplets, 2. fluidization: 
coalescence of moist granules + interception of dry particles by moist granules, 3. collision of smaller 
particles and atomized droplets, 4. exhaust of non-agglomerated material from drying chamber. 
 
Primary hot air is entering at the top and is used to dry the atomized particles, in 
addition a secondary air flow is introduced at the bottom of the system to fluidize the 
agglomerate particles.  Different agglomeration processes can be distinguished in this 
concept.  The main agglomeration mechanism (forming the strongest granules) occurs 
in the fluidization zone and relies on the moist surface of particles to coalesce or to 
intercept dry particles.  This is the primary agglomeration mechanism as the residence 
time of particles in this zone is the longest.  As smaller particles are propelled high 
into the chamber due to the fluidizing air, there is the possibility of these fine particles 
colliding with each other (especially just above the fluid bed where they are still moist 
and particle density is the highest) or with atomized droplets, both enlargement 
phenomena. A third agglomeration mechanism (limited to the atomization zone) 
occurs when individual droplets merge.  Non-agglomerated material being exhausted 
from the spray-drying chamber is collected in the cyclone and these fines are recycled 
into the spray-drier.  Size and characteristics of particles produced using this 
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technique depend on parameters such as drying air temperature and spray 
characteristics, e.g. agglomerate size grows using a coarser spray and lower 
temperature as in that case particles dry slower and have a higher moisture content, 
enhancing agglomeration tendency.  If required an additional external fluid bed can be 
added to the system (3-stage) in which the agglomerates are discharged for final 
drying to the required residual moisture content. 
 
3.1.5.3.Extrusion 
 
Extrusion, the most studied continuous granulation technique for pharmaceutical 
applications, employs one (single) or two (twin) screws rotating inside a barrel to 
continuously transport, mix, and agglomerated wetted particles, the energy required 
for agglomeration provided by shear and/or material densification.  Depending on the 
degree of densification inside the barrel the material discharged from the extruder can 
immediately be used, e.g. extrusion process run without die block or requires an 
additional milling or chopping stage to reduce the dense extrudate to granules having 
an acceptable particle size range.   
 
Although pharmaceutical applications of this technique have already been described 
about two decades ago by various sources for effervescent and paracetamol granules, 
in recent years several research groups have contributed to the body of knowledge 
about extrusion as a tool for continuous pharmaceutical granulation. Recently, the 
Warner-Lambert Company filed a patent application for a continuous 
granulation/dryer system using a twin-screw granulator/chopper device for the 
granulation of active ingredients and additives. Schroeder and Steffens (2002) 
developed a planetary roller consisting of a central screw (spindle) around which 
several intermeshing planetary screws are positioned (see figure below).  
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Figure 6:  Planetary roller. 
 
This design allows the introduction of nitrogen under pressure, inducing a foaming 
effect at ambient pressure and yielding a porous agglomerate, thus influencing the 
tableting properties of the material. Keleb et al. (2002) reported on the use of a 
laboratory scale co-rotating twin-screw extruder, running the process without a die 
block as in that case the limited densification allowed the immediate production of 
granules having the proper size, thus eliminating an additional milling step.  
Interestingly, Keleb et al. (2004) also provided actual data of an extrusion process 
continuously run over an 8-hour period.  Sampling at regular intervals showed that the 
particle size, friability and tableting properties of placebo granules (α-lactose 
monohydrate containing 2.5% polyvinylpyrrolidone) were not significantly different 
as a function of time.   
 
A major advantage of the extrusion technique seems the flexibility in output capacity, 
allowing development work as well as production on the same apparatus: (a) Keleb et 
al. (2004) were able to cover a range in capacity from 5.6 to 18.5 kg/h using the same 
extruder, (b) Schroeder (2004) claimed that a specific type of planetary roller 
(BCG10) can process 0.5 kg as well as 100 kg, simply by extending the run time of 
the equipment (i.e. 3 min and 10 h, respectively).  Obviously the small batch can only 
be processed if the granulation process reaches steady-state extremely fast after start-
up.   
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Contrary to agglomeration techniques using a fluid bed, granulation by extrusion 
yields wet granules, hence these systems must be linked to a continuous drier (e.g. 
fluid bed or microwave). The Bohle Company developed an integrated granulating 
and drying system consisting of the planetary roller combined with a microwave drier.  
To avoid the drying step, one could run a melt granulation process in the extruder 
using a molten binder (e.g. wax, polyethyleneglycol) for particle agglomeration.  
Upon discharging the granules into an atmosphere of ambient temperature the binder 
solidifies to consolidate the granule. A similar process is possible in a fluid bed, 
spraying a molten binder onto the fluidized particles.  Using the melt granulation 
process, it is essential to determine the effect of the binder on the dissolution 
properties of the granules.   
 
The quality of granules produced by extrusion depends on several parameters: 
extrusion temperature, design of the screws (i.e. the number of (back) mixing and 
densification zones), accuracy of powder and liquid dosing unit.   
 
Processes which can be classified in a similar category as extruders are ploughshare 
mixers (Lödige) and horizontal high-shear mixer (HEC, Niro), however the 
commercially available systems have too large production capacities to be useful 
within the pharmaceutical industry.   
 
3.1.5.4.Instant agglomerators 
 
A few systems rely on high-speed mechanical agitation to continuously mix powder 
and liquid, thus ensuring instant formation of agglomerates.  A special feature 
characterizing these granulators is the very short residence time (seconds), as a 
consequence product hold-up (i.e. material being processed in the equipment at a 
given time) is limited, reducing waste at the end of the production cycle.  These 
systems are capable of high production capacities, but (theoretically) also allow 
processing limited quantities of material due to the small product hold-up.  However, 
if one is to use these systems to process small quantities it is essential to rigorously 
determine the equilibrium time as at start-up one possibly has to discard a too large 
amount of product before granules of constant quality are obtained.   
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The Nica M6 mixer/granulator (see figure below) (Ivarson mixer)  
 
 
Figure 7: Nica M6 Mixer/Granulator. 
 
uses a high-speed turbine to instantly mix the solids with the granulation liquid, 
whereas the Schugi Flexomix (Hosokawa) (see figure below) is equipped with blades 
rotating at high speed inside the processing chamber to generate sufficient mixing 
intensity and accomplish instant agglomeration.  
 
 
Figure 8: Schugi Flexomix instant agglomerator. 
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Similar to the granulation process by extrusion, the above-mentioned equipment 
produce wet granules, hence they must be linked to a continuous drying system (e.g. 
fluid bed).  Due to the short residence time inside the mixing chamber the accuracy of 
the powder and liquid dosing units is essential to ensure an end-product of constant 
quality.  Whereas the Nica mixer/granulator must be fed with a pre-blended powder, 
the Schugi Flexomix is also capable of mixing the powder components in the system 
and is already used in applications for bulk pharmaceuticals, although it has not 
specifically been designed for pharmaceutical purposes.   
 
As these processes should run without interruption, an essential feature needed is that 
the systems has to be self-cleaning: no scale should form on e.g. the mixer wall or 
blades as this compacted material could break off and mix with other less-dense 
granules, creating a non-homogeneous end product. To avoid this, the Schugi 
Flexomix is equipped with an interesting feature: the process chamber is fitted with 
external rollers flexing the elastomeric mixing chamber to prevent build-up of 
material on the inside. 
 
3.1.5.5.Roller compaction 
 
Roller compaction (see figure below) can be used as a continuous dry granulation 
process, a technique which does not require a drying phase, hence high production 
capacities can be obtained using relatively small equipment.  
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Figure 9: Flow diagram of roller compaction. 
 
However, the absence of water also causes roller compaction’s main problem: granule 
formation is strictly related to the compactibility of the material (under high 
compaction forces) as—contrary to wet granulation—capillary forces do not 
contribute to the binding mechanism.  As a result a large amount of fines is formed 
during milling of the compacts to their appropriate agglomerate size.  Although roller 
compactors can be equipped with a recycling unit for fines, a possible negative 
influence of recycling fines on drug uniformity has been reported. By controlled 
wetting of the powder formulation in a continuous fluid bed before roller compaction 
Inghelbrecht and Remon (1998) were able to dramatically reduce the amount of fines 
formed after milling and even improve the quality of the resulting tablets. However 
this approach eliminated the main advantage of roller compaction (a dry process, not 
requiring a drying phase), hence one should balance the added value of this approach 
against this disadvantage for each specific application. 
 
3.1.5.6.Semi-continuous granulation 
 
Combining two well established techniques, the high-shear granulation and fluid bed 
drying resulted in a semi-continuous agglomerator, the Multicell®.   
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The entire equipment train includes: 
 
• A feeding and dosing system. 
• A horizontal 30-liter high speed plough shear mixer with an airless spray 
system. 
• A rotary high speed sieving machine for wet sieving. 
• Three sequential fluid bed dryers. 
• A rotary high speed sieving machine for dry sieving. 
• Final product container. 
 
 
Figure 10: The Multicell®, 1. Master batch, 2. Flexible docking station, suction shoe of the IPC, 3. Post 
hoist for the IPC, 4. IPC, hopper, filter system, waging and discharging unit, 5. High shear 
mixer/granulator, 6. Airless high pressure dosing pump for the binder solution, 7. Solution tank, 8. Wet 
sieve, 9. Fluid bed dryers, 10. Product separator, 11. Dry sieve, 12. Conveying system with metal 
filters, 13. Lifting device, 14. Final product IBC. 
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Figure 11: The Multicell® at Pfizer / Goedecke, Freiburg, Germany. 
 
The principle of the operation is simple.  The first portion of the powder blend, which 
weighs about 8kg (+/- 2kg) is metered into the high shear mixer and moistened with 
an aqueous binder solution or with water if the binder is part of the pre-blend.  After 
the granulation process is finished this first portion is transferred through a high speed 
rotation sieving machine into the first chamber of the sequential fluid bed dryers.  The 
second portion of the powder blend is metered into the high shear mixer while the first 
one is pre-dryed.  The first pre-dryed portion is then transferred to the second 
chamber, the second portion into the first drying chamber, and the third portion is 
metered into the high shear mixer.  The process is continued until all the required 
portions which define the variable batch size have passed the equipment train.  The 
output of the equipment train is regulated by the slowest step of the process which is 
normally the drying process.  Typically the sequence is five minutes, providing an 
output of 96kg/hour (4).   
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3.1.5.7.The acceptance of continuous granulation processes 
 
The utilization of continuous granulation processes in the pharmaceutical industry has 
not been widely spread, and this has various reasons.   
 
The implementation of a continuous granulation process, resembling the food 
industry, only pays off for high volume products.  The volumes produced in the 
pharmaceutical industry are very small compared to the food industry.   
 
Regarding most of the continuous granulation processes, these mostly do not stand up 
to the high regulatory requirements made on the granulate.  The raw materials will 
have to be pre-blended in a batch mixer, before starting the continuous process, 
thereby loosing the advantages of a continuous process.   
 
One of the characteristics of continuous processes is the fact that the dwell period of 
the product is not really known inside the equipment.  There is only an average dwell 
period known for the product, whereas parts of the product clearly fall below that 
average time or exceed it.  This can have major influence on the quality of the 
product.   
 
For continuous processes the start-up and shutdown of the process often prove 
themselves to be problematic regarding product quality.  During start-up, equilibrium 
often does not kick in right away, therefore a certain amount of product will have to 
be discarded.  The same goes for the shutdown, a part of the product will have to be 
discarded.  Also the question will have to be raised, what happens with the product 
inside the equipment if the system shuts down due to a system failure (6).   
 
Continuous processes always come with the advantage of higher automation level, 
leading to reduction in personnel.  But this also means that the remaining personnel 
will have to be trained more. 
 
3.1.5.8.The Multicell® approach 
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Semi-continuous processes are capable of using the advantages of continuous 
processes and at the same time avoiding the disadvantages mentioned above.   
 
The biggest disadvantage of continuous processes is that the dwell period of the 
product in the equipment is not definable, as they are not divided into compartments 
whereas the product would be quantitatively moved from one compartment to 
another.  Also the quality of the start-up and shutdown material cannot be verified and 
therefore will have to be discarded.   
 
That is where the advantages of the semi-continuous processes come clear.  The 
processing of the raw materials is divided into definite compartments, which do not 
only represent process steps but also partial steps.  The product is quantitatively 
moved from one compartment to another and therefore the dwell period of the product 
is known in the equipment and can be controlled. 
 
It is evident that a batch is now manufactured as many small sub-batches.  The batch 
size is now flexible as the granulate quality parameters are now dependent on each 
and every subunit.  Now the batch size depends on the number of sub-batches 
produced, and not on the size of the equipment.  The quality of the sub-batches is 
reproducible, meaning that the quality of the first sub-batch corresponds to the quality 
of the last sub-batch.  Therefore no part of the batch will have to be discarded after 
starting up the equipment or during shutdown (5). 
 
3.1.6. Granulation scale-up process 
 
Scale-up is normally identified with an incremental increase in batch size until a 
desired level of production is obtained.   
 
The scale-up from the laboratory equipment to production-sized units is dependent on 
equipment design, which may or may not have been scalable as far as its dimensional 
feature or components selection is concerned.  The importance of scalability is well 
understood and accepted by the manufacturers of fluid bed processors.  Various sizes 
in their product line are logically designated and manufactured (3).   
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3.2. Introduction 
 
It has been shown in many different publications that the implementation of the 
Multicell® could bring many advantages into the pharmaceutical industry.   
 
• It contributes to the principles of Time-to-Market as it shortens the 
development time of the market image form. 
• Opportunity to optimize process at a small scale and avoids scale-up (pilot 
scale = commercial scale). 
• Provides stability results from the commercial equipment at an early 
development stage 
• Avoids the need for multiple biostudies. 
• It contributes to on of the ultimate principles of a lean manufacturing 
philosophy; Demand-driven production.   
• Higher product output. 
• Less floor space. 
• Better process control due to smaller scale.   
 
Also very a very important fact about the Multicell® is that this approach fits the needs 
of the new concepts of the FDA concerning risk-based management of critical 
processes such as the problem of scale-up and fulfills needs of FDA’s PAT initiative 
(4, 7, 8, 9).   
 
In the following approach it will be attempted to translate some of these statements 
made about the Multicell® into cash (“money talks…”) to make it more interesting for 
upper management.   
 
3.2.1. Economical evaluation of semi-continuous granulation 
 
One of the reasons why the Multicell® is not yet more used in the pharmaceutical 
industry is the silo management structure prevailing today.  Talking to people from 
marketing they would immediately be turned on by the idea of having a continuous 
process in manufacturing, leading to less personnel and higher automation.  The same 
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goes with Research & Development people, they would be very interested in having 
equipment which would save them a few scale-up steps and finally production would 
be thrilled to have a process which would ease the transfer of the formulation from 
R&D to production.   
 
“…Companies tend to operate in silos – R&D, manufacturing and marketing.  This is 
a very proprietary culture.  Knowledge and information sharing is the basis to 
overcome inefficiencies…” (10) 
 
 
But the reality shows us that there is little communication between the silos.  Up to 
now the Multicell® has only been implemented in production.  In order tap the full 
potential of the Multicell® it would also have to be implemented in R&D.  That way 
not only the obvious production advantages appear, but also the previously mentioned 
“Time-to-Market” advantage and the avoidance of the scale-up exercise.   
 
Let us look at what that implementation in production brings along. 
 
3.2.1.1.Comparison of discontinuous granulation and the semi-continuous 
 
Werani et al. recently presented an interesting comparison between the traditional 
batch granulation and the Multicell®: 
 
 
 142
 
Technology Lödige 900/WSG 300 Multicell Difference
Process  Batch process  Semi-continuous  
Batch size fixed to equipment 
capacity 
flexible depending on 
process time 
 
Mode of 
operation 
manual-driven and 
monitored 
almost lights-out-operated  
Floor space 130m2 100m2 - 23% 
Investment 1.6 Mio US$ 2.0 Mio US$ + 25% 
Equipment 
volume 
900 l (270 +/- 50kg) 30 l (8 +/- 2kg)  
Output 55kg/h 96kg/h + 75% 
Overall output 10kg/24h/m2 20kg/24h/m2 + 100% 
Table 1: Comparison between classical batch and semi-continuous granulation process. (4) 
 
Based on these information a comparison was performed on the volume of an average 
production site with 44 different products produced in 3 granulation rooms.  Each 
granulation room has roughly the same equipment volume which is mentioned in the 
table above.  The batch sizes vary from 76.8kg up to 456kg.   
 
We will start by showing the results of the granulation rooms A, B and C for one year 
of production.  In the table below there is an overview for granulation room A. 
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Products 
A 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size 
[kg] 
Total 
amount 
[kg] 
Gran. 
Duration / 
Batch [h] 
Total 
Gran 
Duration 
[h] 
Change 
- overs 
aaa 24 5 229.9 5'517.6 2.6 63.4 5 
bbb 3 3 220.0 660.0 9.0 27.0 1 
ccc 5 5 231.8 1'158.8 6.5 32.5 1 
ddd 451 12 243.8 109'931.3 6.5 2'931.5 38 
eee 6 7 204.6 1'227.6 5.0 30.0 1 
fff 13 7 207.0 2'691.0 4.5 58.5 2 
ggg 59 8 210.0 12'390.0 3.9 230.1 8 
hhh 1 1 200.0 200.0 4.0 4.0 1 
iii 116 10 253.3 29'378.2 4.0 464.0 12 
jjj 3 3 204.0 612.0 3.0 9.0 1 
kkk 27 7 235.0 6'345.0 2.6 70.7 4 
lll 7 7 240.0 1'680.0 3.4 23.9 1 
mmm 6 3 290.0 1'740.0 5.8 34.5 2 
nnn 19 5 290.0 5'510.0 5.2 99.0 4 
ooo 10 5 286.0 2'860.0 5.6 56.3 2 
ppp 111 10 144.0 15'984.0 5.9 650.5 12 
Total 861   197'885.5  4'784.9 95 
Table 2: Granulation room A production volume for one year.   
 
A change-over from one product to another has an average duration of eight hours 
(one shift) resulting in a total change-over time during one year of 760 hours.  This 
leads to a total occupancy time of the equipment of 5’544.9 hour per year.  
Granulation rooms B and C are shown below. 
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Products 
B 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size 
[kg] 
Total 
amount 
[kg] 
Gran. 
Duration / 
Batch [h] 
Total 
Gran 
Duration 
[h] 
Change 
- overs 
qqq 7 4 200.0 1400.0 4.0 28.0 2 
rrr 1 1 150.0 150.0 3.8 3.8 1 
sss 2 2 250.0 500.0 1.8 3.5 1 
aaa 30 5 229.9 6897.0 2.6 79.2 6 
ttt 8 4 344.4 2755.2 8.0 64.0 2 
uuu 61 8 208.0 12688.0 3.5 213.5 8 
vvv 47 8 230.0 10810.0 2.5 117.5 6 
www 2 2 217.0 434.0 4.0 8.0 1 
xxx 3 3 247.8 743.4 3.5 10.5 1 
yyy 1 1 210.0 210.0 3.5 3.5 1 
ddd 27 5 243.8 6581.3 6.8 183.6 6 
eee 1 1 204.6 204.6 4.0 4.0 1 
fff 3 3 207.0 621.0 4.5 13.5 1 
zzz 7 4 200.0 1400.0 3.9 27.3 2 
abb 2 2 210.0 420.0 6.0 12.0 1 
acc 2 2 200.0 400.0 7.5 15.0 1 
ggg 40 8 210.0 8400.0 3.9 156.0 5 
hhh 18 6 200.0 3600.0 4.0 72.0 3 
iii 154 10 253.3 39002.0 4.1 628.3 16 
add 2 2 300.0 600.0 5.3 10.5 1 
aee 1 1 200.0 200.0 7.0 7.0 1 
aff 56 8 76.8 4300.8 4.3 239.7 7 
mmm 18 6 290.0 5220.0 5.8 103.5 3 
nnn 21 4 290.0 6090.0 5.2 109.4 6 
ooo 6 3 286.0 1716.0 5.6 33.8 2 
ppp 97 10 144.0 13968.0 5.9 568.4 10 
Total 617   129311.3  2715.5 95 
Table 3: Granulation room B production volume for one year.   
 
Granulation room B also has 95 change-overs during one year which sums up to 760 
hours.  The total occupation time of the equipment is 3’475.5 hours. 
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Products 
C 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size 
[kg] 
Total 
amount 
[kg] 
Gran. 
Duration / 
Batch [h] 
Total 
Gran 
Duration 
[h] 
Change 
- overs 
agg 19 7 340.0 6460.0 4.5 85.5 3 
ahh 53 7 345.0 18285.0 4.7 247.0 8 
ajj 179 10 331.3 59297.3 5.0 895.0 18 
akk 4 4 165.6 662.5 5.0 20.0 1 
all 32 8 261.6 8371.2 3.8 121.6 4 
amm 1 1 310.0 310.0 18.5 18.5 1 
ann 5 5 456.0 2280.0 7.0 35.0 1 
aoo 26 6 246.0 6396.0 7.4 192.4 5 
app 1 1 228.0 228.0 5.5 5.5 1 
aqq 43 8 300.0 12900.0 2.8 121.7 6 
arr 502 10 330.0 165660.0 3.5 1757.0 51 
ass 3 3 340.0 1020.0 15.0 45.0 1 
Total 868   281870  3544.2 100 
Table 4: Granulation room C production volume for one year.   
 
Granulation room C has 100 change-overs during one year which sums up to 800 
hours.  This leads to a total occupation time of 4’344.2 hours.   
 
Granulation rooms A, B and C are all run in five days and two shift with three FTE’s 
(Full Time Equivalent) working on each shift.  Let us summarize: 
 
 Gran A Gran B Gran C 
Batches 861 617 868 
Granulate [kg] 197’855.5 129’311.3 281’870.1 
Production time [h] 4’784.9 2’715.5 3’544.2 
Change-over [h] 760 760 800 
Total occupation [h] 5’544.9 3’475.5 4’344.2 
FTE / shift 3 3 3 
Shifts 2 2 2 
Table 5: Summarization of the conventional granulation output. 
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As Dörr tested with his work (7) 28 products out of 30 market formulations could be 
transferred directly onto the Multicell® without any formulation changes.   
 
Now if we assume the best case and suppose that all existing products can be 
transferred without problems from the conventional granulation onto the Multicell® 
and basically replace granulation room number one and number three, the following 
can be observed for step 1. 
 
 Multicell® A Gran B Multicell® C 
Batches (861) 617 (868) 
Granulate [kg] 197’855.5 129’311.3 281'870.1 
Production time [h] 2061.3 2’715.5 2’936.1 
Change-over [h] 1520 760 1600 
Total occupation [h] 3’581.3 3’475.5 4’536.1 
FTE / shift 1 3 1 
Shifts 2 2 2 
Table 6: An overview on the production after replacing two conventional granulation rooms with the 
Multicell®. 
 
It can be observed that overall the change-over duration doubled itself compared to 
the conventional granulation.  This is due to the fact that although the Multicell® is 
equipped with a WIP (Washing in Place) system which has a duration of 
approximately 200 minutes there are still some spots which will have to be cleaned 
manually as e.g. the gaskets of the dosing system, the mixer, the sieving machine, the 
fluid bed dryers and of the strainer.  Also the sieves of the sieving machine will have 
to be cleaned manually as well as the intakes of the temperature probes in the fluid 
bed dryers.  As this comparison should not be made too optimistic, a change-over 
duration of 16 hours will be estimated.   
 
As the production time makes up about 80% of the total occupation time this does not 
have too much impact on the total occupation time.  The output of the Multicell® 
reduces the production time of 57% and at the same time it doubles the change-over 
time for room A.  This leads to a new total occupation time of 3’581.3, a total 
decrease of 1963.6 hours.  The production time in room C is reduced of 17% but the 
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change-over time is also doubled leading to a slight increase in total occupation time 
of 191.9 hours.   
 
So what has happened just be replacing the conventional granulation with the 
Multicell® is that we can see that the Multicell® is capable of handling the number of 
products and volume of an average production site, with only one FTE per shift 
instead of three.  The reason why all rooms where not replaced is simply because that 
it has to be expected that some products will not be transferable onto the Multicell® 
and due to the long change-over times, low volume products should not be produced 
semi-continuously.   
 
That leads us to step 2 of our comparison.  It could be observed in tables 2 and 3 
above that these rooms shared some of the products.  There are 11 products produced 
in room B which are also produced in room A.  As there has already been capacity 
gain in room A these products should all be produced in room A.   
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Products 
Multicell 
A 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size [kg] 
Total 
amount 
[kg] 
Total Multicell 
Duration[h] 
Change – 
over Duration 
aaa+ 54 5 229.9 12'414.6 129.3 176.0 
bbb 3 3 220.0 660.0 6.9 16.0 
ccc 5 5 231.8 1'158.8 12.1 16.0 
ddd+ 478 12 243.8 116'512.5 1'213.7 640.0 
eee+ 7 7 204.6 1'432.2 14.9 16.0 
fff+ 16 7 207.0 3'312.0 34.5 48.0 
ggg+ 99 8 210.0 20'790.0 216.6 208.0 
hhh+ 19 6 200.0 3'800.0 39.6 64.0 
iii+ 270 10 253.3 68'380.2 712.3 432.0 
jjj 3 3 204.0 612.0 6.4 16.0 
kkk 27 7 235.0 6'345.0 66.1 64.0 
lll 7 7 240.0 1'680.0 17.5 16.0 
mmm+ 24 3 290.0 6'960.0 72.5 128.0 
nnn+ 40 5 290.0 11'600.0 120.8 128.0 
ooo+ 16 5 286.0 4'576.0 47.7 64.0 
ppp+ 208 10 144.0 29'952.0 312.0 336.0 
Total 1'276   290'185.3 3'022.9 2'368 
Table 7: Room A after implementation of the Multicell® and the addition of the mutual products from 
room B (product names in bold with +).   
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Room B then looks like this: 
 
Products 
B 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size 
[kg] 
Total 
amount 
[kg] 
Gran. 
Duration / 
Batch [h] 
Total 
Gran 
Duration 
[h] 
Change 
- overs 
qqq 7 4 200.0 1400.0 4.0 28.0 2 
rrr 1 1 150.0 150.0 3.8 3.8 1 
sss 2 2 250.0 500.0 1.8 3.5 1 
ttt 8 4 344.4 2755.2 8.0 64.0 2 
uuu 61 8 208.0 12688.0 3.5 213.5 8 
vvv 47 8 230.0 10810.0 2.5 117.5 6 
www 2 2 217.0 434.0 4.0 8.0 1 
xxx 3 3 247.8 743.4 3.5 10.5 1 
yyy 1 1 210.0 210.0 3.5 3.5 1 
zzz 7 4 200.0 1400.0 3.9 27.3 2 
abb 2 2 210.0 420.0 6.0 12.0 1 
acc 2 2 200.0 400.0 7.5 15.0 1 
add 2 2 300.0 600.0 5.3 10.5 1 
aee 1 1 200.0 200.0 7.0 7.0 1 
aff 56 8 76.8 4300.8 4.3 239.7 7 
Total 202   37011.4  763.8 36 
Table 8: Room B after loosing all mutual products to room A.   
 
Room C stayed just like it was after step 1.  Let us have an overview of what is 
happening. 
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 Multicell® A Gran B Multicell® C 
Batches (1’276) 202 (868) 
Granulate [kg] 290’185.3 37’011.4 281'870.1 
Production time [h] 3’022.8 763.7 2’936.1 
Change-over [h] 2’368.0 288.0 1600 
Total occupation [h] 5390.8 1’051.7 4’536.1 
FTE / shift 1 3 1 
Shifts 2 1 2 
Table 9: An overview of the status in the three rooms after step 2. 
 
It can be observed that the total occupation time in room A has reached the 
approximate occupation time which it had with the conventional granulation 
equipment, but this time with only 1 FTE per shift instead of 3 FTE’s per shift.  Room 
B has decreased its total occupation time down to 1052 hours from 3475 hours.  This 
way it is enough to run that room with one shift instead of two.  Room C is still 
unchanged. 
 
Now the won capacity in room B should be exploited with other products in order to 
keep the low volume products away from the semi-continuous equipment which have 
longer change-over times.   
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Products 
B 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size 
[kg] 
Total 
amount 
[kg] 
Gran. 
Duration / 
Batch [h] 
Total 
Gran 
Duration 
[h] 
Change 
- overs 
qqq 7 4 200.0 1400.0 4.0 28.0 2 
rrr 1 1 150.0 150.0 3.8 3.8 1 
sss 2 2 250.0 500.0 1.8 3.5 1 
ttt 8 4 344.4 2755.2 8.0 64.0 2 
uuu 61 8 208.0 12688.0 3.5 213.5 8 
vvv 47 8 230.0 10810.0 2.5 117.5 6 
www 2 2 217.0 434.0 4.0 8.0 1 
xxx 3 3 247.8 743.4 3.5 10.5 1 
yyy 1 1 210.0 210.0 3.5 3.5 1 
eee 7 1 204.6 1432.2 4.0 28.0 7 
zzz 7 4 200.0 1400.0 3.9 27.3 2 
abb 2 2 210.0 420.0 6.0 12.0 1 
acc 2 2 200.0 400.0 7.5 15.0 1 
add 2 2 300.0 600.0 5.3 10.5 1 
aee 1 1 200.0 200.0 7.0 7.0 1 
aff 56 8 76.8 4300.8 4.3 239.7 7 
amm+ 1 1 310.0 310.0 18.5 18.5 1 
app+ 1 1 228.0 228.0 5.5 5.5 1 
ass+ 3 3 340.0 1020.0 15.0 45.0 1 
akk+ 4 4 165.6 662.5 5.0 20.0 1 
ann+ 5 5 456.0 2280.0 7.0 35.0 1 
bbb+ 3 3 220.0 660.0 9.0 27.0 1 
ccc+ 5 5 231.8 1158.8 6.5 32.5 1 
jjj+ 3 3 204.0 612.0 3.0 9.0 1 
lll+ 7 7 240.0 1680.0 3.4 23.9 1 
Total 241   47054.9  1'008.2 52 
Table 10: Room B after receiving all low volume products from rooms A and C.   
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Products 
Multicell 
A 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size [kg] 
Total 
amount 
[kg] 
Total Multicell 
Duration[h] 
Change – 
over Duration 
aaa 54 5 229.9 12'414.6 129.3 176.0 
ddd 478 12 243.8 116'512.5 1'213.7 640.0 
fff 16 7 207.0 3'312.0 34.5 48.0 
ggg 99 8 210.0 20'790.0 216.6 208.0 
hhh 19 6 200.0 3'800.0 39.6 64.0 
iii 270 10 253.3 68'380.2 712.3 432.0 
kkk 27 7 235.0 6'345.0 66.1 64.0 
mmm 24 3 290.0 6'960.0 72.5 128.0 
nnn 40 5 290.0 11'600.0 120.8 128.0 
ooo 16 5 286.0 4'576.0 47.7 64.0 
ppp 208 10 144.0 29'952.0 312.0 336.0 
Total 1251   284'642.3 2'965.1 2288 
Table 11: Room A after moving all low volume products to room B. 
 
Products 
Multicell 
C 
Batches/ 
year 
Batches/ 
Campaign 
Batch 
Size [kg] 
Total 
amount 
[kg] 
Total Multicell 
Duration[h] 
Change – 
over Duration 
agg 19 7 340.0 6460.0 67.3 48.0 
ahh 53 7 345.0 18285.0 190.5 128.0 
ajj 179 10 331.3 59297.3 617.7 288.0 
all 32 8 261.6 8371.2 87.2 64.0 
aoo 26 6 246.0 6396.0 66.6 80.0 
aqq 43 8 300.0 12900.0 134.4 96.0 
arr 502 10 330.0 165660.0 1725.6 816.0 
Total 854   277369.5 2889.3 1520 
Table 12: Room C after moving all low volume products to room B 
 
Now let’s have an overview of the status after step 3, after moving all low volume 
products into room B. 
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 Multicell® A Gran B Multicell® C 
Batches (1’251) 241 (854) 
Granulate [kg] 284'642.3 47’054.9 277’369.5 
Production time [h] 2'965.0 1’008.2 2’889.3 
Change-over [h] 2'288.0 416 1’520 
Total occupation [h] 5253.0 1’424.2 4’409.3 
FTE / shift 1 3 1 
Shifts 2 1 2 
Table 13: Final status after step 3.   
 
It has been shown that by replacing the conventional granulation rooms with the 
Multicell® a radical decrease in production time could be achieved and altogether the 
total occupation time could be decreased creating extra capacities for production.  
Thereby the shifts could be reduced from two down to one for conventional 
granulation, saving three FTE’s already.  By running the two Multicell® on two shifts 
with only one FTE per shift another 8 FTE’s could be saved, still having some free 
capacities in room B.   
 
In order to try to feature the savings in cash flow the costs of implementation will 
have to be considered.  For this case it will be assumed that not only the Multicell® 
costs will have impact on the cash flow.  There will probably have to be done some 
HVAC (Heating, Ventilation and Air Conditioning) upgrading and the costs for 
qualification and validation could also be considered.  Here is a summarization of the 
costs (HVAC and Qualification / Validation based on rough estimations) and savings. 
 
Costs [kCHF] Multicell A Multicell C Total 
Equipment 2630 2630 5260 
HVAC 150 150 300 
Qual. / Val. 50 50 100 
Total 2830 2830 5660 
Table 14: Total costs of Multicell® implementation in thousands of dollars. 
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The average costs of one FTE in Switzerland for pharmaceutical sites are 
approximately 100’000CHF per year.  As mentioned above the implementation of the 
Multicell® saved FTE’s by easing the operation of the equipment and reducing shifts. 
 
 Room A Room B Room C Total 
FTE 4 3 4 11 
Value [kCHF] 400 300 400 1100 
Total    1100 
Table 15: Savings based on reduced personnel.   
 
Assuming that all investments and implementation work will be performed in the first 
year and the FTE savings will start in the second year, the cash flow will look 
something like this: 
 
What has not been incorporated into these calculations is for example the possible 
costs of the change-requests which might have to be submitted.   
 
Also not included into these considerations are the possible savings due to reduced 
floor space and shorter throughput time.  The FTE savings are also conservative as the 
operation of the Multicell® could even be controlled by 0.5 FTE (12), which would 
mean that one person could theoretically run both Multicell® granulation rooms during 
one shift, saving two more FTE’s.   
Multicell implementation Cash-Flow
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Figure 12: Cash-flow with a breakeven point of about 6 years. 
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As can be seen in the above figure the breakeven point will be reached around five 
years and an EBIT of approximately 4 Million CHF after 10 years after implementing 
the Multicell® in this case study.   
 
These results show that the introduction of semi-continuous processes into the 
pharmaceutical industry does not only support lean manufacturing but also brings 
high saving potentials with it.  But it should be made clear that the implementation of 
the Multicell® in the production only, does not exploit the possible savings which can 
be achieved with it.  Additionally to that there will only be one validation of the 
process if the Multicell® is implemented in development, bringing in extra savings 
due to validation costs.  The FTE savings is just a piece of the possible savings 
achievable by being faster on the market.   
 
3.2.1.2.Time to market 
 
In order to achieve the main advantage of the Multicell® the silos operation, prevailing 
in the pharmaceutical industry today, will have to be broken down (13).  The 
interfaces between development and production is often extremely stiff, the 
researchers hardly communicate with the manufacturers and just deliver their 
formulation to the launch site and don’t want to have anything more to do with it.  
The manufacturer will then have to try to run the formulation on the production 
equipment and often this procedure takes a long time.  In order to easy these 
restrictions the researchers should accompany their formulation into manufacturing 
and not leave until the formulation runs on production equipment (14).  This 
procedure would be so much easier if both departments had the same equipment.  In 
order to achieve this, R&D should also purchase a Multicell® for their use.   
 
That way a pharmaceutical formulation can be optimized in early development on the 
Multicell®, thereby providing stability results from the commercial equipment at an 
early development stage.  Thereby the need for multiple biostudies is also avoided.  
By optimizing the formulation at such an early stage and having the Multicell® in 
R&D and at the production site, there will be no need for troublesome scale-up 
exercises (4).   
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Altogether this will have an impact on the development duration and hence “Time-to-
Market”.  But what does that high investment for R&D bring in for a researching 
company?   
 
The average costs to develop a new drug have reached an average of 802 million US$ 
in the year 2000 and the average time which goes by from the discovery of the active 
substance until market commercialization is 12 – 13 years (13).  The development of 
the drug product is only a small part of the total time.  Basically the pharmaceutical 
development only has time from the first delivery of active substance until the 
beginning of phase II clinical studies to develop the market formulation, including 
scale-up (which will not be necessary with the Multicell®).  This time is in average 
just about ¾ of a year (15).   
 
 So it is clear that in that time, every day counts.  The time savings potential has been 
well-investigated by Ewers, Küppers and Weinmann in their book “Pharma Supply 
Chain”.  There they also propose the implementation of the Multicell® and 
furthermore other improvements in the chemical production in order to speed up the 
delivery of the active substance.  With all improvements which are suggested they see 
a “Time-to-Market” improvement of about one too one and a half year (16).  
 
The “Time-to-Market” savings reachable with the Multicell® roughly sum up to 5 – 10 
weeks (16).  It is difficult to say how much that is worth, but there are some very good 
examples worth mentioning.     
 
Assuming that a product has an on-patent life of five years and during these five years 
there are 600 – 1200 manufacturing days of that product per site.  Depending on 
product they have different sales volume and so different values.  In the table below 
there are some examples of what one manufacturing day brings in to the company. 
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Sales volume Cash delivery 
2 Billion drug $1.6 million per day 
1 Billion drug $830’000 per day 
0.5 Billion drug $417’000 per day 
0.175 Billion drug $150’000 per day 
Table 16: Drug manufacturing revenues (17). 
 
The blockbuster product Lipitor from Pfizer e.g. delivers at least 5.7 million US$ per 
manufacturing day to Pfizer (17).   
 
This makes it clear that every day counts when trying to get a product on the market.  
A delay of only a week could cost the company revenues up to 11.2 million US$, 
which easily pays up the implementation costs of the Multicell®.   
 
Another example to emphasize the need to get fast to the market is a research which 
shows that on average, for every month a product is late to market it will lose 10% of 
its gross profit potential (18).  
 
The implementation of the Multicell® does not only apply to the researching industry.  
Generics companies thrive on the fact of being first on the market after a drug patent 
expires.  A generic company can be sure that they are not alone when a patent on a 
blockbuster drug is running out, but it is a cruel world and only the fastest generic 
companies win.  The drug developer earns 50% of the available revenue on the drug 
in their patent life.  But as soon the patent runs out the generics appear on the market 
and the first one gets 25% of the available revenue.  The second generic company on 
the market only gets 15% and all the other generics makers coming to the market 
divide the remaining 10%.   
 
3.2.1.3.The line of the future 
 
If one considers continuous and semi-continuous processes for the pharmaceutical 
industry, tableting and packaging are the processes which are already continuous.  A 
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connection between the rotary press and a packaging line is possible, i.e. if the tablets 
will not have to be coated.  Granulation and coating are the processes which are, up to 
now almost always run in batch mode, making it necessary to run tableting in batch 
mode also.  Now when we have shown that the implementation of a semi-continuous 
granulation process is lucrative, the possibility of a direct connection between the 
granulation process and tableting is possible.  The discharged sub-batches from the 
Multicell® could be dispatched directly into a depot over the rotary press and the 
tablets from the rotary press could also be transported directly onto the packaging 
line, making the whole process continuous.   
 
But what about coating?  Another semi-continuous production system exists which is 
called the Bohle concept.  The production line consists of an automatic dispensing 
system dosing the materials into a container, from where the materials are vacuum 
transported into the bowl of a high-shear mixer.  This single pot system combines 
agglomeration and drying (vacuum, possibly accelerated by microwave or gas 
stripping).  Next the dry product is milled and sieved on-line and after final blending 
fet into the compression machine.  Tablets discharged from the press fall on a 
conveying belt and are transported to a holding container, before being fed into a 
continuous coating system, consisting of two independent coating drums.  This is 
designed as a semi-continuous production process as the next dispensing process into 
the holding container can be started as soon as the initial sub-batch is introduced in 
the high-shear mixer.  Granulation of the second sub-batch is initiated as soon as the 
granulating bowl is cleaned, again creating a process where sub-batches pass 
sequentially through the system.   
 
 
Figure 13: Semi-continuous production line (Bohle concept) (2). 
 
 159
As we can see from the Bohle concept, such an automated dispensing system could be 
set up in front of the Multicell®, dosing the needed raw materials into the high-shear 
mixer.  After the granulate is tableted, the tablets could then be dispatched into a 
continuous coater called LeQtracoat® (Phoqus, Kings Hill, England).  The benefits of 
the LeQtracoat® is the fact that there is no drying needed for the coated tablets, as the 
technique is a dry powder electrostatic tablet coating.  The coated tablets could then 
be transported directly onto the packaging line.  As this process is continuous then 
there is also no coating scale-up needed.  The current capacity of the LeQtracoat® is at 
75’000 tablets per hour but according to Phoqus, the next generation is in 
development and should be able to handle 200’000 tablets per hour, which is enough 
to keep up with most rotary presses (19).   
 
 
Figure 14: The possible “Line of the Future”, featuring 1. the Glatt Multicell®, 2. the Courtoy Modul®, 
3. LeQtracoat® and 4. a Klöckner packaging machine. 
 
The line of the future is of course fully controlled by PAT.  For the Multicell® one 
could implement NIR spectrometers on the fluid bed dryers, controlling the moisture 
1 2
3 4
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of the drying granulate making sure that the granulate always contains a predefined 
moisture.    
 
3.3. Conclusion 
 
Above it has been shown that there are many different possibilities for the 
implementation of continuous granulation but the aspect of a semi-continuous 
granulation process is the most profitable one as it does not possess the many 
disadvantages of continuous processes.   
 
The reason why the Multicell® has not established itself yet in the pharmaceutical 
manufacturing and R&D is the fact that the silo thinking is still prevailing and that the 
couple of machines which have already been implemented, were only implemented in 
manufacturing, not taking advantage of the saving potential included in shorter 
“Time-to-Market”.  An interesting Stelex survey was published in Pharmaceutical 
Technology showing that 62% of the respondents believed that PAT could facilitate 
the implementation of continuous processes into pharmaceutical manufacturing (20).  
This shows that the awareness for the need of continuous and semi-continuous 
processes is very high.   
 
It is clear that the new manufacturing process will bring high savings due to a shorter 
“Time-to-Market”  and the ability of tailoring batch sizes to the demands of the 
marketplace (“just in time” manufacturing) reducing stock.  Also this new 
manufacturing process fulfills ideally the prerequisites of a drug quality system for the 
twenty-first century and the Food and Drug Administration’s Process Analytical 
Technlogy initiative (21) 
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4. Comparison of Rotary Presses and their Simulation by MCC PressterTM 
 
4.1. Theory 
 
4.1.1. Definition of a tablet 
 
The word tablet originates from the Latin word tabuletta, a diminutive of tabula which 
means a board or even a cover of a book.  This term, being aimed at the shape, was 
used for different solid dosage forms such as pills, pastilles and trochisci.  The 
derivated word from Latin does not really fit to the solid dosage forms today as they 
are mostly cylindrical (1).   
 
Tablets are solid preparations each containing a single dose of one or more active 
substances and usually obtained by compressing uniform volumes of particles. Tablets 
are intended for oral administration. Some are swallowed whole, some after being 
chewed, some are dissolved or dispersed in water before being administered and some 
are retained in the mouth where the active substance is liberated. 
The particles consist of one or more active substances with or without excipients such 
as diluents, binders, disintegrating agents, glidants, lubricants, substances capable of 
modifying the behaviour of the preparation in the digestive tract, colouring matter 
authorised by the competent authority and flavouring substances. 
Tablets are usually right, circular solid cylinders, the end surfaces of which are flat or 
convex and the edges of which may be bevelled. They may have lines or break-marks 
and may bear a symbol or other markings. Tablets may be coated (2). 
 
4.1.2. History 
 
The undisputed forerunners of the tablet are the pills, pastilles, rotuli, trochisci, 
morsels, pellets, boli and other shaped dosage forms which were intended for peroral 
application.  The ancient Greece made beadlets called “katapotia” out of bad tasting 
drugs and the ancient romans made “pilulae”.  Later these pills were coated with 
silver or even gold to cover the bad taste of some drugs which were the forerunners of 
the dragée.  The first tablet came when William Brockedon patented the first manual 
tablet press.  This press compressed with impact without any binders and was dosed 
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volumetrically.  This machine should change the market of solid dosage drugs but this 
change was very slow.  It took a few more decades until the first tableting machine 
patents were issued in America.  1874 McFerran obtained a patent for machines to 
produce compressed tablets, 1875 Remington and 1876 Dunton.  From the year 1877 
the American medical fraternity prescribed tablets more frequently to their patients 
and the tablet manufacturing started in an industrial manner (3).  The advantages of 
the tablet are such as: 
 
• Possible to manufacture in immense volumes.   
• Exact dosing achievable 
• Comfortable and safe administration 
• As a dry medicament it has a long shelf life 
• Easy to store and to transport 
• Most of the solid active ingredients can be processed into a tablet 
• Controllable release of drug effects 
• Taste masking 
 
4.1.3. Compression 
 
During tableting a powder formulation is filled into a die volumetrically and then 
compressed with the help of punches which immerse into the die.  During 
compression the particles inside the die experience different deformation stages 
between the tips of the upper- and lower punch tip.  The precompression has come to 
an end when the particles in the die cannot glide past one another any more.  During 
the further immersion of the punches into the die the next stage is reached, i.e. the 
deformation of the particles.  The deformation of the particles starts off as an elastic 
deformation which is reversible.  It increases the force which the punches will have to 
overcome to immerse further into the die.  As the elastic deformation energy barrier 
has been exceeded by the punches, the irreversible deformation takes place.  This 
point is called the yield pressure, i.e. the force which the material in the die needs to 
reach plastic deformation.  The plastic deformation phase does not increase the 
needed force for further immersion of the punches into the die.  Some brittle materials 
fracture when this much force is applied therefore brittle material should be avoided 
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for tablet formulations.  Just as highly elastic materials should be avoided as the yield 
pressure would have to be very high to reach plastic deformation.  Cohesive- and 
adhesive force, solid bond bridges and mechanical clasping are responsible for 
holding the tablet together after compaction.  In order to enable these bonds the 
contact area of the granulate particles has to be enlarged.  During compression the 
particles are pressed together and so decreasing the porosity of the powder therefore 
increasing the contact area.  The bigger the contact area is, the more bonding points 
will evolve between the particles.   
 
Crystalline materials show an ordered inner structure in the shape of a crystal lattice.  
These lattices mostly include some defects which weaken the structure bringing forth 
a favorable gliding plane.  In these gliding planes the particle bonds are formed.  
Amorphous materials on the other hand do not feature any favorable gliding planes.  
Therefore their deformation evolves more homogeneous.   
 
Thus it is obvious that the chemical properties of the powder particles are not the only 
important parameters but also the crystalline structure of the particles.  Also very 
important for the deformation process is the plastic deformation.  The plastic 
deformation is time dependent leading to the conclusion that the compression force 
will have to hold the pressure for a certain time before the plastic deformation yield 
pressure has been achieved.  Otherwise the deformation will remain elastic and the 
powder will stay powder instead of turning into a tablet.  This means that the tableting 
process cannot be run as fast as some would like.  The production capacity limit is 
therefore not only determined by the machine capacity but also by the minimal dwell 
time needed to reach plastic deformation (4).   
 
 
 
4.1.4. The Traditional Rotary Press 
 
The compaction on a rotary press takes place with an upper and a lower punch which 
are respectively pressed towards each other with the help of compression rolls.  These 
punch pairs are placed in a rotating turret along with the dies whereas during one 
rotation of the turret one pair of punches produce one tablet.  The raising and lowering 
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of the upper and lower punches are mainly done by cams.  An additional lowering 
cam supports tough movements of the upper punches in front of the compression rolls 
and a lifting cam after the tablet ejection.  According to this one rotation of the turret 
produces as many tablets as the number of punch pairs placed in the turret.  This 
number can vary from one punch up to 73 punch pairs.   
 
The operating method of a traditional rotary press can be described as follows.  The 
turret is turned horizontally and counterclockwise with the help of a gear or a spiral.  
The upper and lower punches are placed in the guiding cams and are lifted and 
lowered with their help.  The lower punches slide on the lower punch guiding cam 
until reaching the filling cam where it will be pulled down and the free space in the 
die will be filled with powder.  Moving further the lower punch will be pushed 
upwards by the adjustable dosing cam and the spare powder will then be scraped off.  
The lower punch will then be lowered again.  During the filling of the die, the upper 
punch was gliding above the filling station and will now be guided downwards 
according to the guiding cam and eventually will be pressed into the die by the 
lowering cam.  Both punches will then be moved under the compression rolls and 
where the punches will be pressed towards each other and make a tablet.   
 
The precompression roll is mostly smaller than the main compression roll or has the 
same size depending on the type of rotary press.  In many cases the precompression 
roll is beneficial as the powder will be de-aerated and big particle crystals will break, 
making it easier to consolidate during plastic deformation.  One can imagine that a 
relief of the strain between the pre- and main compression roll and then anew 
compression under the main compression roll should have positive influence on the 
crushing strength of the tablets.  Generally it can be said that the effect of a 
precompression roll is highly dependent on the powder formulation.   
 
The upper punch will then be lifted up by the guiding cam removing itself from the 
tablet in the die.  The lower punch will be pushed up by the ejection cam and will 
eject the tablet upwards.  The tablet will then be scraped off the die table by the tablet 
scraper and slides down from the die table across a chute into a container.  The upper 
punch will then be lifted further until it reaches its highest position and reaches the 
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filling station.  At the same time the lower punch will be pulled down by the guiding 
cam and will reaches the filling station and the cycle starts again.   
 
 
 
Figure 1: Top view of a tablet press cycle 
 
 
Figure 2: The turret of a Fette 2090® and a schematic illustration of the function of a rotary press. 
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4.1.5. Tablet Press Instrumentation 
 
In order to monitor and control a rotary press, certain sensors must be placed at 
certain locations on the machine.  These sensors are called transducers.  A Transducer 
is a device that converts signals from one form to another.  Rotary press transducers 
typically measure applied force, turret speed, or punch position.  In order to be able to 
use the signals coming from the transducers they will have to be amplified and then 
converted to digital form in order to be processed by a data acquisition system.   
 
Nowadays the preferred way of instrumenting rotary presses is with strain gages.  
Strain gages are foil, wire, or semiconductor devices which convert pressure or force 
into electrical voltage.  When a thin wire is applied with stress it will become longer 
and thinner.  These two factors lead to a higher electrical resistance.  If an electrical 
current is sent through this wire, it will be affected by the change in the resistance of 
the conduit.  This principle is used in strain gage-based transducers.  Foil gages, 
known for robust application range, useful nominal resistance and reliable sensitivity 
control are most commonly used for instrumentation of compression, precompression 
and ejection forces.  Semi-conductor-based strain gages are inherently more sensitive 
but suffer from high electrical noise and temperature sensitivity.  Such gages are not 
commonly used in tablet press instrumentation except for measurements of die-wall 
pressure and take-off forces.   
 
In order to ensure signal balancing of the strain gages the strain gages are arranged in 
a special way which is called a Wheatstone bridge.  The “full” bridge is composed of 
two pairs of resistors in a circle with two parallel branches used for input ant two for 
signal output.  By applying the so-called excitation voltage, which is typically 10V 
DC, to the bridge input and changing the resistance of different “legs” of the bridge 
by adding special resistors, we can make sure tat there is a zero output voltage when 
no load is applied to the transducers.  This is called zero balance.   
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Figure 3: A typical Wheatstone bridge arrangement of strain gages. 
 
Once the bridge is balanced, a small perturbation in the resistance of any “leg” of the 
bridge results in a nonzero signal output.  The output of the Wheatstone bridge is 
normally expressed in millivolts per volt of excitation per unit of applied force.  E.g. 
the a sensitivity of 0.2mV/V/kN means that applying 10kN force and 10V excitation 
will produce 20mV output.  To utilize such output it usually needs to be amplified 
several hundred times to reach units of volts.   
 
Another important function of the Wheatstone bridge is balancing of temperature 
effects.  Although individual strain gages are sensitive to temperature fluctuations, the 
Wheatstone bridge arrangement provides for temperature sensitivity compensation, so 
that the resulting transducer is no longer changing its output to any significant degree 
when it heats up.   
 
In a typical bending beam application (such as compression roll transducer), one side 
of the beam experiences tension while the other side undergoes compression.  By 
mounting two gages on each side the sensitivity of the transducer can be doubled.   
 
During research and development the measured compression force is usually 
compared to the actual position of the punch in the die.  For these purposes the Linear 
Variable Differential Transformer (LVDT) can be used.  LVDT is a device that 
produces voltage proportional to the position of a core rod inside a cylinder body.  It 
measures displacement or a position of an object relative to some predefined zero 
location.  On tablet presses, LVDT’s are used to measure punch displacement and in-
die thickness.  They generally have very high precision and accuracy.   
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Figure 4: Linear Variable Differential Transformer (LVDT). 
 
In a production environment, typical tablet weight control mechanism is driven by 
signals that are coming from a compression force transducer.  Strain gages may be 
installed on a column connecting the upper and lower compression wheel assemblies.  
This transducer measures what is generally known as main compression, i.e. a diluted 
average of the forces acting on the upper and lower punches.   
 
As described above, the punches are guided under the pre- and main compression 
rolls.  As the positions of the rolls are fixed during compression, the force measured 
during compression depends on the amount of powder in the die.  The more powder in 
the die the higher the compression force measured.  This fact is utilized for the tablet 
weight controls during production.   
 
With the help of the measured force at each position of the punches a force versus 
time diagram can be created.  In these diagrams the dwell time can be determined by 
measuring the length of time in which the force curve is above 90% of the peak force.   
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Figure 5: Force signal of the lower punch and reference signal indicating the mid of the punch head 
under the compression roller.  The Dwell time is shown on the right side of the figure (5). 
 
 
 
 
 
4.1.6. Displacement (Courtoy) 
 
Tablet weight control using “displacement” is based on the measurement of thickness 
variations under constant force and is measured at precompression. This measurement 
is possible when using the so-called “pneumatic compensator”. 
 
The displacement-tablet weight control principle is fundamentally different from the 
principle based upon compression force. When measuring displacement, the control 
system’s sensitivity does not depend on the operating point on the graph (i.e. it does 
not depend on the tablet weight) but depends on the applied precompression force. In 
fact, the lower the precompression force, the more sensitive the monitoring/control 
system. 
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Figure 6: The pneumatic compensator 
 
As indicated in the above drawing, the upper precompression roller is attached to an 
air-piston, which can move up/down in an air-cylinder. The air pressure [p] in the 
cylinder is set as a product parameter at initial product set-up and is kept at a constant 
value by the machine’s control system. This pressure [p] multiplied by the piston 
surface [Spiston] is the constant force at which the piston – and consequently the roller 
– is pushed downwards against a fixed stop. The lower precompression roller is 
mounted on a yoke and its vertical position can be adjusted through the control system 
by means of a servomotor. The position of the lower precompression roller determines 
the precompression height. At every precompression, the upper punch hits the upper 
roller and is initially pushed downwards into the die. As the lower punch is pushed 
upwards by the lower roller, the powder is being compressed, while the exerted 
compression force increases. At a certain point (depending on set air pressure, 
precompression height and powder characteristics) the reaction force exerted by the 
powder on the upper punch equals the force exerted by the air pressure on the piston. 
The punch has to continue its way under the roller, because the turret is spinning. As 
the piston/roller precompression assembly cannot exert a force above 
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Equation 1 
pistonSpF ×=max  
 
no further compression of powder is possible. The upper punch will push the upper 
precompression roller assembly up and continue its way under the roller. In fact, the 
top punch, powder slug between punches and bottom punch will move together, 
following the bottom precompression roller. During this movement, there is no further 
compression and the top precompression roller will move up and back down. During 
the time the upper roller makes this up/down movement, the compression force on the 
punch – and therefore on the powder – remains constant and is equal to Fmax. An 
LVDT position sensor accurately measures the movement of the upper roller 
assembly. This vertical movement will reach its maximum value when the punch is 
right under the centre of the roller. This maximum value is registered by the control 
system and is called the “displacement”. The displacement is measured and recorded 
at the precompression section of the Courtoy. 
 
It is easy to understand that 
 
Equation 2 
[ ]slugsedprecomprestheofheightSW ____××= ρ  
 
Equation 3 
( )[ ]dEqArPCHSW +×+××= )2ρ  
 
• W is the weight of the pre-compressed powder slug, and therefore also the first 
layer/final tablet weight 
• ρ is the density of the pre-compressed powder slug (i.e. NOT the powder bulk 
density and not the final tablet density, but the density of the slug after pre-
compression and prior to main compression) 
• S is the surface area of the die opening 
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• PCH is the Precompression height measured as the distance between the 2 
extreme tips of upper and lower punch when the punches are right under the 
centre of the rollers and the upper-roller is in its lowest position 
• EqAr is the “equivalent arrow”, a correction factor taking into account the 
concave part of the punch tips 
• d is the displacement. 
 
This can be re-formulated as follows:  
 
Equation 4 
( )[ ] dSEqArPCHSW ××+×+××= ρρ 2  
 
where the following conditions apply: 
• ρ is constant from tablet to tablet as the pre-compression force on each slug is 
the same: Fmax. All powder slugs are pre-compressed to the same density, 
thanks to the use of the air compensator. 
• S is constant, depending only on tablet size 
• The precompression height PCH is constant as long as the lower pre-
compression roller is not moved 
• EqAr is constant as it depends only on the punch tip shape  
 
resulting in  
 
Equation 5 
dBAW ×+=  
 
Equation 6 
( )[ ] .2 ConstEqArPCHSA =×+××= ρ  
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Equation 7 
.ConstSB =×= ρ  
 
The relation between what is measured (the displacement) and what needs to be 
controlled (tablet weight) is a linear relationship. This linear relationship makes the 
control algorithm very simple. Yet at the same time very accurate. 
 
 
Figure 7: The linear weight versus displacement relationship.   
 
The above graph clearly shows the relationship between W and d, but also clearly 
indicates the influence of the other parameters ρ, S, PCH and EqAr. One of the 
important advantages of the “displacement control” system is the automatic 
calculation of the tolerance. If the allowable tolerance on the weight is for example 
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3%, it will correspond to an allowable displacement tolerance of 3% on [PCH + (2 x 
EqAr) + d]. As PCH and EqAr are known at any moment, the tolerance on d can 
easily be calculated. Important to note is that the tolerance on the measured signal 
(being the displacement d) is independent from the operating point on the weight-
versus-displacement graph. This is not the case with a compression force-controlled 
system, where the tolerance on the force varies with the working point on the graph. 
Moreover the upper and lower force tolerances are different, as can be seen from the 
graph below. 
 
 
Figure 8: Force tolerance as a function of weight tolerance. 
 
Another important advantage of the “displacement” control system is its 
independence from the machine’s stiffness. As the displacement is measured at 
precompression under relatively low compression forces (typically between 1 and 3 
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kN), the deformation of the press is negligible. This is entirely different in case of a 
compression force control system, which measures the actual compression force at 
main compression, where forces can go up to 100 kN. As no 2 compression machines 
have the same stiffness (stiffness of individual parts and stiffness of joints can never 
be exactly the same), variations in the force-versus-weight characteristic of any 2 
machines – even of the same model – are inevitable. The graph below illustrates that 
with the same compression force set point and same set distance between compression 
rollers, the weaker machine exhibits more deformation, resulting in a thicker (i.e. 
heavier) tablet. This means that for the same tablet weight and final compression 
height, the weaker machine will have to run at a lower compression force set point, 
resulting in tablets with lower crushing strength. Moreover, the variation in force / 
tablet weight varies with the rigidity of the complete system (i.e. tablet + tablet press), 
resulting in different force tolerance limits between various machines for the same 
tablet weight tolerance. It is clear that, in case of compression force control, simple 
transfer of force set point, force tolerance limits and compression height (i.e. distance 
between main compression rollers) is impossible, requiring parameter set-up per 
product and per machine. 
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Figure 9: Influence of machine rigidity on force – weight relation. 
 
The stiffness-independence of the “displacement” control system makes production 
exchange between displacement-controlled presses much easier, allows for more 
straightforward product scale-up, more flexible production, easier production transfer 
between different sites in case of a multinational pharmaceutical company. 
 
The use of an air compensator has the additional and important advantage of an 
increased and controlled dwell time during precompression. In fact, during the up- 
and downward movement of the upper precompression roller, the compression force 
remains constant. As the dwell time is defined as the time during which compression 
force is above 90% of its peak value, the dwell time will be extended by the longer 
flat part in the compression profile shown in the graph below. 
 
 179
 
Figure 10: Force and displacement profiles on precompression using air compensation. 
 
If the precompression height PCH is reduced by raising the lower compression roller, 
the point of initial contact and the point at which the upper roller starts moving up, 
will move to the left. This results in an increase in displacement, but also in a longer 
dwell time. A longer dwell time in turn improves the de-aeration of the powder and 
the re-arrangement of the granules in the die prior to the final compression. These two 
factors increase the crushing strength of the tablets considerably and prevent potential 
capping problems. The PCH and precompression force can be set up so as to offer 
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optimal dwell time. Once fixed, the control system automatically calculates and sets 
the tolerance on the displacement as a function of weight tolerance (6). 
 
4.1.7. Scale-up in tableting 
 
Scale-up is generally defined as the process of increasing the batch size.  Scale-up of a 
process can also be viewed as a procedure for applying the same process to different 
output volumes.  There is a subtle difference between these two definitions: batch size 
enlargement does not always translate into a size increase of the processing volume.  
E.g. for the tableting process, a scale-up simply means enlarging the output by 
increasing the speed.   
In tableting applications, the process scale-up involves different speeds of production 
in what is essentially the same unit volume (die cavity in which the compaction takes 
place).  However there are still kinematic and dynamic parameters that need to be 
investigated and matched for any process transfer.  One of the main practical 
questions facing tablet formulators during development and scale-up is whether a 
particular formulation will sustain the required high rate of compression force 
application in a production press without lamination or capping.  Usually, such 
questions are never answered with sufficient credibility, especially when only a small 
amount of material is available and any trial-and-error approach may result in costly 
mistakes along the scale-up path.  As tablet formulations are moved from small-scale 
research presses to high speed machines, potential scale-u problems can be eliminated 
by simulation of production conditions in the formulation development lab.  In any 
process transfer from one tablet press to another, one may aim to preserve mechanical 
properties of a tablet (density and, by extension, energy used to obtain it) as well as its 
bioavailability (e.g. dissolution that may be affected by porosity).  A scientifically 
sound approach would be to use the results of the dimensional analysis to model a 
particular production environment.  Studies done on a class of equipment generally 
known as compaction simulators or tablet press replicators can be designed to 
facilitate the scale-up of tableting process by matching several major factors, such as 
compression force and rate of its application (punch velocity and displacement), in 
their dimensionless equivalent form (7).   
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The only real test to determine that the scale-up batch will run well on the selected 
rotary press in production is a “use test”, i.e. the batch must be run on the rotary press 
in question.  The most important characteristics of the powder formulation to be 
compacted are particle size and particle size distribution, density and /or porosity, 
powder flow, cohesiveness and lubrication.  The one consideration to keep in mind 
during scale-up is the speed of the press, which will directly affect the time available 
for the die filling to occur and the available time for plastic deformation.  Only high-
speed compaction simulators or other equipment that controls dwell time will give 
any indication of potential problems with high-speed rotary presses.  The most 
important material properties to the compaction operation are elastic deformation 
behavior, plastic deformation behavior and viscoelastic properties which are the 
mechanisms of deformation.  We remember, elastic deformation is a reversible 
process but plastic deformation and brittle fracture are not.  More importantly, plastic 
deformation and viscoelastic behavior are kinetic phenomena, i.e. time is important 
and they can be affected by press speed.   
 
The effect of the rotary press speed on the powder formulation is of primary concern 
in tableting scale-up.  Whether the product development work was performed on a 
single-stroke press or a smaller rotary press, the objective in operation will be to 
increase efficiency, in this case the tablet output rate and thus the speed of the rotary 
press.  For material that deforms exclusively by brittle fracture, there will be no 
concern.  Materials that exhibit plastic deformation, which is a kinetic phenomenon, 
do exhibit speed sensitivity.  The usual parameter indication is that target tablet 
crushing strength cannot be achieved at the faster rotary press speed.  Sometimes 
slowing the rotary press down is the only option for the operator of the rotary press to 
correct the problem.   
 
No matter what type of tablet press was used in research and development or in the 
pilot plant, there is no possible way to experience the phenomenon on a full-size batch 
and the associated time of the compaction run.  There are several problems which can 
be expected such as build-up of heat due to the length of the operation of the press.  
This temperature increase could have effects on the stability of the active compound 
or even have softening effects on any low melting ingredients.   
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As explained above, the two major elements in the formation of a tablet are the forces 
applied to the blend and the length of time those forces are applied.  This time is also 
called the dwell time and is the time in which the flat portion of the punch head is in 
contact with the compression roll.  Dwell times significantly differ upon scale-up.  
Dwell times are also different between different manufacturing presses which could 
even be in the same production area.  The dwell times on typical development presses 
run from 80 to 500msec.  Manufacturing scale rotary presses reach dwell times down 
to 4msec per compaction event.  So basically it is obvious that these differences 
between the development presses and the manufacturing presses can result in scale-up 
nightmares, leading to capping, lamination and die binding (8).   
 
4.2. Introduction 
 
There are many different kinds of rotary press manufacturers on the market today and 
all state that their presses produce the best available quality of tablets on the market.  
Most of the rotary presses on the market are based on the same concept, having a 
precompression- and a main compression roll.  These rolls are generally monitored 
with a force control, controlling the weight of the tablets.  The concept of filling the 
dies is also generally the same, having a feeding mechanism filling the dies from 
above, requiring the powder to have good flowing properties if the machine should 
run with high speed. 
 
Three different rotary presses were tested on their performance with 2 different 
routine production formulations.  The products to run on the different rotary presses 
were picked out according to their properties.  There was one “trouble-free” product 
and one “worst case” product based on previous experience in manufacturing. 
 
The three different rotary presses were selected, trying to keep them as different from 
each other as possible, concerning their tableting concept.  The following three 
presses were selected. 
The Fette 2090®, representing the usual concept of compression rolls monitoring and 
feeding mechanism, 
the IMA Comprima 300®, representing a new concept of die feeding which feeds the 
dies sideways with the help of centrifugal force and the Courtoy Modul®, representing 
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a new concept for the compression rolls whereas the tablet weight is controlled using 
“displacement” of the pneumatic precompression roll and thereby prolonging the 
dwell time during precompression.   
 
The results with these two products on the different presses were simulated on the 
MCC PressterTM.  The MCC PressterTM is a rotary press simulator which is able to 
simulate most rotary press type on the market based on compression force and dwell 
time.  It is a high speed single station tablet press which replicates the rotary tablet 
presses linearly.  Production press parameters and output speed are selected from a 
database and the appropriate tooling and compression rolls are installed into the MCC 
PressterTM.   
 
Based on the speed at which the different rotary presses were running on, during their 
performance trials, the MCC PressterTM was set up to simulate their respective dwell 
times and as close as possible to their production parameters.  Most importantly the 
punch gap during precompression and main compression was simulated as it could be 
that the force measurements vary between presses.  The tablets gained from these 
simulation runs were then inspected on crushing strength, disintegration and 
dissolution profile and these compared to the produced tablets on the respective rotary 
press.   
 
The object of this work was to determine if the PressterTM is capable of preventing 
scale-up problems which occur when moving a formulation from lab scale or pilot 
scale onto manufacturing scale rotary presses.   
 
4.3. Materials and Methods 
 
As mentioned above, the formulations used for these comparison tests are routine 
production formulations.  The ingredients are listed in Table 1. 
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 Product A, “trouble-free” Product B, “worst case” 
Excipients Hydroxypropyl-methyl-
cellulose 
Poloxalkol 
Lactose monohydrate 
Polyvinylpolypyrrolidon 
Glyceryl monostearate 
Polyethylene glycol 4000 
Avicel PH 102 
Polyvinylpolypyrrolidon 
Aerosil 
Magnesiumstearate 
 
Active Pharmaceutical 
Ingredient (API) 
a b 
c 
Granulation Wet granulation Dry granulation 
Table 1 
4.3.1. Powder Evaluation  
 
4.3.1.1.Particle Size Distribution 
The particle size distribution is an important parameter for predicting the flowing 
properties and behavior of powders.  Important parameters of the powder particles are 
the general size of the particles and their shape.  Having a homogeneous particle size 
is very important as otherwise a segregation of the different powder ingredients is for 
sure, leading to a problem in content uniformity of the tablets.  Another important 
parameter is the shape, as the particle size distribution can be homogeneous but with 
needle shaped particles, making the flowing properties poor (9).   
 
The particle size and its distribution for the PressterTM powder samples were 
determined gravimetrically on a Retsch AS 200 Control (Retsch GmbH & Co. KG, 
Haan, Germany).  Approximately 50g of powder was used for each measurement.  
The sieving duration was set at 5 minutes, the amplitude was set at 1mm and the 
vibration intervals lasted 10 seconds.   
 
4.3.1.2.Density  
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The bulk and tap density of the two formulations was determined with a JEL STAV 
2003 Stampfvolumeter (JEL Präzisionswerkzeuge, Stuttgart, Germany).  Bulk density 
was determined after filling 100g of the powder formulation into a measuring cylinder 
and reading the volume of the powder from the cylinder.  The bulk density represents 
the state in which the powder formulation is during powder flow.  Generally the 
particles lie inordinate besides one another and do not show any preferred orientation.  
With mechanical vibration it is possible to carry enough energy onto the particles that 
they will overwhelm the inter-particular friction and settle into a higher orientation.  
With higher orientation of the particles, the powder cylinder will drop and indicate the 
tap density (10). Tap density was determined by tapping the measuring cylinder 1250 
times two times in a row and determining the volume of the powder cylinder.  If the 
volume of the powder cylinder did not sink more than 2cm3 after the second 1250 
times the first value will be used.  If the powder volume sank more than 2cm3 after the 
second 1250 times the measurement will have to be repeated.  Having determined 
these parameters it is possible to calculate the Hausner ratio (HR) using 
 
Equation 8 
⎥⎦
⎤⎢⎣
⎡−
⎥⎦
⎤⎢⎣
⎡−
=
ml
gdensityBulk
ml
gdensityTap
HR  
 
The Hausner ratio can be used to determine the compaction tendency of a powder 
formulation which is important for transportation and the tableting process.  The 
Hausner ratio should not exceed 1,20 as the powder formulation tends to sink in 
volume and consolidate, thereby deteriorating the flowing properties of the powder 
formulation.   
The true density of each powder formulation was determined with a helium 
pycnometer (AccuPyc 1330, Micrometitics Instrument Inc., Norcross, GA, USA).  
The experimental sample was accurately weighed and loaded into the sample cell.  
The sample volume was computed by measurements of the pressure observed by 
filling the sample chamber with ultra-high pure helium gas followed by discharging 
the gas into a second empty chamber.  The measurements were repeated for 5 such 
cycles. 
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4.3.1.3.Flowing Properties 
 
In order to determine the flowability of a granulate formulation a funnel was used 
according to the flowability test method 2.9.16 from the Ph. Eur. (11).  The powder 
flow determination was repeated three times and the mean value of the results was 
determined. 
 
 
Figure 11: Flow funnel and nozzle.  Dimensions are in millimeters.   
 
4.3.2. Compact Preparation and Evaluation 
 
4.3.2.1.Compression 
 
The following three rotary presses were tested with the products A and B, whereas the 
Fette 2090® is used for routine production of these products, having the highest 
experience.  The other two, IMA Comprima 300® and Courtoy Modul® were tested at 
their respective manufacturing site.   
 
The tests were started at a slow speed, i.e. a long dwell time and gradually speeded up 
to a shorter dwell time.  During production, samples were taken at each achieved 
dwell time and evenly throughout the test.  These samples were then tested on 
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crushing strength, disintegration, content uniformity and dissolution rate (only Fette 
2090®) as these parameters are the most common ones to change during a scale-up 
procedure or a transfer from one rotary press to another even though the production 
parameters are kept constant.   
 
The dwell time was calculated using 
 
Equation 9 
[ ]
TPHPCD
NPLmDwelltime ××
××= π
3600000sec  
 
Whereas: 
L = Flat portion of the punch head 
NP = Number of Punches 
π = 3.141 
PCD = Pitch Circle Diameter 
TBL/H = Tablets per Hour 
 
These achieved dwell times were then set up on the MCC PressterTM along with all 
other parameters such as the size of the compression rolls, punch gap during 
maximum compression and the corresponding compression tooling.  
 
 
Fette 2090®:   As mentioned above, the Fette 2090® (Fette GmbH, 
Schwarzenbek, Germany) is used for routine production of products A and B.  The 
Fette 2090® is a 43 station rotary tablet press equipped with EU B-Tooling for these 
tests.  The punch gap during the production of the sampled batches is mentioned 
below.   
 
 Product A punch gap:  Pre Co. 2.3mm / Main Co. 1.9mm 
 Product B punch gap:  Pre Co. 2.5mm / Main Co. 1.1mm 
 
Product A routine tooling: 7mm, round, flat, beveled edge.   
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Product B routine tooling: 10 x 5.2mm, oval, convex.   
 
Product A tablet parameters: 128mg weight, 3mm thickness, 50N crushing 
strength 
Product B tablet parameters: 150mg weight, 3.6mm thickness, 100N crushing 
strength 
 
For the dwell time calculation, the following values are needed: 
 
 Flat portion of the punch head  = 9.65mm 
 Number of punches   = 43 
 Pitch circle diameter   = 410mm 
 
The diameter of the Pre – and Main Compression rolls are both 250mm.  In figure 1 
the respective dwell times can be observed for the Fette 2090®. 
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Figure 12: Showing the correlation between tableting speed and dwell time for the Fette 2090®. 
 
IMA Comprima 300®: A performance test was done on the IMA Comprima 
300® (IMA Industria Macchine Automatiche S.p.A, 
Bologna, Italy), a 36 station rotary tablet press 
equipped with special IMA compression tooling.  This 
rotary press is representing a completely new tableting 
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technology principle.  Filling of the dies by centrifugal force from inside the turret 
requires dies with a special lateral opening, as powder is located in the centre of a 
rotating die table and piped to dies through holes.  Also the tablets are ejected 
downwards instead of upwards as is normal with the traditional rotary presses.  There 
is a complete separation of lubrication and product area and an automatic Cleaning-
In-Place (CIP) system.  These are the most remarkable characteristics of the 
innovation tablet press IMA Comprima 300®.   
Theoretically the filling of the dies should occur more accurately the faster the turret 
spins and so leading to lower standard deviations of tablet weight.   
The CIP should enable a fully automatic cleaning during change-over with only one 
person in about 4 hours, instead of up to three persons for standard rotary presses (12).   
Due to the innovative centrifugal die filling system the yield of the IMA Comprima® 
is exceptional.  Where standard technology rotary presses loose a lot of powder due to 
the dust suction from the die table, the IMA Comprima® does not loose any powder 
due to the centrifugal filling.   
 
The routine powder formulations were also transferred to the test site, 50kg 
respectively for product A and B.  The IMA Comprima 300® is equipped with 
different kinds of punches than the usual EU B-Tooling.  The IMA Comprima 300® 
punch shafts are permanently attached to the turret and only the punch tips are 
exchangeable.  Therefore the standard tooling could not be installed and the punch 
tips available at IMA, which were the closest to the standard tooling, had to be used.   
 
 Product A punch gap:  Pre Co. 2.0mm / Main Co. 1.4mm 
 Product B punch gap:  Pre Co. 3.1mm / Main Co. 2.4mm 
 
Product A alternative tooling: 7mm, round, convex.   
Product B alternative tooling: 10 x 4mm, oval, convex.   
 
Product A tablet parameters: 128mg weight, 3.5mm thickness, 50N crushing 
strength 
Product B tablet parameters: 150mg weight, 4.1mm thickness, 100N crushing 
strength 
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For the dwell time calculation, the following values are needed: 
 
 Flat portion of the punch head  = 25mm 
 Number of punches   = 36 
 Pitch circle diameter   = 437mm 
 
The diameter of the Pre – and Main Compression rolls are respectively 140mm and 
300mm.  In figure 2 the dwell times can be observed for IMA Comprima 300®. 
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Figure 13: Showing the correlation between tableting speed and dwell time for the IMA Comprima 
300®. 
 
Courtoy Modul®:   A performance test was done on the Courtoy Modul® 
(Courtoy nv, Halle, Belgium), a 38 station rotary tablet press equipped with EU B-
Tooling.  The Courtoy Modul® has, different to the standard rotary press, a 
displacement tablet weight control instead of the traditional compression force weight 
control.  This approach is not dependent on the tablet weight but rather on the applied 
force.  Another “irregularity” to the standard rotary press is the fast change-over 
concept which the Courtoy Modul® has to offer.  This concept should enable a 
change-over in as little as one hour with one person.  This is possible due to an 
Exchangeable dust-tight Compression Module (ECM) which can be built out of the 
manufacturing-press and a ready second module can be built in and production can 
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start again.  This requires that the ECM will not be opened during production, 
otherwise the room will have to be cleaned as well.   
 
The respective routine compression tooling for product A and B were installed into 
the Courtoy Modul®.   
 
 Product A punch gap:  Pre Co. 2.3mm / Main Co. 1.7mm 
 Product B punch gap:  Unknown 
 
Product A routine tooling: 7mm, round, flat, beveled edge.   
Product B routine tooling: 14 x 5.2mm, oval, convex.   
 
The routine powder formulations were also transferred to the test site, 50kg 
respectively for product A and B.  The Courtoy Modul® was set up according to the 
requested tablet parameters. 
 
Product A tablet parameters: 128mg weight, 3mm thickness, 50N crushing 
strength 
Product B tablet parameters: 150mg weight, 3.6mm thickness, 100N crushing 
strength 
 
For the dwell time calculation, the following values are needed: 
 
 Flat portion of the punch head  = 9.65mm 
 Number of punches   = 38 
 Pitch circle diameter   = 425mm 
 
The diameter of the Pre – and Main Compression rolls are both 240mm.  In figure 3 
the dwell times can be observed for Courtoy Modul®. 
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Figure 14: Showing the correlation between tableting speed and dwell time for the Courtoy Modul®. 
 
MCC PressterTM:  A single-station development tablet press which 
reproduces the dwell time of manufacturing-scale tablet presses.  The PressterTM 
(Metropolitian computing corporation, East Hanover NJ, USA) can be set up to match 
the rate, roll wheel configuration and tooling of many manufacturing-scale tablet 
presses.  This enables developers to eliminate compaction rate as a variable upon 
scale-up.  As described above, the three different manufacturing presses contain 
different pre- and main compression rolls.  The corresponding roll sizes were installed 
previous to the simulations of the different manufacturing presses.  Also the 
corresponding compression tooling for each of the routine production formulations 
were installed previous to simulation.  After setting up the correct parameters and the 
corresponding rolls and compression tooling the simulation started with the longest 
dwell time used during the performance test of the manufacturing press.  The 
granulate of the routine production formulation was filled by hand into the die, after 
weighing the correct amount.  After producing thirty tablets for every dwell time, ten 
tablets were directly tested on crushing strength and thickness.  The rest of the tablets 
were set aside for other tests such as disintegration and dissolution.   
 
4.3.2.2.Crushing strength 
 
The crushing strength is one of the most important tablet properties to be observed 
during development and scale-up.  The crushing strength is a function of the 
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compaction force and is related to the disintegration and dissolution rate.  The 
crushing strength is also dependent on the rotary press speed, i.e. the dwell time, 
which makes it very important to observe the effects of speed on the crushing strength 
of the tablet during development and eventually scale-up.   
 
The crushing strength of the produced tablets was determined be compressing the 
tablet between two jaws which crushed the tablet.  The machine measures the force 
which is applied to the tablet and detects when it fractures.  For these crushing 
strength tests the Schleuniger Tablet Tester 8M (Dr. Schleuniger Pharmatron AG, 
Solothurn, Switzerland) was used.   
 
4.3.2.3.F-Test and t-test 
 
In order to evaluate the results of the comparison between the crushing strength of the 
tablets from the manufacturing presses and from the PressterTM an F-test and a t-test 
were performed.   
 
The F-test tests if the difference between two different standard deviations from two 
independent data series is significant or just a coincidence.  For the actual test the 
probability of error value α was chosen with 5%.  I.e. hypothesis H0 says with a 
probability of error of 5% that the standard deviations of the two data series 
differentiate coincidentally.   
 
Equation 10 
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s1 and s2 are the standard deviations from the two different crushing strength data 
series with n1 and n2 amount of samples.  The degree of freedom f is then determined 
with  
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F-test H0 is true if 
 
Equation 12 
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Whereas Fb is the calculated F value, Ft is the value estimated from the table, 
depending on α, f1 and f2.  H0 is false if 
 
Equation 13 
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If the compared standard deviations do not differentiate according to the F-test, then 
that is called a homogeneous variance.  In that case it can be tested if the average 
values of the data series differentiate coincidentally or significantly.  That is done 
with the t-test from Student.  The t-test hypothesis H0 says with a probability of error 
of 5% (α=5%) that the average values of two data series only differentiate 
coincidentally 
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The degree of freedom is determined with 
 
Equation 16 
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t-test H0 is true if 
 
Equation 17 
),2( ftt tb α<  
 
where tb is the calculated value and tt is the value estimated from the table, depending 
on 2α and f as the double sided t-test is used in this case.  A one sided t-test can only 
be used if the trend of the values is known, e.g. during a stability test of 
pharmaceuticals whereas one can assume that the amount of active ingredient in the 
tablet will decrease with time and not increase. 
 
4.3.2.4.Disintegration 
 
The disintegration of a dosage form into its primary granules or particles is the first 
step toward the dissolution of the drug substance.  Disintegration methods usually 
involve the submersion of the dosage form into the dissolution medium or in water at 
approximately 37°C.  The time required for the dosage form to break down into its 
primary granules or particles is then recorded as the disintegration time.  There have 
been done a whole lot of experiments in order to characterize the disintegration 
process itself.  The disintegration time is related to the granule size of the tablet.  With 
decreasing granule size the disintegration time of the tablet increases to a maximum.  
Also the decrease in disintegration time has been correlated to the capping propensity 
of the tablets, thereby supporting the theory that the mechanical integrity of the tablets 
played a role in the disintegration time (13).  The viscosity, surface tension and 
penetration angle of the penetrating solution also influence the disintegration of the 
tablet accompanied with the mean diameter of the capillaries in the tablet, and as the 
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mean capillary diameter alters with different compression forces (14) it is clear that 
disintegration is a very important parameter to observe when changing tableting 
presses or scaling up.   
 
The disintegrating time of the produced tablets was determined by a Sotax DT3 
disintegrator (Sotax AG Basel, Allschwil, Switzerland) according to Ph. Eur. (15).  
Product A was disintegrated in 37°C water, whereas product B was disintegrated in 
37°C gastric juice.   
 
4.3.2.5.Dissolution Profile 
 
The dissolution characteristic of a dosage form is one of the most important 
parameters to keep an eye on throughout development, scale-up and equipment and 
process changes.  The dissolution of the drug substance can influence the 
bioavailability if the dissolution rate is the limiting factor for the absorption (16).  For 
dissolution comparison between tablets made from two different manufacturing 
presses or during scale-up from research, clinical or bio-batches it is not sufficient to 
compare with a single point testing, i.e. saying that if both tablets are dissolved in e.g. 
30 minutes they are “the same”.  In these cases there is a dissolution profile required 
and a determination of a difference factor (f1) and a similarity factor (f2) according to 
the SUPAC document for immediate-release dosage forms (17).  With the following 
equation 
 
Equation 18 
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the difference factor (f1) is determined by subtracting the “postchange” from the 
“prechange” dissolution value, where n is the number of time points, R is the 
dissolution value of the reference (prechange) batch at time t, and T is the dissolution 
value of the test (postchange) batch at time t. 
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The similarity factor (f2) is a logarithmic reciprocal square root transformation of the 
sum of squared error and is a measurement of the similarity in the percent (%) 
dissolution between the two curves. 
For curves to be considered similar, f1 values should be close to 0, and f2 values should 
be close to 100. Generally, f1 values up to 15 (0-15) and f2 values greater than 50 (50-
100) ensure sameness or equivalence of the two curves and, thus, of the performance 
of the test (postchange) and reference (prechange) products. 
 
The dissolution profile was determined with a Sotax AT70 Smart (Sotax AG Basel, 
Allschwil, Switzerland) according to the Ph. Eur. 2.9.3. “Dissolution Test for Solid 
Dosage Forms” or USP<711>, “Dissolution” at a speed of 50 rpm and the samples 
were then manually quantified with an Uvikon XS UV (Szabo-Scandic 
HandelsGmbH und Co KG, Vienna, Austria) at the predetermined time intervals.   
 
4.3.2.6.Content Uniformity of the drug substance 
 
Content uniformity is dependent on the powder properties.  It is clear that the content 
uniformity of the active substance in tablets is vital for the patient.  As the feeding 
mechanism is known to be able to influence the segregation of the granulate 
formulation it is interesting to observe the content uniformity of the produced tablets 
from the three different rotary presses.  An example is known from a tableting scale-
up from an intermediate batch size to a manufacturing-size batch.  There all previous 
scale-up steps were performed without problems until the dosing system was changed 
from hand scooping the powder into the hopper of the tablet press and using an 
overhead-feed duct.  This overhead-feed duct acted as a classifier for the granulate 
formulation as the length and the angle of the ductwork fostered segregation (18).  
According to the Ph. Eur. the content uniformity test is performed on ten randomly 
selected tablets from a batch.  Each tablet should be analyzed for amount of active 
ingredient with a suited analytical method.  If all tablets are within 85% and 115% of 
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the average content and the standard deviation is under 6% they will meet 
expectations.  The U.S.P. has a slightly different method.  The ten randomly selected 
tablets must lie within 85% and 115% of the declared content.  It did not make any 
sense to measure the content uniformity of the tablets made by the PressterTM as each 
and every tablet was hand weighed into the die.   
 
The content uniformity was determined with an HPLC method on a TSP (Thermo 
Separation Products GmbH, 64291 Darmstadt, Germany).   
For product A there was used a reversed phase RP-8 silica sphere-5 with a mean 
particle size of 5µm and 4,6mm internal diameter.  A flow rate of 2ml/min was 
employed with UV wavelength detection at 220nm.  The selected mobile phase was 
acetonitrile/ammonium carbamate (55:45).  An isocratic HPLC method. 
For product B there was used a Nucleosil C18,5µm column, 125mm long and an 
internal diameter of 3,0mm.  A flow rate of 0,4ml/min was employed with UV 
wavelength detection at 265nm.  The selected mobile phase A was 
Water/Acetonitrile/Trifluoroacetic acid (90:10:0,1) and mobile phase B was 
Water/Acetonitrile/Trifluoroacetic acid (10:90:0,1).  A reversed phase HPLC method.   
 
4.4. Results and Discussion 
 
4.4.1. Powder Evaluation  
 
4.4.1.1.Particle Size Distribution 
 
Normally the particle size distribution is only homogeneous if all the particles have 
the same source.  Powders made of more than one particle collective tend to have a 
flattened maximum or even more than one maximum if the particle size distributions 
are farther apart.  That is what is seen in the particle size distribution of the products 
A and B, a flattened overall distribution with two maximums.  Tables 2 and 3 contain 
the absolute values of the particle size distribution.   
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Figure 15: Particle size distribution of Product A with two flattened maximums 
 
 
Particle size class  
Product A       
[µm] 
Wt/wt 
[%] 
Sieved 
total [%] 
Residual 
total [%] Mass [g] 
0-90 21.9 21.9 78.1 11.01 
90-125 19.5 41.4 58.6 9.81 
125-180 19.4 60.8 39.2 9.75 
180-250 11 71.9 28.1 5.55 
250-355 8.4 80.3 19.7 4.23 
355-500 7 87.3 12.7 3.51 
500-710 8.5 95.7 4.3 4.26 
710-1000 3.9 99.6 0.4 1.95 
1000-1400 0.3 100 0 0.17 
>1400 0 100 0 0.02 
Table 2 
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Figure 16: Particle size distribution of Product B with two flattened maximums 
 
 
 
Particle size class 
Product B       
[µm] 
Wt/wt 
[%] 
Sieved 
total [%] 
Residual 
total [%] Mass [g] 
0-90 9.4 9.4 90.6 4.76 
90-125 7.9 17.4 82.6 4.01 
125-180 8.4 25.8 74.2 4.23 
180-250 9.5 35.2 64.8 4.78 
250-355 10 45.2 54.8 5.04 
355-500 12.6 57.8 42.2 6.36 
500-710 19 76.8 23.2 9.58 
710-1000 18 94.8 5.3 9.07 
1000-1400 5.2 100 0 2.65 
>1400 0 100 0 0 
Table 3 
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4.4.1.2.Density  
 
The following tables show the results of the density tests.   
 
Product A density determination: 
      ml g ml/g g/ml 
Bulk 
volume:     211 100 2.11 0.474 
Tapped volume (1250 taps): 175 100 1.75 0.571 
Tapped volume (2500 taps): 173 100 1.73 0.578 
True density:       0.778 1.2861 
Table 4 
Product B density determination: 
      ml g ml/g g/ml 
Bulk 
volume:     182 100 1.82 0.55 
Tapped volume (1250 taps): 146 100 1.46 0.68 
Tapped volume (2500 taps): 144 100 1.44 0.69 
True density:       0.773 1.2936 
Table 5 
 
The resulting Hausner ratio from these results using equation 1: 
 
 Product A = 1,20 
 Product B = 1,24 
 
According to the Hausner ratio, product B does not have ideal prerequisites for 
manufacturing as the Hausner ratio exceeds 1,20.  When powder formulations exceed 
the Hausner ratio of 1,20 it can be expected that the powder densifies during 
transportation or during any applied vibration, e.g. during compression if the 
container is placed upon a rotary press.  It is clear that if the powder formulation 
densifies during manufacturing the weight of the tablets might change, as the filling 
into the dies is volume controlled with the lower punch.     
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4.4.1.3.Flowing properties 
 
Product A shows good flowing properties which are shown in the table below.  
Product B on the other hand shows poor flowing properties.   
 
Product Flowability [g/sec] 
A 13.2 
B 8.7 
Table 6: Powder flow properties of products A and B. 
 
 
4.4.2. Compact Preparation and Evaluation 
 
4.4.2.1.Compression 
 
Here the performance tests of the different manufacturing-presses will be described 
along with some “highlights” during the test, i.e. possible problems which came up 
during compression of the products A and B on other manufacturing-presses.   
 
Fette 2090® routine manufacturing experience: 
 
The samples used for the graphs below were taken out of routine manufacturing 
batches at different velocities.   
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Figure 17: Weight Uniformity of Product A at 110, 150 and 180k tbl/h.    
 
The good flowing properties of product A are easily observed in the above graph, 
whereas the weight standard deviation (illustrated with the error bars) only shows 
very little difference with increasing speed.  Also the average weight of the tablets 
stays constant. 
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Figure 18: Weight Uniformity of Product B at 65.5, 110 and 153k tbl/h.   
 
In the above graph it is clearly to be seen that product B possesses poorer flowing 
properties than product A.  The weight standard deviations are higher and also 
increase with higher speed.  Also the average weight of the tablets is not as constant.   
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IMA Comprima 300® test: 
 
The granulate material for the performance tests was taken out of a produced 
commercial batch.  Both test materials, product A and B, were sent to IMA by truck.  
Before the test-runs began, the barrels were rolled on the floor for 3 minutes, as the 
material had been standing for some while and shipped by truck which could have 
caused a pre-densification of the granulate material.  For the test run, the material was 
shoveled into the turret by the operator.  Each test started with the speed 250´000tbl/h.  
During the test-run, samples were taken regularly additionally to the automatic IPC of 
the IMA Comprima 300®.   
 
The test-run of product A started off with 250’000tbl/h.  Product A did not show any 
problems with the unusual die filling system of the IMA Comprima 300®.  The 
granulate material is filled into the die sideways with help of centrifugal force.  This 
way the standard deviation of the tablet weight should theoretically decrease as faster 
the manufacturing-press produces, in contrast to the force feeding of the die from 
above on the die table where the standard deviation of the weight increases with 
increasing production speed.   
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Figure 19: Relative standard deviation of tablet weight during the IMA Comprima 300® test-run, 
decreasing with increasing speed. 
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The relative standard deviation (Srel) of tablet weight from the manufacturing-press is 
shown in the above figures.  As in theory, the relative standard deviation does 
decrease with higher tableting speed.  It has been said that the IMA Comprima® can 
only process powder formulations which have good flowing properties as the feeding 
mechanism for the die is only the centrifugal force coming from the rotating turret and 
no force feeding is possible.  Product B being a problematic product was then tested 
on the IMA.  As expected, the compression did not run without problems.  The 
relative standard deviation of the compression force of the punches was too high (13 – 
15%), therefore the machine automatically stopped several times.  The values of Srel 
of the compression force recommended in literature are 5 – 10%, which would lead to 
a weight Srel of about 0.7 – 1.5%.  It was then suggested mounting rubber rings on 
the lower punches in order to increase the vacuum force in the die.  This way the 
granulate did not only experience centrifugal powers on its way into the die, but was 
additionally being sucked into the die.  This way, the Srel of the compression force 
was reduced (5 – 7%) and the machine was able to press the granulate.  One stop 
occurred after the rings were mounted.  One die opening seemed to be blocked, as the 
compression force measured on this punch was too low.  After dismounting the die 
and cleaning the material out of the die channel the machine was running again.  It 
was decided to increase the speed up to 3000’000tbl/h and after that the machine 
finished the material without further problems.  This verifies the statements made on 
the IMA Comprima 300®, that as faster the machine runs, the better.  
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Figure 20: Relative standard deviation of tablet weight during the IMA Comprima 300® test-run, 
decreasing with increasing speed. 
 
As can be seen in the figure above the Srel also decreased with increasing speed in 
this case.  In this case, in spite of previous predictions, product B was possible to 
process on the IMA Comprima 300® after equipping the lower punches with rubber 
rings which created an additional vacuum force to the centrifugal force which helped 
the powder formulation to flow into the die.  By using the IMA Comprima® the 
production output could at least be doubled with the products in question.   
 
The yield of the IMA Comprima® was found to be very good.  Where standard rotary 
presses show a yield loss of up to 2% it was measured to be about 0.3%.  Regarding 
this from an economical point of view this could lead to massive savings, depending 
on the cost of the product being processed.  Below is an example, based on 
information from IMA, Bologna.   
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Figure 21: Based on the costs of product per kilogram, assuming 2% product loss for standard rotary 
press and 0,5% product loss for the IMA Comprima®.  Further assumptions are a batch size of 2000kg 
and 11 batches per month.   
 
The CIP system was tested with product B, which we remember, is the “worst case” 
product and it also happens to be a bastard to clean.  The standard cleaning cycle 
consisted of 10 minutes pre-washing, 10 minutes washing with acid detergent, 10 
minutes rinsing with deionized water and 2:30 hours of hot air drying making a total 
of 3 hours.  Additionally to that time the removal of the compression tools takes about 
30 minutes and the re-fitting another 30 minutes making a total of 4 hours change-
over time between products.   
With the standard cleaning procedure from IMA applied for product B the machine 
was not visually clean.  There was still typical product B remains on the turret and in 
the processing area, which consist of a thin sticky layer of product.  After the second 
cycle the processing area was visually clean.  After having a look into the turret some 
more remains were found of product B which was gone after the third cleaning cycle.  
Additional product specific optimization is mandatory and might solve the problem.  
For example using 2 different detergents, acid and alkaline and longer phases.  Even 
tripling each cleaning phase, excluding drying, a total change over time of about five 
hours could be reached which is still far beneath the change over time of standard 
rotary presses which can be done in about 6 hours with three persons instead of one 
for the IMA Comprima® (12).   
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Courtoy Modul® test: 
 
The granulate material for the performance tests was taken out of a produced 
commercial batch.  Both test materials, product A and B, were sent to Courtoy by 
truck.  Before the test-runs began, the barrels were rolled on the floor for 3 minutes, as 
the material had been standing for some while and shipped by truck which could have 
caused a pre-densification of the granulate material.  The granulate was then filled 
into a container and heaved onto the Courtoy Modul®.   
The test run of product B was started first.  Unfortunately this test had to be aborted as 
the lower punches kept getting stuck in the die due to the sticking properties of 
product B.  Therefore there are no data on product B from the Courtoy Modul®, only 
product A.  During this test it was shown that the dust-tight construction of the 
Exchangeable Compression Module (ECM) had to be opened in order to get to the 
punches.  So in cases when something has to be done with the punches during 
production, such as polishing them once in a while during production, the ECM 
concept of change-over does not work.  Dust will be released out of the dust-tight 
ECM and the room and the rest of the machine will have to be cleaned and so 
prolonging the change-over time.   
 
Product A on the other hand performed very well on the rotary press.  The weight 
regulation for the running-in process was very comfortable.  The approximate dosing 
was set for 128mg and then a few tablets were produced and twenty tablets weighed.  
After giving the average weight into the computer the machine regulated itself on the 
basis of the average weight.  One part of the test run was to increase the speed of the 
rotary press until the relative standard deviation (Srel) would exceed the tolerance 
limits of three percent.  Starting from 224’000 tablets per hour the speed was 
gradually increased to 240’000tbl/h and then to 250’000tbl/h.  At this speed the Srel 
of the displacement was about 1,5 – 2% (the relation of the Srel of displacement is 
linear to the Srel of the weight of the tablets).   
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Figure 22: The relative standard deviation of weight during the test-run of product A. 
 
In the above figure it can be seen that the Srel does increase with higher speed but 
does not exceed the three percent limit.   
As mentioned before, the Courtoy Modul® offers the Exchangeable Compression 
Module (ECM) technology which enables a complete change-over to a new product in 
as little as one hour.  This requires a double set of all periphery equipment and of the 
ECM.  This way, one is able to remove the used ECM after production out of Courtoy 
Modul® and install the ready second ECM for the next product.  All periphery 
equipment should be changed in the same manner.  Due to the dust tight construction 
of the ECM there should be no cleaning necessary in the room.  The removed ECM is 
then cleaned offline, along with all periphery equipment, and prepared for the next 
product.  In order to verify this, a change-over was simulated before starting with 
product A.  Starting the change-over test it was obvious that the whole construction of 
the press is very impressive.  The mechanical handling is very simple and robust 
which makes the change-over very easy and possible with only one Allen-key.  For 
the offline cleaning there are two features worth mentioning which make the cleaning 
easier and faster, the removable plates holding the punch scraper seals and the 
removable plates supporting the dies.   
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Figure 23: Plates with punch scraper 
 
 
 
Figure 24: Plates supporting the dies 
 
The offline cleaning of the ECM takes about three to four hours for one operator.  
This corresponds to the time needed cleaning conventional compression tooling.   
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For the change-over test it was assumed that there was a ready second ECM unit set 
up for the next product along with a second set of periphery and a ready granulate 
container.   
The ECM has to be removed out of the machine and out of the room without spilling 
any powder.  That is why it has to be made sure that also the suction pipes and all 
other openings will be sealed.  This is done with the help of lay-flat tubing parts.  
Every junction of the ECM to the Courtoy Modul® is sealed with lay-flat tubing parts.  
When the ECM is removed out of the press, the lay-flat tubing is unfolded, closed 
with two plastic clamps and then the tubing is cut with a head scissor between the 
clamps.   
 
 
Figure 25: Unfolded lay-flat tubing closed with clamps. 
 
This way any potential powder contamination is prevented.  In 22 minutes 
the ECM was out of the press and in approximately 30 minutes all product 
specific equipment (granulate container / periphery) were removed.  
Assuming we had another ECM ready for installation, we used the same 
ECM we just removed and installed it again.  Also the granulate container 
was dismounted and mounted again demonstrating the Buck docking system 
of containment.  The Buck docking system consists of an active and a 
passive valve, which together seal two containers.  The active valve 
operated manually or by an automated system, is mounted on the press, 
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while the passive valve is fitted on the mobile container.  When docked, the two 
valves are interlocked for complete containment.   
 
This complete change-over lasted 61 minutes and was done by one operator.  The 
periphery was not attached to the press again, therefore is realistic to assume tat a 
change-over with double sets of equipment would be possible to realize in 60-90 
minutes.   
 
Apart from a small amount of powder trickling down from the active Buck valve 
when it was removed from the press during the change-over, the room and the press 
itself were optically clean.   
 
MCC PressterTM:  
 
As the granulate of product A and B was weighed and filled into the die of the 
PressterTM by hand, it did not make any sense to inspect the achieved samples on 
content uniformity or weight uniformity.  Worth mentioning about the weight control 
during the PressterTM tests is that the dosing cam was pulled down to its maximum, 
i.e. 17mm.  This was done in order to prevent material leaving the die when the first 
yank of the press station carriage occurred for the tableting procedure.   
 
The PressterTM is equipped with a strain gage on the ejection cam, measuring the peak 
ejection force.  During the simulation of the different rotary presses it was eye-
catching that as faster the press station was, the higher the ejection force. 
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Figure 26: With higher speed (lower dwell time) the ejection force increased. 
 
As can be seen in the above graph, the ejection force increases with higher speed.  
Also it is conspicuous that product B has much higher ejection forces than product A.  
Product B is known for its bad flowing properties and making the lower punches stick 
and hard of moving.  Interestingly the ejection forces of the IMA simulation with the 
9.5x4.3mm punches showed the highest ejection forces of all.  These samples also had 
the highest crushing strength of all product B samples. 
 
4.4.2.2.Crushing strength 
 
All manufacturing-presses were tested with product A and B and these 
manufacturing-presses were then simulated on the PressterTM with the same products.  
The results are displayed in the graphs below.   
 
 214
DT Hardness Profile Product A
PreCo 2.3mm / Co 1.9mm 
20.00
30.00
40.00
50.00
60.00
70.00
80.00
6 8 10 12 14
DT[msec]
H
ar
dn
es
s[
N
]
Presster
Fette 2090
 
Figure 27: The crushing strength results of the Fette 2090® simulation compared to the actual 
manufacturing crushing strength results. 
 
With product A the PressterTM shows very good crushing strength correlation to the 
Fette 2090® manufacturing-press results.  The PressterTM graph shows a linear 
correlation between dwell time and crushing strength.  The decrease of crushing 
strength with shorter dwell time is very well recognizable.  The Fette 2090® graph 
also shows a decrease in crushing strength with shorter dwell time with a slight 
plateau between 10msec and 8msec.   
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Figure 28: The crushing strength results of the Fette 2090® simulation compared to the actual 
manufacturing crushing strength results. 
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With product B the PressterTM shows very good crushing strength correlation to the 
Fette 2090® manufacturing-press results.  The biggest difference between both graphs 
is at approximately 14,5msec where it reaches 7,1N.  Again the PressterTM graph 
shows an excellent linear correlation between shorter dwell time and decreasing 
crushing strength.  The Fette 2090® graph also shows decreasing crushing strength 
with shorter dwell times although somewhat steeper than the PressterTM graph 
between 10msec and 6msec.   
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Figure 29: The crushing strength results of the IMA Comprima 300® simulation compared to the actual 
manufacturing-press results. 
 
With product A the PressterTM shows excellent correlation to the manufacturing-press 
results of the IMA Comprima 300®.  The PressterTM graph shows decreasing crushing 
strength with shorter dwell times just as well as the IMA Comprima 300® graph.   
 
 216
DT Hardness Profile Product B
PreCo 2.5mm / Co 1.1mm
60.00
80.00
100.00
120.00
140.00
7.50 8.00 8.50 9.00 9.50 10.00
DT[msec]
H
ar
dn
es
s[
N
]
Presster 10x5.2
IMA 10x4
 
Figure 30: The crushing strength results of the IMA Comprima 300® simulation compared to the actual 
manufacturing-press results. 
 
Product B on the PressterTM on the other hand does not compare as well to the IMA 
Comprima® manufacturing-press results.  A slight decrease of the crushing strength is 
recognizable with shorter dwell times but the two graphs are parallel shifted.  This 
was to expect, as the tooling used for this simulation did not equal the compression 
tooling used at IMA which were 10x4mm, oval and convex.  The compression tooling 
used for the simulation above is the same as were used for the Fette 2090®, i.e. 
10x5,2mm, oval and convex as well as the punch gap during pre- and main 
compression.  As the tooling geometry was different (i.e. the punch tip surface was 
greater than the compression tools used at IMA) and has a significant effect on 
relative volume and total porosity (19) it could be expected that the crushing strength 
would not compare.  The average main compression force applied on the tablets 
during this simulation on the PressterTM was 10,5kN.   
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Figure 31: The crushing strength results of the IMA Comprima 300® simulation compared to the actual 
manufacturing-press results. 
 
As the correct compression tooling which was used at IMA was not available for the 
PressterTM, it was tried to use compression tooling with smaller punch tip surface.  For 
this test a punch tip of 9,5x4,3mm was used which has a smaller punch tip surface 
than the compression tooling used at IMA.  The punch gap used for this test was the 
same used for the IMA Comprima 300® manufacturing press, 3,1mm for 
precompression and 2,4mm for main compression.  The results above show us that the 
IMA Comprima® manufacturing-press results have been contained by the two 
PressterTM results.  Looking at the resulting average main compression force from the 
9,5x4,3mm compression tooling of 14,1kN and the average main compression force 
from the 10x5,2mm compression tooling of 10,5kN it is obvious that the crushing 
strength increases.  It is most probably due to the high compression force of the 
smaller punch tips which lead to the reversed graph of the PressterTM, where the 
crushing strength increases with shorter dwell times.  The average main compression 
force of the IMA Comprima® manufacturing-press was 9,55kN.   
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Figure 32: The crushing strength results of the Courtoy Modul® simulation compared to the actual 
manufacturing-press results. 
 
The Courtoy Modul® crushing strength graph does not show the typical course as has 
been observed with the other two manufacturing-presses.  From approximately 
6,5msec down to 5msec it shows the typical decrease in crushing strength with shorter 
dwell times.  But at 4,5msec there is a sudden crushing strength increase which then 
decreases rapidly again at 4msec.  In addition there is a sudden decrease in crushing 
strength at approximately 8,2msec which actually acts in accordance with the 
PressterTM graph which also shows a decrease of crushing strength after 7msec.  
Otherwise the simulation graph from the PressterTM does not compare to the Courtoy 
Modul® results and it is parallel shifted of about 7N.  This can be explained by the 
fact that the Courtoy is equipped with the pneumatic precompression roll and 
compresses to constant force, not to constant thickness as the other manufacturing-
presses do.  Also the pneumatic precompression roll prolongs the dwell time under the 
precompression roll and so providing an additional time for stress relaxation ad 
effectively increasing the tablet crushing strength.   This effect could not be simulated 
by the PressterTM just by using the corresponding size of the compression rolls without 
the pneumatic precompression.  A pneumatic precompression roll is available from 
MCC and every PressterTM can be equipped with one, but for these tests, this option 
was not available.  The PressterTM setup of the punch gap was based on the Courtoy 
manufacturing-press settings and resulted in an average main compression force of 
13,8kN. 
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These results show that with the corresponding compression tooling, the crushing 
strength behavior of a tablet can be predicted for different punch gap distances and 
different speeds with very little material for different manufacturing-presses as long as 
the compression technology matches the manufacturing-press in question.  In the case 
of the Courtoy Modul® simulation the pneumatic precompression roll was not 
available and so the results did not correlate.  Also in the case of the IMA Comprima 
300® the corresponding tooling used for product B was not available for the 
PressterTM leading to similar crushing strength results but parallel shifted due to the 
different punch tip geometry.   
 
4.4.2.3.F-test and t-test 
 
In the following tables the results of the F-test and the t-test are given for each 
manufacturing-press, product and dwell time.  In order to determine Ft for the F-test, a 
table is needed with the chosen probability of error α.  In this case, having 10 values 
in each data series, the degree of freedom is 9 and the resulting value Ft then for α 5% 
is 3,18 and for α 1% is 5,35.   
As can be seen, all F-tests except one are true for Ft α5%, i.e. they have a 
homogenous variance.  One F-test for the Fette 2090® was not true for Ft α5%, but 
true for Ft α1% which means that the variance difference of the two data series might 
be systematical (20).   
 
Based on these results, having a homogenous variance of the samples, the t-test could 
be performed.   Similar to the F-test, a table is needed here in order to determine the tt 
value.  According to the chosen probability of error, in this case a double sided α 5% 
and f = 18 degree of freedom the value 2,10 was determined from the table.  The 
results show that the difference of the average values of crushing strength between the 
PressterTM and the manufacturing presses are either only a coincidence or very 
significantly different.   
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Products 
Presster 
DT’s 
s1 s2 Fb Ft 5% Ft 1% tb tt5% 
6,52 1,84 1,70 1,17 3,18  4,42 2,10 
8,19 1,51 1,25 1,46 3,18  4,05 2,10 
10,71 1,35 0,94 2,05 3,18  1,18 2,10 
A 
13,78 1,80 1,25 2,08 3,18  1,20 2,10 
6,52 2,71 2,05 1,74 3,18  0,93 2,10 
8,20 3,59 2,99 1,44 3,18  1,01 2,10 
9,95 4,45 2,05 4,68 3,18 5,35 1,95 2,10 
B 
14,58 2,69 2,40 1,24 3,18  6,25 2,10 
Table 7: F-test and t-test results on Fette 2090® crushing strength values 
 
 
 
 
 
 
 
 
Products 
Presster
DT’s 
s1 s2 Fb Ft 5% tb tt5% 
8,22 2,01 1,65 1,48 3,18 1,48 2,10 
8,90 1,84 / / 3,18 / 2,10 A 
9,65 1,37 1,76 1,66 3,18 1,66 2,10 
8,34 3,25 2,64 1,52 3,18 5,97 2,10 
8,92 2,87 / / 3,18 / 2,10 
B 
10x5,2 
9,71 3,61 3,53 1,05 3,18 6,01 2,10 
8,37 2,64 2,63 1,00 3,18 23,56 2,10 
8,90 2,59 / / 3,18 / 2,10 
B 
9,5x4,3 
9,70 4,08 3,53 1,34 3,18 12,57 2,10 
Table 8: F-test and t-test  results on IMA Comprima® crushing strength values 
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As the IMA Comprima 300® was only run at two different speeds, there were no 
samples available for the comparison of 8,9msec.   
 
Products 
Presster
DT’s 
s1 s2 Fb Ft 5% tb tt5% 
5,93 1,93 1,79 1.16 3,18 6,13 2,10 
7,06 2,31 1,48 2,45 3,18 10,49 2,10 A 
8,44 1,96 1,70 1,33 3,18 9,16 2,10 
Table 9: F-test results on Courtoy Modul® crushing strength values 
 
The significant difference calculated for the Courtoy Modul® with the t-test can be 
explained with the pneumatic precompression roll, which was not in place on the 
PressterTM.  Comparing the dwell time / crushing strength profiles graphs above it is 
noticeable that the values which do lie apart do have a significant difference of 
average crushing strength according to the t-test (20).   
 
 
 
 
4.4.2.4.Disintegration 
 
As described above under materials and methods, the tablet samples from the 
PressterTM and the manufacturing-presses were tested on disintegration.  The results 
are displayed in the figures below.   
 
 222
Disintegration Product A - Fette 2090
0.00
50.00
100.00
150.00
200.00
250.00
300.00
350.00
400.00
450.00
6.00 8.00 10.00 12.00 14.00 16.00
Dwelltime[msec]
Ti
m
e 
[s
ec
]
Dis. Presster
Dis. Fette
 
Figure 33: Disintegration results from Fette 2090® and the PressterTM simulation of Fette 2090®. 
 
The disintegration results from the product A Fette 2090 samples could be predicted 
quite well with the corresponding dwell time samples from the PressterTM.  The 
biggest difference is to seen at approximately 6,5msec where it reaches 64 seconds 
which corresponds to a 16.8% deviation to the true disintegration time of the Fette 
tablets produced at this speed.   
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Figure 34: Disintegration results from Fette 2090® and the PressterTM simulation of Fette 2090®. 
  
The disintegration time of product B could not be predicted quite as well with the 
PressterTM for Fette 2090®.  There the biggest difference is to be seen at 
approximately at 9,8msec where it reaches 34 seconds.  The PressterTM sample only 
needs 24 seconds to disintegrate whereas the Fette 2090® sample needs 60 seconds.  
This difference still is not essential for the tablet as the maximum disintegration time 
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is set at 10 minutes for this immediate release tablet and both samples are far beneath 
that value.  Another factor which should also be mentioned is that the actual 
disintegration time determination is very difficult for this tablet as when it is put into 
gastric juice it macerates and disintegrates into large flakes which block the 
observation of the tablet.  Therefore it is possible, that the actual disintegration time is 
dependent on the person doing the test.   
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Figure 35: Disintegration results from IMA Comprima 300® and the PressterTM simulation of IMA 
Comprima®. 
 
Simulating the IMA Comprima® manufacturing-press the PressterTM predicted the 
disintegration time of the IMA samples very well.  The two graphs in the figure above 
show a maximum difference of two seconds.   
[msec]
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Figure 36: Disintegration results from IMA Comprima 300® and the PressterTM simulation of IMA 
Comprima®. 
 
 
The disintegration results in the above figure correlate very well to the crushing 
strength results of the same samples.  The crushing strength of the manufacturing-
press samples were about eight to nine Newtons harder than the simulated tablets 
from the PressterTM.  Here the disintegration time of the simulated tablets is about 1,5 
to 1,8 seconds shorter which is not significant but still shows a correlation of crushing 
strength (and density) to the disintegration time.  This is again confirmed in the figure 
below.   
 
[msec]
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Figure 37: Disintegration results from IMA Comprima 300® and the PressterTM simulation of IMA 
Comprima®. 
 
 
As mentioned above, the crushing strength shows a good correlation to the 
disintegration time.  Here in the above figure the manufacturing-press samples from 
the IMA Comprima® are displayed with the simulated tablets with the 9,5x4,3mm 
compression tooling.  As shown above the crushing strength of these PressterTM 
tablets exceeded the crushing strength of the manufacturing-press of about 22 to 28 
Newtons and this corresponds to a disintegration time difference of about five 
seconds.   
 
[msec]
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Figure 38: Disintegration results from Courtoy Modul® and the PressterTM simulation of Courtoy 
Modul®. 
 
Corresponding to the crushing strength results of the Courtoy simulation the 
disintegration time also does not match.  The manufacturing-press samples show an 
increased disintegration time compared to the PressterTM samples and also a higher 
consistency between dwell times.  This supports the assumption that compressing 
with constant force results in more uniform tablets, even though it is only during 
precompression (19).    
 
4.4.2.5.Dissolution Profile 
 
The dissolution profiles of product A and B were unfortunately only available from 
Fette 2090® and from the PressterTM.  For the generation of the dissolution profiles, 
three routine manufacturing-batches were tested on dissolution with 12 tablets each 
and the different dwell times done on the PressterTM  also with 12 tablets for each 
dwell time.  The dissolution time points used for sampling were 10, 20, 30 and 40 
minutes.  The dissolution profiles are displayed in the following graphs.   
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Figure 39: Dissolution profiles from routine manufacturing batches 
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Figure 40: The dissolution profiles of the different dwell times from the PressterTM 
 
Product A seems to have a very similar dissolution profiles produced on the 
manufacturing-press Fette 2090® and on the PressterTM.  The difference in the 
dissolution rate between the different dwell times of the PressterTM samples can be 
seen very well in the above graph.  The dissolution rate of the sample with the longest 
dwell time, i.e. 13.6msec also is the slowest one to liberate the active ingredient out of 
the tablet.  As we could see very well comparing the crushing strength values was that 
the longer the dwell time the harder the tablets will get and so, the liberation of the 
active ingredient is slowed down.  As the dwell time decreases so does the crushing 
strength and the liberation of the active ingredient is faster.  The error bars on each 
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sampling point represent the minimum and the maximum concentration of the active 
ingredient from the 12 analyzed tablets.  In order to double check our assumption, that 
the profiles are equivalent, the dissolution values of the PressterTM tablets were 
compared with the manufacturing batches using the difference factor f1 and the 
similarity factor f2 proposed be the SUPAC document for immediate release dosage 
forms (17).  Every dwell time sample from the PressterTM was compared to all three 
routine manufacturing-batches, where the PressterTM samples were treated as the test 
values (postchange) and the Fette samples were treated as the reference values 
(prechange).   
 
 6,4msec 7,7msec 10,5msec 13,6msec 
f1 to S0001 2,61% 2,61% 8,33% 11,82% 
f1 to S0002 2,87% 2,87% 6,61% 9,70% 
f1 to S29400 10,18% 9,66% 2,30% 3,64% 
f2 to S0001 68,92% 68,62% 54,55% 49,81% 
f2 to S0002 75,85% 73,72% 60,01% 52,70% 
f2 to S29400 49,81% 50,59% 81,49% 74,47% 
Table 10: Difference factor and similarity factor for Product A 
 
All estimated difference factors were under 15% which implies that the dissolution 
factors of the Fette 2090® and the PressterTM are not dissimilar.  According to the 
similarity factor all dissolution rates of the PressterTM samples are equivalent to the 
Fette 2090® samples except two factors which missed the target of 50% by 0.19%.  
Considering that the hardest tablets from the PressterTM samples (dwell time of 
13.6msec) did not compare to the fastest dissolving tablets from the manufacturing-
batches (S0001) and that the slowest dissolving sample from the manufacturing-
batches (S29400) did not compare to the fastest dissolving sample from the PressterTM 
samples, this difference is can be overlooked.  According to this in-vitro test, the 
samples can be considered to be equivalent.   
 
The same dissolution tests were performed on product B.  The only difference this 
time is that product B contains two active ingredients a and b.  Below the graphs are 
displayed with the corresponding dissolution profiles.  Three routine manufacturing-
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batches were tested and their batch numbers are listed in the legend of the below 
graphs with the corresponding active ingredient a or b noted behind the batch number.   
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Figure 41: Dissolution profiles from routine manufacturing batches 
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Figure 42: The dissolution profiles of the different dwell times from the PressterTM 
 
At first sight the dissolution profiles of the routine manufacturing-batches and the 
PressterTM samples look equivalent.  Also very clearly to see is that the active 
ingredient a dissolves faster than b in both graphs.  As done with product A, a double 
check was done with help from the difference factor f1 and the similarity factor f2.  In 
this case, having two active ingredients, active a from all different dwell time 
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PressterTM samples was compared to active a from the three routine manufacturing-
batches samples and the same with active b.   
 
 
 
 
 
 
 
 
 
 
 
 7,7msec 9,7msec 14,4msec
f1a to S00100 0,0% 0,25% 0,51% 
f1a to S68100 0,25% 0,0% 0,25% 
f1a to S68200 0,25% 0,0% 0,25% 
f1b to S00100 0,0% 0,78% 0,26% 
f1b to S68100 0,78% 0,0% 0,52% 
f1b to S68200 0,78% 0,0% 0,52% 
f2a to S00100 100,0% 97,58% 95,60% 
f2a to S68100 97,58% 100,0% 97,58% 
f2a to S68200 97,58% 100,0% 97,58% 
f2b to S00100 100,0% 91,20% 97,58% 
f2b to S68100 91,20% 100,0% 95,60% 
f2b to S68200 91,20% 100,0% 95,60% 
Table 11 
 
As can be seen in the above table all difference factors f1 are far from being close to 
15%, they are rather zero or slightly above.  This means that there is almost no 
difference to be measured between the routine manufacturing-batches samples and the 
PressterTM samples.  Further, the similarity factor f2 above 90% in all cases, meaning 
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that the routine manufacturing-batches samples and the PressterTM samples are 
equivalent according to this in-vitro test.  
 
According to these results, it is safe to say, that the most important parameter of the 
tablet for the patient could be predicted by the PressterTM simulating the Fette 2090® 
for products A and B.   
 
4.4.2.6.Content Uniformity of the drug substance 
 
The content uniformity (CU) of a tablet formulation should always be watched closely 
when transferring a product from rotary press A to rotary press B.  What can happen 
is, as mentioned before, that different feeding mechanisms might facilitate powder 
segregation.  This is of course very interesting to observe for tablet formulations 
which contain low doses of the active ingredient, e.g. product A in our case which 
only contains 4% active ingredient in one tablet.  Product B contains over 50% of 
active ingredient and should not show any problems for CU.   
 
In the graphs below, the CU of product A and B is shown on all three rotary presses, 
Fette 2090®, IMA Comprima 300® and the Courtoy Modul®.  The standard deviation 
of the samples is illustrated with the error bars in the graph.   
 
Fette 2090 - Average of Declared Content Product A
90%
95%
100%
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110%
1 2 3 4 5 6 7 8 9
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100000
120000
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180000
200000
220000
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l/h
API Speed
 
Figure 43: CU of Product A on the Fette 2090® along with the corresponding velocities, 110’, 180’ and 
200’k tbl/h.   
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Product A seems to be totally unimpressed of the increasing speed of the Fette 2090®.  
It does not show an increasing standard deviation and the CU stays constant.   
 
Fette 2090 - Average of Declared Content Product B
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95%
100%
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110%
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Figure 44: CU of Product B with both active ingredients, a and b.  Sampling at 65.5’, 110’ and 153k 
tbl/h. 
 
In the graph above it can be observed that the CU of product B is well within the 
limits of the Ph.Eur. and the USP.  With increasing speed it seems that the standard 
deviation does increase which is completely normal as the weight uniformity also 
increases with higher speed.   
 
IMA Comprima 300 - Average of Declared Content product A
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Figure 45: CU of Product A on the IMA Comprima®. 
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The IMA Comprima 300® already showed that the weight uniformity standard 
deviation decreased with higher speed.  Here it is also clear that the standard deviation 
of CU of product A seems to decrease with higher speed.  Also the CU is well within 
the limits of Ph.Eur. and USP.   
 
IMA Comprima 300 - Average of Declared Content Product B
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Figure 46: CU of Product A on the IMA Comprima®. 
 
In the above graph it can be observed that the CU is also well within the limits for 
product B which has very poor flowing properties.  Also the standard deviation 
decreases with higher speed.   
 
Courtoy Modul - Average of Declared Content Product A
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Figure 47: CU of Product A on the Courtoy Modul®. 
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Here it is very clear to see that the CU standard deviation of product A increases with 
higher speed.  This is again what one would expect with a traditional die filling 
system, filling the dies from above.   
 
Altogether it can be said that all three rotary presses produced tablets with CU within 
the limits of the Ph.Eur. and USP.  According to expectations the standard deviation 
increased with higher speed on the traditional filling systems and decreased on the 
centrifugal die filling system.   
 
4.5. Conclusion 
 
From these results it is apparent that the compression behavior of a tablet formulation 
can be predicted for manufacturing scale rotary presses, provided that the PressterTM 
is equipped with the corresponding tooling such as punches and compression rolls.  In 
our case the crushing strength behavior of the tablets could be predicted by setting up 
the corresponding punch gaps used on the manufacturing presses, on the PressterTM.  
Disintegration, a parameter very dependent on the crushing strength, could also be 
predicted with the PressterTM but with the same variations as for the crushing strength.  
The most important parameter for the final appraisal of the samples is the dissolution 
rate of the tablets.  We found out that the PressterTM was capable producing tablets 
with the same dissolution rate as the Fette 2090® for both products.   
 
The only deviations were found to be with the IMA Comprima® / product B samples, 
where the corresponding tooling used for the IMA trials was not available for the 
PressterTM, leading to a difference in crushing strength and disintegration due to the 
different punch tip geometry.  Also in the case of the Courtoy Modul® simulation, the 
PressterTM could not be equipped with a pneumatic precompression roll and so, did 
not match the crushing strength and disintegration results obtained from the Courtoy 
Modul® trials, which is most probably due to the extended dwell time during 
precompression with the pneumatic precompression roll.   
 
Regarding the content uniformity of the tablet samples obtained during the 
manufacturing press trials, it can be said that all three rotary presses produced tablets 
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well within the CU limits of the Ph. Eur. and the USP.  According to expectations the 
standard deviation increased with higher speed on the traditional filling systems (Fette 
2090® / Courtoy Modul®) and decreased on the centrifugal die filling system (IMA 
Comprima 300®). 
 
Also worth mentioning is the observation made during the tests on the PressterTM, that 
product B had very high ejection forces which increased with higher speed.  This 
observation made during early development could have shown the sticking properties 
of the granulate material and so providing more time for the improvement.   
 
The PressterTM with it’s ability to simulate different rotary presses simply by 
implementing the corresponding compression rolls and tooling, clearly has an 
advantage over many other research tableting presses.  But there are also some 
limitations which have to be mentioned. 
 
• The PressterTM is not capable of simulating the feeding process of the 
manufacturing presses. 
• The heating effect of tablets due to long run times at high speed cannot be 
simulated. 
• The distance of the pre- and main compression rolls is not adjustable (56.2cm, 
whereas the Fette has 31.2cm). 
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5. 100% control of soft gelatine capsules with a diode array NIR spectrometer - 
VisioNIR 
 
5.1. Theory 
 
5.1.1. NIR – historical review 
 
In the year 1800 William Herschel discovered warming radiation beyond the visible 
red light, that he presented the Royal Society under the title ‘Experiments on the 
Refrangibility of the invisible Rays of the Sun’.  Today we know it must have been 
NIR, because the legendary telescope constructor used usual glass, which is not 
penetrable for longer wavelengths as infrared light.  Hence the NIR area is also called 
’Herschel-region’.   
 
But it was necessary to wait until 1881 when Abney and Festing recorded the spectra 
of a couple of organic liquids realizing the importance of atomic groupings in the NIR 
spectrum and hydrogen bonding in particular.  Coblentz identified the characteristics 
of CH-bonds in 1905 and postulated the bands could be part of a harmonic sequence.   
 
The evolution of spectrographic instruments was underway, the diffraction grating 
(initially produced by winding a thin wire around a pair of fine threads) had been 
developed and the prism was well established.  Christiansen and Rayleigh both 
produced relatively narrow-band optical filters, using index-matching and dyes.  Just 
as Max Planck rounded off the 19th century with his radiation law, in 1891, Michelson 
published a paper describing the two-beam interferometer.  Only one year later 
Rowland produced large ruled gratings and invented the concave diffraction grating, 
which became later the mainstay of spectrometer design. 
 
Prior to the Second World War the near-infrared region was not considered to be 
particularly useful for the spectroscopy of organic compounds.  It was observed that 
NIR bands are severely overlapped, difficult to resolve and to interpret.  If samples 
were not dried before Near Infrared Analysis (NIRA) the changes in hydrogen 
bonding due to the effects of sample temperature, ionic strength and analyte 
concentration also would complicate the interpretation of mainly overlapping spectral 
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bands.  Changes in hydrogen bonding produce real and apparent band shifts as well as 
flattening and broadening of band shapes.  The molecular absorptions found within 
the NIR region have significantly lower intensity in comparison to the fundamental 
infrared absorptions.  Thus, the changes in absorbance in the NIR region would be 
very small with regard to concentration changes.  The relatively low extinction 
coefficients would place severe restrictions on the allowable noise levels and stability 
for any NIR instrument if quantitative work is carried out.  Besides, sample 
presentation and the more or less obvious measurements by reflectance involve 
aspects which were not conceivable with the traditional infrared spectroscopy.   
 
By the mid 1950s Karl Norris had drifted into the very near-infrared but was limited 
by detectors to < 1’000nm.  At the U.S. Department of agriculture he demonstrated 
the potential value of this region for quantitative work by making measurements of 
agricultural products in the 1960s.  The growing need to provide research facilities for 
fast, quantitative determination of moisture, protein, and oil provided the impetus for 
developing reliable calibrations.   
 
The only commercially available instruments at that time were those developed to 
optimize measurements in the ultraviolet and visible regions, with the NIR capability 
only as an added feature.  Adequate measurements without modifications were not 
possible, so that Norris decided to launch a new instrument specifically designed for 
recording NIR spectra.  This instrument introduced tungsten halogen light sources, 
interference filters and uncooled lead sulfide detectors.  The first operational unit was 
presented at the 1971 Illinois State Fair.  Subsequently a first manufacturer designed a 
rotating filter grain quality analyzer.  These instruments were non-user friendly 
dedicated systems with analog circuitry.  The first dedicated on-line NIR analyzer 
appears to have been produced by Pier-Instrument in Germany in the late 1960s.  It 
was vacuum tube based and employed two interference filters for the measurement of 
moisture.  In the mid-1970s another manufacturer offered instruments for food 
analysis.  This new instrument included features like dust-proof sealed optics and 
internal temperature control, thus improving the ruggedness and long term wavelength 
stability of the instrument.  It also utilized the integrating sphere to give both 
reference reading and signal integration for each measurement.  Many improvements 
of the commercially available instruments succeeded.  The competition was initially 
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very intensive to win a large order for instrumentation from the U.S. Federal Grain 
Inspection Service which had adopted NIR initially as an approved method for 
analysis.   
 
Obviously, the late 1960s and early 1970s saw the birth of what was to become the 
laboratory instrument sector of NIR analysis.  By 1985, instruments had embedded 
microprocessors, memory was still expensive but there was a new versatility.  Sets of 
calibrations could be stored, input data could be powerfully manipulated and results 
could be analyzed.  Several new manufacturers appeared on the scene and a new 
group arose; the third party software vendors.   
 
With personal computers rapidly dropping in price and massively increasing in 
performance, powerful data analysis software became available for data treatments, 
such as smoothing, curve fitting, regression etc.  At last, principal components 
analysis and cluster analysis, with their origins in the 1930s, could be harnessed.  
Chemometrics, the name given to this expanding field by Svante Wold, had been 
born.  Full wavelength instruments challenged wavelength pre-selection and the 
relative merits of the two methods have been the subject of much controversy.  New 
optical techniques have also arisen with wavelength selection by non-linear optical 
crystals, acousto optical tunable filters (AOTF) and wavelength specific emitting 
diodes and laser diodes.  The use of fiber-optical delivery means that in some 
applications a laboratory instrument can operate in the production environment or in 
hazardous areas.  Over the last two decades, NIR technology has gained wide 
acceptance, deepening market penetration and maturity.  The implementation of more 
powerful processors, better algorithms representing improved NIR modeling will lead 
to easier and more robust calibrations.   
 
5.1.2. Spectral regions 
 
Out of a spectroscopist’s view NIR describes the transition between absorption of 
light energy due to transfer of electrons in the visible range (400 – 800nm or 25’000 – 
12’500cm-1) and absorption due to molecular vibration in the mid-range infrared 
region (2’500 – 5’000nm or 4’000 - 200cm-1).  In the area of NIR (780 – 2’500nm or 
12’821 - 4000cm-1) overtones and combinations of the vibration of CH, OH, SH and 
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NH bonds are mainly observed.  All the absorption bands are the results of overtones 
or combinations of overtones originating in the fundamental mid-IR.   
 
Due to absorption of light energy stretching and deformation of bonding angles are 
caused.  The consequences are molecular vibrations.  The difference between NIR and 
mid-IR is only the frequency of these vibrations.  Whereas in mid-IR primarily 
fundamental vibrations are induced, the more powerful NIR provokes first, second or 
higher overtones.  Partially combinations of fundamentals and overtones are resulting.  
They are due to strongly overlapping absorption bands.   
 
5.1.3. Physical background 
 
Vibrational spectroscopy is based on the concept that atom-to atom bonds within 
molecules vibrate with frequencies that may be described by the laws of physics.  
When these molecular vibrators absorb light of a particular frequency, they are 
excited to a higher energy level.  At room temperature, most molecules are at their 
rest or zero energy levels.  That is, they are vibrating at the least energetic state 
allowed by quantum mechanics.  The lowest, or fundamental, frequencies of any two 
atoms connected by a chemical bond may be roughly calculated by assuming that the 
band energies arise from the vibration of a diatomic harmonic oscillator and obey 
Hooke’s law.   
 
Equation 1: Hookes law valid for ideal diatomic harmonic oscillator, with ν = vibrational frequency, k 
= classical force constant, µ = reduced mass of the two atoms.   
µπν
k
2
1=  
 
This works fairly well for diatomic molecules and is not far from the average value of 
two-atom stretch within a polyatomic molecule.  This approximation gives the 
average or center frequency of the band.  Because the reduced masses of the involved 
atoms CH, OH and NH are 0.85, 0.89 and 0.87 respectively, the ‘ideal’ frequencies 
would be quite similar.  But in actual molecules, the electron-withdrawing or donating 
properties of neighbors determine bond strength, length and thus frequency, so that an 
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average value is of little use in structural determinations.  These differences underline 
the development of a real spectrum.  The k values (bond strength) vary widely and 
create energy differences, which can both be calculated and used in spectral 
interpretation.   
 
 
Figure 1: Potential energy diagram of vibrational mode calculated as (a) an ideal harmonic diatomic 
oscillator, and (b) an actual anharmonic diatomic oscillator (Epot = potential energy, ED = dissociation 
energy, r0 = interatomic distance, νx = energy level). 
 
Fundamental frequencies 
 
Unlike the classical spring model for molecular vibrations, there is no infinite number 
of energy levels.  Instead of a continuum of energies, there are discreet energy levels 
described by the quantum theory.  The time independent Schroedinger equation is 
solved using the vibrational Hamiltonian for a diatomic molecule.  Somewhat 
complicated values for the ground state (ν = 0) and succeeding excited states are 
obtained upon solving the equation.  Absorption of a photon of suitable energy can 
cause the molecule to change between vibrational energy levels.  At room temperature 
only the ground state has a significant population, so that transitions due to absorption 
at these temperatures occur from the ground state.   
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A simplified version of these levels may be written for the energy levels of diatomic 
molecules, where the Hooke’s law terms can be seen: 
 
Equation 2: Valid for ν = 0, 1, 2, … and h = Planck’s constant. 
µπνν
khE
22
1 ⎟⎠
⎞⎜⎝
⎛ +=  
 
Rewritten using the quantum term hν, the equation reduces to  
 
  
Equation 3: : Valid for ν = 0, 1, 2, … and h = Planck’s constant. 
ννν hE ⋅⎟⎠
⎞⎜⎝
⎛ +=
2
1  
 
In case of a non-linear molecule with N atoms, there are a considerable number of 
energy levels.  Ideally, one can treat such a molecule as a series of diatomic, 
independent, harmonic oscillators and the above equation can be generalized to  
 
Equation 4: Valid for ν1, ν2, ν3,… = 0, 1, 2, … and h = Planck’s constant. 
( ) ∑−
=
⋅⎟⎠
⎞⎜⎝
⎛ +=
63
1
,...321 2
1,,
N
i
ii hE ννννν  
 
Transition between ground state and excited energy level one (ν = 1) gives the 
fundamental absorption if this leads to change in molecular dipole moment allowed 
by selection rules.  Transitions between ground state and excited energy level two (ν = 
2) or higher ones (ν > 2) give overtones.  Transitions between multiple states can 
occur and give rise to combination bands.  NIR spectra contain these overtones and 
combinations derived from the fundamental vibrations which appear in the mid-IR.  
From the selection rules viewpoint, overtones and combinations are not allowed, but 
appear as weak bands due to anharmonicity or Fermi resonance.   
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5.1.3.1.Anharmonicity and overtones 
 
In practice the so-called ideal harmonic oscillator has limits.  As the mass approaches 
the point at which the spring is attached to the ceiling, the real compression forces that 
counteract the bulk of the spring are often disregarded in calculations.  As the spring 
stretches, it eventually reaches a point where it looses its shape and fails to return to 
its original coil.  This ideal case is shown in part (a) of the potential energy diagram 
(figure 1).  The barriers at each end of the cycle are approached in a smooth and 
orderly fashion.  In molecules, likewise, the respective electron clouds of the two 
boundary atoms restrict the approach of the nuclei during the compression step, thus, 
creating an energy barrier.  On extension of the stretch, the bond eventually breaks 
when the vibrational energy level reaches the dissociation energy.  The barrier at 
smaller distances increases at a rapid rate, while at the far end of the stretch it slowly 
approaches zero (shown in part (b) of the potential energy diagram).  The energy 
levels in the anharmonic oscillator are not equidistant, but slightly closer as the energy 
increases.  This phenomenon is expressed by the following equation. 
 
Equation 5: The anharmonic oscillator, where ωe = (1/2 π)(ke / µ)1/2 = vibrational frequency, xe = 
anharmonicity constant, ke = anharmonicity force constant, and µ = reduced mass of the two atoms. 
terms higherxhhE eee +⋅⎟⎠
⎞⎜⎝
⎛ +−⋅⎟⎠
⎞⎜⎝
⎛ += ωνωνν
2
2
1
2
1  
 
In practice, the anharmonicity constant is between 1 and 5%, thus, the first overtone 
wavelength of a fundamental of 3’500nm would be 
 
Equation 6: Computation of the first overtone wavelength of an exemplary fundamental. 
( )...31
2
500'3 2 +++= ee xxλ  
 
Depending on structural or ambient conditions, the number may range from 1’768nm 
to 1’850nm for this example.  However, it would generally appear at 1’750nm plus a 
relatively small shift to a longer wavelength.  Due to forbidden transitions, the 
overtones are between 10 and 1’000 times weaker than the fundamental bands.  Thus, 
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a vibration band would have to be in their third or fourth overtone to appear in the 
NIR region of the spectrum.  For example, a fundamental carbonyl stretching 
vibration at 1’750cm-1 or 5’714nm would have a first overtone at about 3’000nm, a 
weaker second overtone at about 2’100nm and a third very weak one at about 
1’700nm.  The fourth overtone, at approximately 1’400nm could be left out.  These 
are based on an example 5% anharmonicity constant.   
 
As a rule, overtones occur at half and third of the fundamental absorption wavelength 
i.e. two and three times the fundamental frequency.  Most overtones peaks arise from 
the stretching and bending modes because the dipole moment is high: OH, CH, SH 
and NH are strong NIR absorbers and form most NIR bands.   
 
5.1.3.2.Combination bands 
 
Another prominent feature of the near-infrared spectrum is the large number of 
combination bands.  In addition to the ability of a band to be reproduced at twice or 
threefold the frequency of the fundamental, here is a tendency for two or more 
vibrations to combine (via addition or subtraction of the energies) to give a single 
band.   
 
A simple system containing combinations bands is the gas sulfur dioxide (SO2).  From 
the simple theory of allowed bands there should be three absorption bands according 
to the following equation. 
 
Equation 7: Calculation of the degrees of freedom. 
6-N3bands of Number ⋅=  
 
These are the symmetric stretch (found at 1’151cm-1), the asymmetric stretch (found 
at 1’361cm-1) and the O-S-O bend (found at 519cm-1).  The tree bands mentioned are 
the allowed bands according to group theory.  However, bands also appear at 606, 
1’871, 2’305 and 2’4991cm-1.  As discussed earlier, it is impossible for the molecule 
characterized as a harmonic oscillator to acquire energy to be promoted from the 
ground state to a second level (second overtone) or higher.  For the anharmonic 
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oscillator, although a first overtone of twice the frequency of the symmetric stretch is 
possible.  This band occurs at 2’305 cm-1, with the 3 cm-1 difference arising from an 
exact doubling of the frequency accounted for by the anharmonicity.   
 
 
Figure 2: Illustration of the anharmonic vibrations of SO2. 
 
This still leaves three bands to be explained.  If the possibility exists that two bands 
may combine as νa – νb or νa + νb to create a new band, then the remaining three bands 
are easy to assign arithmetically.  The total bands for SO2 can be assigned as seen in 
the table below.  In the same manner, any unknown absorption band can, in theory, be 
deduced from first principles.  When the bands in question are CH, NH and OH (4000 
- 2500cm-1), the overtones and combinations make up much of the NIR spectrum. 
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ν(cm-1) Assignment 
 
519 ν2 
606 ν1 - ν2 
1’151 ν1 
1’361 ν3 
1’871 ν2 + ν3 
2’305 2 ν1 
2’499 ν1 + ν3 
Table 1: Band assignments for the infrared spectrum of SO2. 
 
While readily apparent in the better-resolved mid-IR, these effects, like fundamentals, 
overtones and combinations of these two, is somewhat difficult to observe in the NIR 
region, often hidden under the broad, overlapping peaks associated with this region.  
Adding Fermi resonance to the overlapping combination and overtone bands already 
seen in the NIR, it is easy to understand why the region was dismissed for so many 
years as unusable.  With current computers and chemometric software, however, these 
broad, undistinguished bands are merely non-esthetic while eminently usable.  The 
NIR signal measured is a complex function of physical and chemical parameters that 
has to be resolved chemometrically.   
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Figure 3: Table of near-infrared absorption bands of common functional chemical groups assigned to 
overtones and combinations.   
 
5.1.4. NIR sampling modes 
 
Different sampling techniques are leading to diverse results.  Depending on the 
interest of information an adequate illumination mode has to be selected.   
 
5.1.4.1.Transmittance 
 
In case of liquids, solutions, goods in bulk, solids and tablets or capsules 
transmittance measurements are very common.  The light source and the detector are 
positioned opposite of each other and the incident light has to cross the whole sample 
to be detected.  Thus the spectrum contains a sum of information about surface and 
core of the sample.  On the other hand this technique is only applicable if light 
intensity is high enough to penetrate the sample depending on the absorption 
coefficient and the sample thickness.   
 
5.1.4.2.Diffuse reflectance 
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In contrast to the prior, the diffuse reflectance mode is used for solid substances and 
requires a different spectrometer configuration.  Whereas source and detector are on 
the same side in an angle of 45° to each other, the light reaches the surface of the 
sample.  Depending on its structure it penetrates some millimeters and the majority is 
absorbed.  The rest is reflected but reaches only partially the detector.  The deeper 
zones of the sample are not regarded.  If the physical properties of the surface, like 
e.g. the particle size, vary a lot the corresponding spectrum may be dominated by 
these influences rather than the chemical information.  If the surface is a 100% 
reflector like Spectralon virtually no absorbance will be recognized.   
 
 
Figure 4: Illustration of NIR measurements in diffuse reflectance and transmittance mode.   
 
5.1.4.3.Transflectance 
 
Transflectance combines both transmittance and reflectance modes and can be used 
for both, solid and liquid substances.  Behind the sample a mirror is installed to reflect 
the light back on the detector being on the same side as the source where diffusely 
reflected and transmitted light is detected in mean time.  While the incident light has 
to cross the sample even twice, here the restrictions of transmittance measurements 
are especially relevant.   
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All of these sampling modes can be combined with, in some cases even, very long 
fiber optic probes out of quartz glass, guiding the incident light to the sampling zone 
or leading the reflected light back to the detector (1).   
 
 
Figure 5: Overview of the different sampling modes that can also be combined (1).   
 
5.1.5. Data transformation 
 
There are many approaches, which describe the procedures during the diffuse 
reflectance mathematically.  J. H. Lambert described this effect already in the year 
1760 with the Lambert’s cosine law.  The experimental verification of this law by 
Pokrowski and Wright showed that the law is only valid with a small angle of 
incidence and a small observing angle.  Gustav Mie developed a theory regarding the 
elemental single-scattering process.  Theories about multiplicative scatter are given 
with the radiative transfer equation and with the Kubelka-Munk function.  A detailed 
description of these theories can be found by Olinger et al. and Ploss HJ.  Olinger and 
Janosch showed that the reflection measurements of analytes in a matrix gave poor 
results using the Kubelka-Munk function.  The linearity between the concentration of 
the analytes and the intensity of the reflectance measurement was not sufficient.  A 
new theory which described the diffuse reflectance for multiple layers was developed 
by Dahm in the year 1999.  The best results are obtained if the intensity of the bands 
is described as the apparent absorption of the measurements with diffuse reflectance.  
If it is assumed that with diffuse reflectance on a sufficient layer thickness, a 
transmission barely takes place, then the apparent absorption is made up of the 
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scattered light and absorbed light.  The calculation is done with the following 
equation 
 
Equation 8 
)log(RA ′−≈′  
 
Equation 9: R’ = Apparent absorption, A’ = reflection, RSample = intensity of the measured sample,   
RReference = intensity of the measured reference. 
Reference
Sample
R
R
R =′  
 
By using log 1/R a nearly linear correlation between the analyte concentration and the 
apparent absorption is achieved.   
 
5.1.5.1.Derivative spectroscopy 
 
The most common data transformation method used in spectroscopy is the making of 
derivative spectra.  Ph. Eur mentions the derivative spectroscopy along with the 
multiplicative scatter corrections (MSC) as an appropriate method of data pre-
treatment.  Works from Blanco et al. show that for quantifications the derivative 
spectroscopy is superior to other methods such as normalization or the multiplicative 
scatter corrections.  As the NIR-spectra can not be described with a definite 
mathematical equation, the derivative has to be calculated with a special algorithm 
and techniques.  A commonly used algorithm is the Savitzky-Golay algorithm, which 
is a box-car function.  The spectrum is divided into many, equally big segments and 
these are then derived under consideration of the neighbor segment.  A disadvantage 
of derivatives is that the signal to noise ratio gets worse with higher derivative factors.  
With the first derivative a basis line shift correction will be done on the spectra.  The 
linear slope of the basis line following the wavelength is eliminated.  Thus, basis line 
offsets occurring due to e.g. different particle size, can be eliminated with the first 
derivative.  The second derivative describes the curvature of the spectra.  By 
establishing the second derivative the spectra will be normalized to their extreme 
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values and border effects will be neglected for several bands.  The signal to noise ratio 
increases by factor four with the second derivative.   
 
5.1.5.2.Chemometrics 
 
Based on the digital measurement technique a spectrum consists of multiple discrete 
measured values.  However the measured values do not correspond to the real values 
as every measurement contains systematical and random errors.  By carefully 
choosing the analyzing method and a thorough validation it is tried to minimize the 
systematical error, and keep it constant.  The random error is eliminated by repeating 
the measurements.  With the help of statistics the average value of the repeated 
measurements can be given as the measured value and the variance can be given as a 
measure of the precision of the analyzing method.  As in most cases, the variance is 
not known and an exact calculation of the measured value is not possible.  With 
empirical approximation calculation it is tried to describe the occurring phenomena 
mathematically, by taking relevant factors into account.  For this there are sufficient 
amounts of measurements needed, the knowledge of the different factors and their 
influence on the measurements results.  In order to be able to use multivariate data, 
chemometrics are put to use.  Chemometrics is a relative young science, which tries to 
extract the relevant information out of a dataset with the help of mathematics and 
statistical methods.  A chemometrical method for data analysis is the mathematical 
distinction and classification of different factors with the help of statistical 
approximation calculation.  A precondition for these calculations is a dataset which 
was created by carefully planned experiments.  The factors contained in the dataset 
must be linearly independent, in order to be able to calculate the single factors from 
the dataset.  One of the most important methods for determining and weighing of the 
factors is the Principal Component Analysis (PCA).   
 
5.1.5.3.Principal Component Analysis (PCA) 
 
PCA forms the basis for multivariate data analysis.  It goes back to the French 
mathematician Cauchy, but was first formulated in statistics by Pearson, who 
described the analysis as finding lines and planes of closest fit to systems of points in 
space.  The most important use of PCA is to represent a multivariate data table as a 
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low dimensional space.  Statistically, PCA finds lines, planes and hyper-planes in a K-
dimensional space that approximate the data as well as possible in the least squares 
sense.   
 
The starting point for PCA is a data matrix (X) with N rows (observations) and K 
columns (variables).  The observations can be analytical samples with measured 
properties being reflected in the variables of spectral origin.  Each X-variable defines 
a coordinate axis in a K-dimensional space.  The principle of representing rows as 
points in a space makes it possible to convert a data table to graphical representation.  
All the observations of X are displayed in K-space as a swarm of points.   
 
 
Figure 6: PCA derives a model that fits the data as well as possible in the least squares sense.  
Alternatively, PCA may be understood as maximizing the variance of the projection coordinates.  Each 
observation is projected onto this line in order to get a coordinate value along the PC-line.  This value 
is known as score.   
 
After mean centering and scaling to unit variance, the data is set ready for 
computation of the first principal component (PC 1).  This component is the line in 
the K-dimensional space that best approximates the data in the least squares sense.  
This line goes through the average point.  Each observation may now be projected 
onto this line in order to get a coordinate value along the PC-line.  This new 
coordinate value is known as a score.   
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Usually one component is insufficient to model the systematic variation of a data set.  
Thus, a second component (PC 2) is calculated.  The second PC is also represented by 
a line in the K-dimensional variable space, which is orthogonal to the first PC.  This 
line also passes through the average point and improves the approximation of the X-
data as possible.   
 
When two principal components have been derived they together define a plane, a 
window into the K-dimensional variable space.  By projecting all the observations 
onto this low dimensional sub-space and plotting the results, it is possible to visualize 
the structure of the investigated data set.  The coordinate values of the observations on 
this plane are called scores, and hence the plotting of such a projected configuration is 
known as a scores plot and represents a tool for geometric interpretation of the 
relationships of the variables.   
 
The scores are accompanied by the corresponding loadings.  Geometrically, the 
principal component loadings express the orientation of the model plane in the K-
dimensional variable space.  The direction of PC 1 in relation to the original variables 
is given by the cosine of the angles.  These values indicate how the original variables 
load into, or contribute to the principal component.  The loadings are used for 
interpreting the meaning of the scores.   
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Figure 7: The principal component loadings uncover how the PC model plane is inserted in the 
variable space.  The loadings are used for interpreting the meaning of the scores.   
 
By using PCA a data table X is modeled as: 
 
Equation 10: The first term represents the variable averages and originates from the preprocessing 
step.  The second term is the matrix product and models the structure.  The third term, the residual 
matrix E, contains the noise. 
EPTxX +′+′= 1  
 
The principal component scores of the applied components (t1, t2, t3, …) are columns 
of the score matrix T.  These scores are the coordinates of the observations in the 
model (hyper-) plane.  Alternatively, these scores may be seen as new variables which 
summarize the old ones.  In their derivation, the scores are sorted in descending 
importance.   
 
The meaning of the scores is given by the loadings.  The loadings of the components 
(PC 1, PC 2, PC 3, …) build up the loading matrix P (figure below).  The loadings 
define the orientation of the PC plane with respect to the original x-variables.  
Algebraically the loadings inform how the variables are linearly combined to form the 
scores.  The loadings unravel the magnitude (large or small correlation) and the 
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manner (positive or negative correlation) in which the measured variables contribute 
to the scores.   
 
 
Figure 8: A matrix representation of how a data table X is modeled by PCA. 
 
Loadings and scores are sufficient to give a satisfactory description of each of the 
variables in the K-dimensional space.  If a high number of observations is involved 
but only few PCs necessary to lead to low residuals, a severe data reduction has taken 
place by the projection of the individual observations on the lines, planes or hyper-
planes (2).   
 
5.1.6. The VisioNIR pattern recognition method 
 
The packaging lines of today run with a speed of up to 1200 blister per minute.  For 
the analysis of each and every tablet or capsule, there is only approximately 5msec 
time available.  Within this time, the measurement, the evaluation and the rejection of 
non compliant products must occur.  The challenge was to develop mathematical 
algorithms and statistics, which are simple and fast enough, to take pace with the 
continuously incoming data every 2 ms of an online inspection system. The necessary 
steps of the evaluation algorithm are presented below (3). 
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5.1.6.1.Data pretreatment 
 
First some data pretreatments are carried out to prepare data for comparison. For 
calibration correction the raw spectrum (figure below) data were standardized to a 
highly reflective spectralon standard and to the diode dark current by using the 
algorithm 
 
 
Figure 9: VisioNIR raw spectra 
 
Equation 11 
n
nn
n Iref
IdarkIraw
Ical
−=  
 
where n is the wavelength number (corresponding from 900 to 1700 nm), Icaln is the 
calibrated intensity, Irawn raw intensity value; Idarkn is the intensity due to diode dark 
current; Irefn is the intensity of reference target (spectralon plate).  This 
transformation includes the correction for odd, even pixel effects, if the intensity 
within the sample area is not uniform.  Next a Gaussian weighting function over seven 
points is used to smooth the raw data (Ismoothed) and reduce the effects of noise. To 
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reduce the effects of different intensity values due to tablet orientation, the data is auto 
scaled (mean centered over the range of wavelengths). 
 
Equation 12 
( ) 212 ⎥⎦⎤⎢⎣⎡ −
−=
∑
n
n
n
n
IsmoothedIsmoothed
IsmoothedIsmoothedIscaled  
 
The first derivative of the data (Ideriv) is taken to highlight differences in the slope 
and position of spectral features between different samples. The first derivative data 
treatment removes additive offsets explicitly that are constant with wavelength. These 
data pre-treatments are carried out with every measured spectrum and the results are 
shown the figure below. 
 
 
Figure 10: Pretreated VisioNIR spectra (1st derivative) 
 
To decide whether a required spectrum and consequently the measured product meet 
the quality control demands a new kind of evaluation statistic was developed. 
 
5.1.6.2.Evaluation statistics 
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A master model is created for each product. The spectrum of each measured product 
is compared with this master model and differences between them are calculated. A 
limit of differences is set to decide whether the sample can distinguish significantly 
from the master model or not.  The master model for each product is created from the 
mean spectrum of the data measured for calibration. 
 
Equation 13 
s
Ideriv
Model s
ns
n
∑
=
,
 
 
where s is the range variable for all spectra acquired and S is the number of spectra. 
The figure below shows the master model spectrum of the interesting product and the 
spectrum of the nearest neighbor model.  The spectra are nearly similar but differ in 
the intensity and slope. These differences are highlighted.   
 
 
Figure 11: Master model spectrum and a faulty product spectrum (wavelength vs. intensity). 
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Some spectral features vary between samples of the same type, due to varying water 
content among or other factors.  To increase the resolving power to distinguish 
between products that are very similar a weighting factor (WFn) is derived. This gives 
more emphasis to features that do not change between the product types. 
 
Equation 14 
nnsns ModelIderivDistModel −= ,,  
 
Equation 15 
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Equation 16 
3
nn SDModelWF =  
 
 
Figure 12: Weighting factor 
 
A combined weighting factor is calculated taking the WFn and the differences 
between the master model spectrum and the spectrum of a measured product into 
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account (above figure).  The combined weighting factor (cWFn) is used to calculate 
the Euclidean distance of each sample within the model. 
 
Equation 17 
( )∑=
n n
n
s cWF
DistModelModelEuclidDist
2
 
 
The mean of this value is used to determine the standard deviation for the model (SD 
Model) 
 
( )
S
ModelEuclidDistModelEuclidDist
SDModel s
s∑ −
=
2
 
 
To enable an acceptable model SD the number of samples required for calibration 
may vary. The mean Euclidean distance (Model Difference Mean) for the model is 
expressed as a difference value in terms of the model standard deviation. 
 
Equation 18 
SDModel
ModelEuclidDistrenceMeanModelDiffe =  
 
In the run mode the pre-treated spectrum for each product is compared against the 
master model spectrum. The Euclidean distance between the derived intensity at each 
wavelength and the corresponding intensity for the model is calculated, with the 
combined weighting factor at each wavelength applied. 
 
Equation 19 
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The `difference value' is calculated in a difference calculation from the distance 
values scaled in term of the model standard deviation. 
 
Equation 20 
SDModel
SampleDisterenceSampleDiff =  
 
A limit is set that is a number of standard deviations from the model difference value. 
 
Equation 21 
ModelSDLimitSDrenceMeanModelDiffetAcceptLimi ×+=  
 
The Limit SD is the number of SDs away from the model difference mean that a 
sample difference value will be accepted as being the same as the same product as the 
model.  A value for Limit SD of 5 gives an error rate of one error by 1.043 × 106 
measurements based on the model data set. The products are rejected on NIR criteria 
if the Sample Difference is larger than the Accept Limit. Also products are accepted if 
the Sample Difference is smaller than the Accept Limit.  In the figure below we can 
see a model in the middle and two different products on each side, which exceed the 
model limit of 5 SD (4).   
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The bigger the difference is, of the products being measured, the bigger the distance is 
on the graph.   
 
5.2. Experimental part 
 
5.2.1. Introduction 
 
The packaging process is one of the most important process steps in the 
manufacturing of pharmaceutical products.  Several studies reveal that, at least, a third 
of all drug recalls are due to packaging errors (5).  If the packaging process is not 
fully under control, the quality of the product can not be guaranteed, as the blister 
might not be completely sealed and therefore not being able to uphold the expiry date, 
or the product might be damaged by some other means during packaging.  In order to 
uphold quality, most packaging lines are equipped with different sensors at various 
positions on the line.  The basic equipment on the line contains a filling control 
camera which controls the blister on the presence of the product or double filling of 
the blister-pockets.  After the blisters are sealed, blisters will be taken out of the line 
regularly and put into a blue bath test to verify that the blisters are correctly and 
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Figure 13: VisioNIR evaluation of spectral data, showing the model in the middle.  On the left and 
on the right the measurements are shown which exceed the model limit. 
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tightly sealed.  Usually there is also a print verification camera which will discard all 
blisters without clear printing on the head foil.  After the blisters are put into the 
folding box, the box will be weighed to be sure that the right amount of blisters are in 
the box.   
 
The present filling control cameras are able to verify if the blister-pockets do have a 
product or even if they are double filled.  Many of the present cameras are black and 
white though, and therefore not able to detect the colour of the product, only shape 
and size.  So during packaging, a mix-up with an equally sized and shaped product 
can not be excluded.  Likewise, if the company has the luxury of a colour camera, a 
mix-up with an equally sized and shaped product, with the same or similar colour, can 
not be excluded as the camera is unable to detect the chemical integrity of the product. 
 
Doing a blue bath test regularly will also not guarantee, that all the blisters are 
correctly sealed, as you only do the test on one cycle every two hours.  All the blisters 
sealed in between the tests might be correctly sealed or might not.   
 
In the case of Sandimmun Neoral soft gelatine capsules (referred to as SIM N from 
now on) there are 5 different types of soft gelatine capsules (SGC’s) in different sizes 
and colours.  There is a colour filling control camera present on the line which is 
supposed to detect whether the SGC´s are present or if a double filling has occurred.  
Also, if the capsules vary in colour, the camera will detect them as a foreign product.  
But as mentioned before, if there are SGC’s which happen to have the same size and 
colour, these SGC’s will be accepted as SIM N by the camera.   
 
The company VisioTec has developed a quality control system called the VisioNIR®.  
VisioNIR® consists of a high resolution camera system, a NIR (Near Infrared 
Spectroscopy) spectrometer and a computer system for controlling the system.  The 
camera system has 2 objectives.  For one it performs an optical control on all products 
(shape, colour, size and fracture) and it locates the exact position of every single 
product for the NIR measurement.  The products in the blister on the packaging line 
pass a zone of 300 × 300mm which is homogenous lighted up with halogen lamps.  
When passing this zone the blisters containing the products are exposed to halogen 
light in order to stimulate molecular vibrations. The reflected light impinges on a two-
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axis mirror and is transferred into a monolithic diode spectrometer with a holographic 
grid via an optic fiber. Next, it is broken down into individual spectral ranges and 
digitized (see figure below).   
 
 
 
 
Figure 14: The setup of the VisioNIR® system.  The halogen lamps stimulate molecular vibrations and 
the reflected light is transferred into the spectrometer via an optic fiber, broken down into its individual 
spectral ranges and digitized.   
 
After the evaluation of the spectrum in the computer, the data obtained are compared 
to the stored set point spectrum, also referred to as the NIR-model.  With this system 
the quality of all products, every tablet or capsule, being packed, independent of the 
batch size, will be determined by comparing the recorded spectra with an existing 
NIR-model of the product which complies to all quality specifications.  If the 
recorded spectra show deviations above a certain limit to the NIR-model or the optical 
camera detects a flawed product, this blister will be discarded. 
 
The VisioNIR system records a spectrum in the wavelength of 900 – 1700nm.  The 
spectrum consists of 128 data points, which are equally spread over the spectral band.   
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5.2.2. Objective 
 
The objective of this project was to determine, if the VisioNIR® system is capable of 
detecting different hidden flaws, not detectable by a solely optical system.  The 
product chosen for the project was Sandimmun Neoral soft gelatine capsules in all 
strengths (10-, 25- grey, 25- yellow, 50- and 100mg) as this product is a life saving 
product and any product flaws could danger the lives of patients.   
 
 
Figure 15: Different strengths and colors of SIM N.  From left: 10-, 25- yellow, 25- grey, 50- and 
100mg. 
 
The following flaw types were examined by VisioNIR® and the spectra were then 
compared to a NIR-model of SIM N SGC’s complying with all quality specifications 
(it should be mentioned, that the following flaws were decided based upon a brain 
storming session and not based upon experience from the manufacturer).   
 
• Empty capsule shell: 
o Means that the shell is completely without content.  This can happen 
via a hole in the shell.  A hole in the shell could theoretically result due 
to improper sealing or due to a force impact on the SGC during 
packaging.   
• Half empty capsule shell:   
o Part of the content of the SGC has leaked out of a hole in the shell. 
• Smudged capsules:   
o An intact SGC which has been smudged with the content of a leaking 
SGC. 
• Low ethanol content:   
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o When SGC are not stored properly in a sealed bag or blister, the 
ethanol content of the SGC quickly decreases and might influence the 
bioavailability of the active ingredient.   
• Mix-up:   
o Some other product than the intended one is on the packaging line. 
• False content of SGC’s:   
o The SGC was filled with something else than the SIM N micro-
emulsion.  This could theoretically happen during the filling process. 
• Placebo:   
o The SGC looks exactly the same and contains the same excipients but 
no active ingredient.   
 
A further goal was also to determine if the VisioNIR® is capable of detecting mix-ups 
between other tablet products.   
 
5.2.3. Project Design 
 
VisioTec has designed simulation equipment consisting of the VisioNIR® system 
described above and an apparatus which moves the products in the blister under the 
VisioNIR®.  The camera system for the locating of the products was not included.  
The VisioNIR® was mounted over a track and on this track there was an aluminium-
slide which could easily be moved with compressed-air.  The slide was capable of 
moving the blisters with the same speed under the VisioNIR® as they would be on a 
conventional packaging line.  This way the recording of spectra of moving products 
was simulated.  A folded foil (unsealed blister) was placed on the aluminium-slide 
and was stuck to it with a double faced adhesive tape. 
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Figure 16: The VisioNIR® system and the packaging line simulator. 
 
The locations of the blister-pockets at the time of measurement were manually entered 
into the controlling computer.  The slide then triggered the measurement of the 
previously saved locations in the controlling computer when passing the light barrier 
placed on the side of the track.  To measure the product it was placed in the blister 
pockets and slid under the VisioNIR® three times.  Every time the slide passed the 
light barrier the measurement was triggered and the XY mirrors collected the reflected 
light at the previously saved locations.  This way it was possible to record NIR-
models of intact SGC’s and then to place prepared SGC’s on the blister (e.g. empty or 
smudged) and record their spectra.  These spectra were then compared to the NIR-
model spectra of the intact SGC’s by transferring the data to an extern PC and there 
the data was analyzed with the software Mathcad11® (Mathsoft Inc., MS, USA).  
Mathcad11® compared the recorded spectra and calculated the deviation of the 
recorded spectra to the NIR-models.  This deviation was then given as the number of 
standard deviations of the model-spectra or as the Euclidian distance from the model-
spectra.  If this distance exceeds a certain value, the Euclidian distance limit, which is 
the model mean difference + 5, the spectra will be rated as different and therefore the 
SGC belonging to the spectra not fulfilling the quality aspects.   
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5.2.4. Project Challenges 
 
It is known that the content of SGC’s is hard to detect with NIR, as the capsule shell 
contains high amounts of titanium dioxide and the grey capsules additionally contain 
black iron oxide, both substances making it very difficult to get light through the 
capsule shell thus generating molecular vibrations of the content.  Therefore there had 
to be done some changes to the original system as the original halogen lamps did not 
suffice to reach the content of the grey SGC’s (25mg and 100mg).   
 
The strength of the halogen lamps was then increased to 800 watt which seemed to 
suffice to reach the content of the capsules.  Having increased the strengths of the 
halogen lamps another problem was encountered.  The 800W strong halogen lamps 
generated so much heat (>70°C), that the SGC’s melted if the stayed too long under or 
close to the lamps.  This concern was solved when the housing of the VisioNIR® 
system was mounted, as the housing is a closed box with a special NIR glass 
separating the lamps from the products.  In this manner the heat was kept in the 
housing and transferred outside with an effective ventilation system.   
 
In order to verify that the SGC’s really were intact after being exposed to the halogen 
lamps some additional stability tests were done, as no stability data existed for this 
extreme temperature.  Intact SGC’s were put on the blister foil and then slid under the 
lamp, afterwards being examined on ethanol and propylene glycol content as these 
evaporate very fast.  It is very important that the content of ethanol stays constant as 
ethanol keeps the active pharmaceutical ingredient from crystallizing.  The active 
pharmaceutical ingredient is not bioavailable in crystalline state.  One bulk of SGC’s 
was exposed three times and one bulk for six times to the lamp.  As a reference one 
unexposed bulk of SGC’s was also examined on ethanol and propylene glycol 
content.  Every bulk consisted of forty SGC’s.  These tests were done on grey SIM N 
25mg as they should absorb the heat the most and therefore lose ethanol faster.  All 
the used capsules came from the same lot.  In the below figure, the results from these 
tests can be observed.   
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Figure 17: Stability of the exposed capsules, showing that the exposure to the hot halogen light does 
not affect the propylene glycol content and only slightly affects the ethanol content after six exposures. 
 
Based on these results it is safe to say that one exposure to the lamp will not damage 
the SGC’s in any way.  It can be observed, that the ethanol content of the SGC’s does 
decrease about 2.3% after six exposures to the lamp.  The propylene glycol on the 
other hand does not seem to be impressed by the light exposure and stays constant 
after six rounds.   
 
5.2.4.1.Making sure not to miss the target 
 
As we could see above, the smaller SGC’s (10- and 25mg) are in the shape of an 
American football.  The blister cups of these capsules are very broad and the shape of 
the capsules lets them roll around in the cup during the yanking movements of the 
packaging line.  This leads to the problem of collecting a measurement from the 
capsule and not from half the capsule and half the aluminum foil.   
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Figure 18: 25mg soft gelatin capsules with the typical American football shape in a blister.   
 
 
Figure 19: 10mg soft gelatin capsules with the typical American football shape in a blister.   
 
As the visual camera detects the capsules they are sill in movement and come to a halt 
under the halogen lamp.  Hence, due to the abrupt stop of the blister band, the 
capsules are set into movement and they roll around the blister cup.  That is why the 
capsule might not be acquired with the spectrometer and so resulting to a wrong 
result.   
 
The area which is measured with every movement of the mirrors was measured to be 
11m in diameter.  Due to that diameter of the blister cup of the 10mm capsules, it 
could be assumed (and the results showed later) that the measuring spot always 
detects the whole capsule and parts of the aluminum foil.   
 
For the 25mg capsules it is another story.  In order to be sure that the capsule was 
detected in the best possible way, there were made three measurements in the blister 
cup.  One in the middle and one on the top and bottom 
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Figure 20: The three measuring spots in the 25mg blister cup. 
 
These measurements were then all compared to the NIR-model and spectrum which is 
closest to the mean model spectrum is used for the final evaluation.  For the 
measurements there were ten capsules measured whereas five capsules were prepared 
and five intact.  These ten capsules were then measured three times and compared to a 
NIR-model recorded before.   
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Figure 21: All spectra recorded compared to a NIR-model.   The first thirty spectra represent the NIR-
model and all spectra after that the test with the intact and prepared capsules.   
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In the figure above it can be observed that after the 29th spectrum (the first spectrum is 
number zero) the intact capsules are measured.  It can be seen that some of the spectra 
exceed the model limit of five Euclidian distances, which only means that the 
measuring spot did not hit the capsule well.  The first five capsules were measured 
with three spots on every capsule, which means that there are fifteen of them.  The 
next fifteen spectra then belong to the prepared capsules.  After the 59th spectrum the 
measurement is repeated.   
 
Below the selection of the closest spectra to the NIR-model can be observed.   
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Figure 22: The five selected spectra from the 15 spectra respectively. 
 
In the above figure the NIR-model is not depicted anymore, but the distinction of the 
prepared capsules to the intact capsules can be observed very well.   
 
5.2.5. Experiments Description and Results 
 
As mentioned above, there are NIR-models needed of the products which fulfil all 
required quality aspects.  These were acquired by placing intact capsules on the blister 
and their spectra was then recorded and saved.  These NIR-models were recorded in a 
standstill and made sure that the mirrors were completely centred on each and every 
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capsule.  The NIR-model then consists of three spectra of every capsule placed on the 
blister.   
 
All prepared capsules were then detected amongst intact capsules and the recorded 
data then transferred to the extern PC where it was evaluated with the help of 
MathCad11®.  There the recorded spectra could be compared to the corresponding 
NIR-model and the Euclidian distance was calculated.  The limit for the capsules 
having the same quality as the model capsules was five Euclidian distances added to 
the model mean difference.   
 
The spectral range used for the evaluation of the measurements was cut down from 
900 – 1700nm(all 128 diodes) to 1060 – 1460nm (diode numbers 27 – 96).  This 
showed much better distinction of the prepared capsules as the relevant information 
seemed to be contained in that area.  Towards the ends of the spectra there was also 
quite much noise.   
 
5.2.5.1.Empty 
 
The SGC’s were emptied with a syringe, making a small hole on each end of the 
capsule and then blowing out the content by injecting air into the capsule.  These 
freshly emptied capsules were then placed on a blister amongst intact capsules and 
then detected and evaluated as described above.  They were detected fresh, otherwise 
the ethanol would have evaporated out of the capsule shell and so changing the 
composition of the capsule shell, making the deviation higher.  By doing this, the 
possibility is being tested of detecting empty capsules which either got damaged in the 
packaging line, thus smudging other capsules, or already empty capsules which 
possibly got damaged shortly after production.   
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Figure 23: 10mg capsules empty.  There is a clear distinction between the empty capsules and the 
intact capsules. 
 
As explained above, a NIR-model is first scanned into the system and this model will 
then be compared to the prepared capsules.  In the above figure, the model consists of 
ten intact 10mg SGC’s which were recorded three times.  These 30 spectra were then 
used as a model.  Five of the prepared SGC’s were then put onto the blister amongst 
five intact SGC’s and then again measured three times.  The above figure shows an 
excellent distinction between the intact capsules and the empty ones.  Also the intact 
capsules were also recognized as good quality capsules.   
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Figure 24: 25mg grey empty.  A distinction of about 7 euclidian distances can be seen. 
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Figure 25: 25mg yellow empty.  An excellent distinction between the empty capsules and the intact 
capsules.   
 
As can be seen in the above figure, the multiple measuring methods were used, as the 
small 25mg SGC’s could be situated anywhere in the blister pocked due to the 
yanking movement of the packaging line, or in this case, the simulator.  From the 
three measurements made on each blister pocket the one measurement which is the 
closest to the NIR-model is sorted out and displayed in the above figure.  We can see 
that the 25mg grey SGC’s could be separated with at least five Euclidian distances 
and the 25mg yellow even with approximately 70 Euclidian distances.   
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Figure 26: 50mg empty.  An excellent distinction between the empty and the intact capsules. 
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Figure 27: 100mg empty.  A clear distinction between the empty and intact capsules. 
 
It was possible to detect all empty capsules for all strengths and types.  As we can see 
on the graphs above, the deviation is the smallest for the capsules which contain black 
iron oxide in the capsule shell (25- and 100mg, grey capsules), which leads to the 
conclusion, that the halogen light doesn’t penetrate them as well as the others.   
 
5.2.5.2.Half-full 
 
These capsules were done the same way as the totally empty ones, except that only 
half of the content was retracted with the syringe.  This simulates the detection of 
fresh damaged capsules which have only lost parts of their content.  The 10mg 
capsules were left out of this experiment as they have so little content. 
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Figure 28: 25mg grey, half full.  The distinction of the half full from the intact capsules is 
approximately 4 euclidian distances. 
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Figure 29: 25mg yellow, half full.  A clear distinction between the half full and intact capsules. 
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Figure 30: 50mg, half full.  A clear distinction between the half full and the intact capsules. 
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Figure 31: 100mg, half full.  A clear distinction between the half full and intact capsules. 
 
It was possible to detect all half-full capsules for all strengths and types.  Again it is 
apparent, that the black iron oxide disturbed the detection of the content as the 
deviation wasn’t as high for these as for the others.   
 
5.2.5.3.Smudged (Lightly and excessive)   
 
The micro emulsion of the SGC’s was blown out with a syringe the same way as was 
done for the preparation of the empty capsules.  The micro emulsion was collected 
and then used for the smudging of the capsules.  The capsules were dipped into the 
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micro emulsion and then placed on the blister, having so much micro emulsion on it, 
that it created a small puddle in the blister cup, simulating an excessively smudged 
capsule.  By doing this the possibility of detecting capsules which have been smudged 
by an open, damaged capsule is being simulated.   
 
 
0 5 10 15 20 25 30 35 40 45 50 55 60
0
10
20
30
40
50
46.244
0
Differencespecnum
NearestDifferenceMean
NearestLimit
ModelLimit
ModelDifferenceMean
590 specnum  
Figure 32: 10mg, excessively smudged.  A clear distinction between the both. 
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Figure 33: 25mg grey, excessively smudged.  A clear distinction from the intact capsules. 
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Figure 34: 25mg yellow, excessively smudged.  A clear distinction from the intact capsules. 
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Figure 35: 50mg, excessively smudged.  A clear distinction from the intact capsules. 
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Figure 36: 100mg, excessively smudged.  A clear distinction from the intact capsules.   
 
The lightly smudged capsules on the other hand where prepared by emptying a few 
capsules into a glass with intact capsules and stir them around until the micro 
emulsion was evenly distributed onto the surface of the capsules.   
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Figure 37: 10mg, lightly smudged (420mg content on 20 capsules).  No distinction from the intact 
capsules. 
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Figure 38: 25mg grey lightly smudged (787mg content on 20 capsules).  No distinction from the intact 
capsules. 
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Figure 39: 25mg yellow lightly smudged (787mg content on 20 capsules).  No distinction from the 
intact capsules. 
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Figure 40: 50mg lightly smudged (1575mg content on 12 capsules).  A distinction from the intact 
capsules is recognizable. 
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Figure 41: 100mg lightly smudged (3150mg content on 12 capsules).  A slight distinction from the 
intact capsules.   
 
The results show that the detection of an excessively smudged capsule is very clear 
whereas the detection of the lightly smudged only delivers a trend, except in the case 
of the 50 and 100mg.  It was observed during the tests that as sooner the capsules 
were detected after being smudged, the higher the deviation the smudged capsules 
showed.  This is most probably due to the evaporation of the ethanol from the micro-
emulsion on the surface, leading to the conclusion that smudged capsules could only 
be detected if they get smudged just before being put under the spectrometer.   
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5.2.5.4.Low ethanol content 
 
In order to prepare capsules with lowered ethanol content, the capsules were stored in 
open blisters at room conditions.  This way the ethanol and propylene glycol 
evaporated from the capsules.  The conditions were monitored during the tests and 
showed an average of 23.5°C and 44.6% relative humidity.   
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Figure 42: The test room conditions during the last 5 weeks of the tests.  Measurements were made 
every hour. 
 
According to stability report, the capsules loose ethanol very fast when they are stored 
openly.  At the room conditions mentioned above the loss of ethanol should be slower 
than at the conditions used for the stability tests.   
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Figure 43: Stability of SIM Neoral SGC.   
 
The limits of the ethanol content are 80 – 120%.  As soon as the ethanol content falls 
below 80% it can not be assured that the active ingredient doesn’t crystallize out of 
the micro-emulsion.  In the crystalline state the active ingredient will not be absorbed 
so an improper storage of the capsules could be dangerous for the patients as the 
probability of an organ rejection rises if the patient does not receive his correct dose.  
By doing this test, the possibility of detecting capsules at the line which do not 
contain the required amount of ethanol is being tested. 
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Figure 44: 10mg capsules after 24 hours storage without blister.  A clear distinction from the intact 
capsules.   
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Figure 45: 25mg grey capsules after 144 hours storage without blister.  No distinction at all. 
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Figure 46: 25mg yellow capsules after 48 hours of storage without blister.  A distinction from the 
intact capsules. 
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Figure 47: 50mg capsules after 144 hours of storage without blister.  A distinction can be seen from 
the intact capsules of about 4 euclidian distances. 
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Figure 48: 100mg capsules after 216 hours of storage without blister.  No distinction at all from the 
intact capsules. 
 
From these results it is shown that the spectra of the capsules do change the longer 
they are stored.  After only 24 hours the 10mg capsules showed deviation to the NIR-
model, the 25mg yellow also after 48 hours and the 50mg showed deviations after 144 
hours of storage.  The 25mg grey and the 100mg did not show any clear distinction to 
the intact capsules after 144 hours and 216 hours respectively.  After this time the 
ethanol concentration still is about 80% according to stability report, and the capsules 
still intact.  It could also be that the grey capsule shell has some impact on the 
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detection, making the detection of ethanol less sensible.  Unfortunately the time did 
not suffice to store the capsules long enough until they showed deviation to the NIR-
model.   
 
In order to be able to predict the actual ethanol content of the capsules at the time 
when detected by the VisioNIR®, samples were put in a climatic exposure test cabinet 
at the room conditions (23.5°C and 44.6% relative humidity) for the corresponding 
times.  After storage the samples were used to determine the ethanol content.   
 
 
 
 
 Ethanol content 
at t0 [%] 
Stored for 
[h] 
Ethanol content 
after storage [%] 
10mg 96.2 24 84.6 
25mg yellow 89.5 48 79.5 
25mg grey 91.61 144 43.6 
50mg  98.0 144 60.0 
100mg 105.3 216 62.3 
Table 2: Ethanol content of the SGC’s before and after open storage. 
 
According to the results in the table above the SGC’s lost their ethanol content faster 
than we should have expected, compared to the stability report.  But it is clear that the 
integrity of the grey capsules is not confirmed as the ethanol content has fallen way 
beneath the allowed limit of 80%.   
 
As a conclusion it can be said that a change in ethanol content of the SGC’s does 
influence their NIR spectra.  The grey capsules though, did not show much difference 
in the spectra and again proved that the analysis of the grey capsule shell is very 
difficult with NIR.  All other capsules could be separated clearly from the intact 
SGC’s with normal ethanol content.   
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5.2.5.5.Mix-up 
 
By using Sandimmun Classic SGC’s instead of SIM Neoral, a potential mix up was 
being simulated.  The 10mg capsules were left out of this test as that dose does not 
exist for the SIM Classic.  Also the grey 25mg capsules were left out of this 
experiment as the grey capsules are so different in colour from the SIM Classic 25mg, 
the yellow one is closer to it.  SIM Classic contains the same active pharmaceutical 
ingredient but does not contain the same excipients as SIM N.   
 
 
Figure 49: SIM Neoral lined up with SIM Classic.   
 
These mix-ups would be possible to detect only based on their colour if there would 
be a colour optical camera placed on the line.  But with NIR this detection is very fast 
and simple, as the contents of the capsule shell are different and therefore the 
deviations in the spectrum should be significant. 
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Figure 50: 25mg yellow SIM N, mixed with 25mg pink SIM Classic.  A clear distinction from SIM 
Neoral. 
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Figure 51: 50mg SIM N, mixed up with 50mg yellow SIM Classic. 
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Figure 52: 100mg SIM N, mixed up with 100mg orange SIM Classic 
 
The detection of a mix-up with VisioNIR® is, based on these results, very reliable.   
 
5.2.5.6.Other Mix-ups 
 
The VisioNIR® system was also tested for other mix-up possibilities and in this case 
for tablets.  The choice for the products was based on their shape, size and colour.  
The tablets chosen may be separated from each other with an optical camera system 
but assuming there would be a black and white camera placed on the line, a mix-up 
would never be detected.   
 
These tablets were placed in an aluminium blister and measured by the VisioNIR®.  
The recorded spectra were then compared in Matchcad11®.   
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Figure 53: Four different products with similar shape compared on the basis of Prexige which is the 
NIR-model in this case. 
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Figure 54: Three different products with similar shape and color compared on the basis of Co-Diovan, 
which is the NIR-model in this case. 
 
As these results show, the distinction between the different tablets is very clear.  The 
VisioNIR® would detect the mix-up as a product not meeting the required quality and 
discard the blister.   
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The possibility of a mix-up between strengths of one product does also exist, i.e. if the 
different strengths are produced with the same granulate and only differ in size.  Than 
the spectrometer does not recognize any deviation from the NIR-model as the 
chemical composition is exactly the same.   
 
5.2.5.7.False content of SGC’s 
 
The unlikely but possible situation could come up, that the capsule shells could be 
filled with the false content.  E.g. that the capsule shell of SIM N could be filled with 
the content of SIM Classic, or even with the content of some completely different 
product.  In order to simulate this possibility, the content of SIM N was removed with 
a syringe by blowing it out and then the empty shell was filled with the content of 
SIM Classic by injecting it into the shell.  Measuring errors were avoided by emptying 
a SIM N capsule and filling it again with its content and then there was checked if 
these capsules differentiated themselves from the untouched ones.  This was not the 
case as seen in the figure below.   
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Figure 55: Measurement of intact 50mg capsules with refilled 50mg capsules.  The NIR-model is 
represented with the first 24 spectra.  After that there is no distinction to be observed.   
 
After having shown that the preparation of the capsule shell does not influence the 
distinction of the falsely filled capsules, the measurements could take place. 
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Figure 56: 25mg grey with false content.  No distinction whatsoever.   
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Figure 57: 25mg yellow with false content.  A good distinction can be observed from the intact 
capsules.   
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Figure 58: 50mg with false content.  Excellent distinction from the intact capsules.   
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Figure 59: 100mg (grey) with false content.  No distinction from the intact capsules. 
 
Again it is conspicuous that the grey capsules (25mg grey and 100mg) with false 
content are not separable from the intact ones.  The yellow 25mg and the white 50mg 
capsules with false content show high deviations compared to the intact ones.  This 
supports the suspicion that the grey iron oxide in the capsule shell of the grey capsules 
doesn’t let as much light through as the yellow and white ones.   
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5.2.5.8.Placebo detection 
 
Detecting placebos would not be possible with any optical camera as the capsules 
look exactly the same because the patients are not supposed to notice any difference 
to the verum capsules.  The only difference between placebo and verum is that the 
placebo does not contain any active pharmaceutical ingredient.  So the only way to 
detect a placebo is to detect the active pharmaceutical ingredient in the capsule.  
Comparing the contents of a placebo SIM N to a verum SIM N there are some 
differences to be observed. 
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Figure 60: NIR spectra of the contents of SIM Neoral placebo and verum.  
 
This application is very interesting for the clinical packaging as they pack blisters 
which partly contain placebo and verum in the same blister and a mix-up between 
blister-pockets could mean that a clinical study’s results are partly or even completely 
falsified.  These studies are mostly double-blind studies in order to achieve objective 
results.  Therefore it is critical that the right capsules land in the right blister pocket.  
These tests were done by mixing placebo with intact verum capsules and then the data 
was treated with the same algorithms as for the other applications.  Unfortunately 
there were no 25mg grey placebo capsules available for this test. 
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Figure 61: 10mg placebe / verum.  There is a narrow distinction to be observed. 
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Figure 62: 25mg yellow placebo / verum.  There is a narrow distinction to be observed. 
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Figure 63: 50mg placebo / verum.  There is no clear distinction to be observed, rather a trend.   
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Figure 64: 100mg placebo / verum.  There is no hint of a distinction to be observed, except for one 
capsule.   
 
The detection of placebos is possible for the 10mg capsules.  For the 25mg yellow 
capsules there is a definite trend for the recognition of placebos as they do show 
higher deviation to the NIR-model but still not exceeding the limits.  The detection of 
50mg placebos also shows a trend but still not high enough for a clear distinction from 
the verum.  The 100mg show almost no difference to the verum capsules and the NIR-
model.  Again it is seen that a grey (100mg) shows the worst detection of all the 
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different capsules.  It is to assume that the 25mg grey would also show a similar 
result.   
 
It was very surprising that the detection of the 50mg placebo was not as clear, as the 
capsules were up to now the best ones to detect.  The capsule shell is white and has 
been letting more light through the capsule shell than the darker capsules.  In order to 
improve the detection of the placebo 50mg the data achieved from the measurement 
were put into a principal component analysis (PCA).  For this the Unscrambler® 
(CAMO AS, Trondheim, Norway) was used.  With PCA it was possible to identify 
the spectral band which gave the most information on the active pharmaceutical 
ingredient.   
 
 
Figure 65: A clear distinction between SIM Neoral 50mg placebo and verum with the help of PCA. 
 
The spectral band between 1080nm and 1210nm (diodes 30 – 50) contained the most 
information on the active pharmaceutical ingredient and using this band it was 
possible to separate the placebo from the verum capsules.  Narrowing the spectral 
band down from 1060 – 1460nm to 1080 – 1210nm with the same data using Mathcad 
then brought a better result. 
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Figure 66: The distinction of 50mg placebo verum after modification of spectral bands. 
 
This result shows that the distinction would be possible using this spectral band.  But 
it has to be considered when using this spectral band the distinction of the other 
parameters could get worse as other physical or chemical parameters might reside in 
other spectral bands.   
 
Considering the same situation for tablets, it was decided to see if the VisioNIR was 
able to separate placebo tablets from verum tablets.  For these tests Glivec 400mg was 
used.  The tablets have the same coating suspension and the same excipients.   
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Figure 67: A clear distinction between tablet placebo and verum  
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It can be seen that the distinction is very clear.  The distinction might get harder with 
lower concentrations of active ingredients in the tablets, but that would have to be 
tested for all individual tablets. 
 
As a conclusion it can be summarized that VisioNIR would be a valuable sensor on 
the clinical packaging line for all SIM Neoral capsules excluding the grey ones.  For 
tablets it would have to be checked, to what limits the distinction still works.   
 
5.3. Conclusion 
 
The following table summarizes the results for SIM N discussed above.
 303
 
SIM N 10mg 25mg grey 25mg yel. 50mg 100mg 
Full/empty √ √ √ √ √ 
Half empty N/A √ √ √ √ 
Li. smudged +/- +/- +/- +/- +/- 
Exc. smudged √ √ √ √ √ 
Low EtOH √ (24h) *1 √ (48h) √ (144h) *2 
Plac./Verum √ N/A √ +/- X 
Mix-up N/A N/A √ √ √ 
False content N/A X √ √ X 
Table 3: SIM Neoral results summarized. 
*1: After 144 hours there was no detectable difference between the stored 25mg grey capsules and 
the fresh ones.   
*2: After 216 hours there was no detectable difference between the stored 100mg grey capsules 
and the fresh ones.   
 
It is conspicuous that when the prepared capsules where not separable that happened 
with the grey capsules, apart from the lightly smudged capsules and the 50mg placebo 
(which could be separated after optimization.  This does lead to the conclusion that 
the grey capsule shell does not let as much light through the shell as the yellow or the 
white ones.   
 
As the VisioNIR system measures with diffuse reflection, the spectrum of the capsule 
shell dominates the total spectra.  The NIR spectra of the capsules consist of the 
spectra of the capsule shell and the spectra of the capsule content.  When measuring 
with diffuse reflection one part of the stimulating light interacts with the capsule shell 
and another part with the content.  The higher the intensity of the stimulating light, the 
deeper it penetrates the capsule and the interaction of the capsule content increases.  
Thus the apparent absorption of the capsule content increases with increasing light 
intensity.  At the same time the apparent absorption of the capsule shell stays the same 
as the thickness of the shell stays constant (6).   
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The system would be a very valuable control system on the packaging line as the 
occurrences of empty capsules reaching the customer and even threatening his life by 
increasing the risk of an organ rejection, would be totally impossible.  Detecting 
freshly smudged capsules on the line is very unlikely as the capsules do need some 
time to make it from the filling station to the camera system.  In this time the lightly 
smudged capsules will not be detectible any more, but a damaged capsule with 
content spilled in the blister-cup will be detected.  Also all mix-up’s would be 
detected and excluded.  The aspect of being able to differentiate between placebo and 
verum seemed very interesting for the clinical packaging.  But as the results showed, 
it proved to be very difficult to separate the both from each other in the case of SIM 
Neoral.  In the case of Glivec the distinction placebo and verum was very clear. 
 
5.4. Outlook 
 
In order to improve the distinction of the placebo capsules and possibly the grey 
scapegoat capsules the light intensity might be increased.  This is on the other hand 
dangerous for SGC’s as the heat might then be too much for the sensitive capsules. 
 
Also, what was not considered in this work is the effect of such a strong light 
exposure on photo-sensible drugs.  There are examples of active ingredients which 
decompose exposed to intensive daylight and others which darken.  This would have 
to be considered before putting VisioNIR onto the packaging line.     
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6. Overall conclusion 
 
6.1. Discussions and conclusions 
 
In this work, Process Analytical Technology has been looked at in terms of in which 
process steps the sensors should be implemented into manufacturing and consequently 
the expected costs were estimated and the anticipated revenue was determined.   
It is clear that the implementation of PAT is very expensive, but it will pay off.  In 
this case-study, an investment of about 4.5 million CHF for each product was needed 
and a break even point was reached after as little as 6 years.  For this study, PAT 
applications were implemented as process controls and not as design help for 
development.  It is essential to expand this study into drug development in order to 
study the impact of PAT onto quality of design.   
 
NIR being the most common recommended PAT sensor, a NIR spectrometer was also 
investigated, for not such a frequent application, namely the packaging line.  Using 
the VisioNIR on soft gelatin capsules, it was able to distinguish the intact capsules 
from empty-, half-empty-, excessively smudged- and mix-up capsules.  Also mix-up 
and placebo detection amongst tablets was no problem on 100% of the product being 
packed.   
 
Further, two different technologies which are recommended from the FDA in terms of 
product understanding and quality by design, were analyzed and the impact on current 
ways of doing development was looked at.   
 
The Multicell®, being a semi-continuous granulation machine is capable of replacing 
the conventional granulation process and at the same time increasing manufacturing 
capacities with reduced personnel needed.  By implementing the Multicell® into 
manufacturing and development a design of quality into granulate can be reached and 
dreadful scale-up exercises can be avoided leading to a faster time to market. 
 
The Presster® was capable of predicting the compression behavior of two different 
tablet formulations on three different rotary presses, in terms of the most important 
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factors which are hardness and dissolution rate.  This is only possible if the correct set 
of compression tools is available for the Presster®.   
 
It is apparent that pharmaceutical companies will have to be innovative if they wish to 
survive the competition on the market today.  From the point of view of the 
researching pharmaceutical companies, they will have to invest in innovation in order 
to get them selves as fast to the market as possible in order to prolong their window of 
exclusivity for a patented product.  From the generics point of view, it is also essential 
to invest in innovative technology, as the generic company which comes first to the 
market, gets the biggest part of the cake.   
 
In the end, the fact will be that when one company has decided to take the innovative 
road, the other companies will be forced to follow in their footsteps.   
 
“…an economical benefit for a pharmaceutical company is a gun to its head”!   
John E. Carroll 
 CfPA PAT course Amsterdam 
(2004) 
 
 308
Curriculum Vitae  
 
 
Personal information         
 
Name    Hedinn Valthorsson 
 
Date of Birth   April 2nd 1975 
 
Place of Birth  Akureyri, Iceland 
 
Parents   Baldvina Sigrun Sverrisdottir 
    Sveinn Valthor Sigthorsson 
 
Professional Experience        
  
Since Jan 2006 Senior Scientist in Global PAT / GQO.  Project manager in 
QbD / PAT pilot project at Novartis (East Hanover, USA).   
Feb 2003 – Dec 2006 PhD Contract at Novartis (Stein AG, Switzerland), working 
on a PhD thesis in collaboration with the University of 
Basel, under the tutorial of Prof. Dr. Hans Leuenberger.  
During the PhD studies I also had the following functions 
at Novartis: 
• Stein Works Project Coordinator 
• PAT Stein Project Team Representative 
• GMP Training Supervisor 
• Think (Employee Suggestion System) Officer 
• MIT Project Leader 
• LEAN Trainer 
    
Internships and Work Experience      
 
Jun 2002 – Dec 2002 Internship in the Merlin Pharmacy in Cologne / Germany 
Dec 2001 – Mai 2002 Internship at Novartis Stein / Switzerland 
April 1999 – Dec 2001 QC laboratory assistant at Actavis / Iceland during 
semester breaks 
 
Education            
 
Feb 2006 Doctorate  wi th  h ighest  honors (Summa cum 
Laude)  in  Pharmaceut ica l  Technology f rom 
Univers i ty  o f  Basel  
Dec 2002 Pharmacis t  (Staatsexamen)  f rom Caro l ina-
Wi lhelmina Univers i tä t  Braunschweig,  Germany 
 
School             
 
Dec 1995 General Qualification for University Entrance 
(Studentsprof) from Flensborg, Hafnarfjördur / Iceland 
 309
 
Language Skills          
 
English  fluent in written and spoken 
    German fluent in written and spoken 
    Danish fluent in written and spoken 
    Icelandic mother tongue 
 
Computer Literacy          
 
    MS Office, MathCad, SIMCA P+ 
 
Private Hobbies           
  
    Martial Arts 
